PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33895548-7	2021	The ERalpha agonist propyl pyrazole triol (PPT) but not the ERbeta agonist diarylpropionitrile (DPN) induced vWF release, while ERalpha silencing counteracted vWF release by E2, suggesting that ERalpha mediates this effect.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	20-41	estrogen receptor 1	Homo sapiens	4-11
33895548-7	2021	The ERalpha agonist propyl pyrazole triol (PPT) but not the ERbeta agonist diarylpropionitrile (DPN) induced vWF release, while ERalpha silencing counteracted vWF release by E2, suggesting that ERalpha mediates this effect.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	20-41	von Willebrand factor	Homo sapiens	109-112
33895548-7	2021	The ERalpha agonist propyl pyrazole triol (PPT) but not the ERbeta agonist diarylpropionitrile (DPN) induced vWF release, while ERalpha silencing counteracted vWF release by E2, suggesting that ERalpha mediates this effect.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	43-46	estrogen receptor 1	Homo sapiens	4-11
33895548-7	2021	The ERalpha agonist propyl pyrazole triol (PPT) but not the ERbeta agonist diarylpropionitrile (DPN) induced vWF release, while ERalpha silencing counteracted vWF release by E2, suggesting that ERalpha mediates this effect.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	43-46	von Willebrand factor	Homo sapiens	109-112
33967959-10	2021	The insulin, HOMA-IR, TG, TC, LDL-C, non-HDL-C, TRLRs, ApoB, ApoCIII and ApoCII/ApoCIII values were higher in the PPT group, while the ApoAI/ApoB ratio was higher in the PNT group.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	114-117	apolipoprotein C3	Homo sapiens	61-68
33967959-10	2021	The insulin, HOMA-IR, TG, TC, LDL-C, non-HDL-C, TRLRs, ApoB, ApoCIII and ApoCII/ApoCIII values were higher in the PPT group, while the ApoAI/ApoB ratio was higher in the PNT group.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	114-117	apolipoprotein C3	Homo sapiens	80-87
33967959-10	2021	The insulin, HOMA-IR, TG, TC, LDL-C, non-HDL-C, TRLRs, ApoB, ApoCIII and ApoCII/ApoCIII values were higher in the PPT group, while the ApoAI/ApoB ratio was higher in the PNT group.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	114-117	apolipoprotein A1	Homo sapiens	135-140
33967959-10	2021	The insulin, HOMA-IR, TG, TC, LDL-C, non-HDL-C, TRLRs, ApoB, ApoCIII and ApoCII/ApoCIII values were higher in the PPT group, while the ApoAI/ApoB ratio was higher in the PNT group.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	114-117	apolipoprotein B	Homo sapiens	141-145
33967959-15	2021	ApoCIII gradually increased in the PPT group within 6 hours after the meal, exhibiting a greater AUC increment (P < 0.001).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	35-38	apolipoprotein C3	Homo sapiens	0-7
33547280-4	2021	Yeast growth assays, polysome profiling, total/hypusinated eIF5A levels and PPT-reporters studies reveal that the variants impair eIF5A function, reduce eIF5A-ribosome interactions and impair the synthesis of PPT-containing proteins.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	76-79	eukaryotic translation initiation factor 5A	Danio rerio	130-135
30916621-7	2021	DDN significantly increased (p = 0.04) the PPT in MTP (44.6%) compared with sham procedure (-5.5%).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	43-46	metallothionein 1B	Homo sapiens	50-53
33672651-6	2021	We treated cells with 17beta-estradiol (E2), 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole (PPT) an estrogen receptor (ER) alpha (ERalpha) agonist, or 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN), an ERbeta agonist.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	45-93	tachykinin precursor 1	Homo sapiens	95-98
33672651-6	2021	We treated cells with 17beta-estradiol (E2), 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole (PPT) an estrogen receptor (ER) alpha (ERalpha) agonist, or 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN), an ERbeta agonist.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	45-93	estrogen receptor 1	Homo sapiens	203-209
33547280-4	2021	Yeast growth assays, polysome profiling, total/hypusinated eIF5A levels and PPT-reporters studies reveal that the variants impair eIF5A function, reduce eIF5A-ribosome interactions and impair the synthesis of PPT-containing proteins.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	76-79	eukaryotic translation initiation factor 5A	Danio rerio	130-135
33547280-4	2021	Yeast growth assays, polysome profiling, total/hypusinated eIF5A levels and PPT-reporters studies reveal that the variants impair eIF5A function, reduce eIF5A-ribosome interactions and impair the synthesis of PPT-containing proteins.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	209-212	eukaryotic translation initiation factor 5A	Danio rerio	59-64
33547280-4	2021	Yeast growth assays, polysome profiling, total/hypusinated eIF5A levels and PPT-reporters studies reveal that the variants impair eIF5A function, reduce eIF5A-ribosome interactions and impair the synthesis of PPT-containing proteins.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	209-212	eukaryotic translation initiation factor 5A	Danio rerio	130-135
33547280-4	2021	Yeast growth assays, polysome profiling, total/hypusinated eIF5A levels and PPT-reporters studies reveal that the variants impair eIF5A function, reduce eIF5A-ribosome interactions and impair the synthesis of PPT-containing proteins.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	209-212	eukaryotic translation initiation factor 5A	Danio rerio	130-135
33230983-12	2020	The body weights were significantly lower, but, serum GH, pituitary GH1 expression levels, and BMDs were higher in PPT group than the other 2 groups after 5 weeks of injections.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	115-118	gonadotropin releasing hormone receptor	Rattus norvegicus	54-56
32648964-12	2021	17beta-E2 or PPT, but not DPN, increased IL-33 gene expression, release, and DUOX-1 production in hBE33 or NHBE cells.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	13-16	interleukin 33	Mus musculus	41-46
32648964-12	2021	17beta-E2 or PPT, but not DPN, increased IL-33 gene expression, release, and DUOX-1 production in hBE33 or NHBE cells.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	13-16	dual oxidase 1	Mus musculus	77-83
33230983-12	2020	The body weights were significantly lower, but, serum GH, pituitary GH1 expression levels, and BMDs were higher in PPT group than the other 2 groups after 5 weeks of injections.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	115-118	growth hormone 1	Rattus norvegicus	68-71
32516271-1	2020	Estrogen replacement therapy including specific estrogen receptor alpha (ERalpha) agonist, 4,4",4""-(4-propyl-[1H] pyrazole-1,3,5-triyl) trisphenol (PPT), improves cognitive function in the females with estrogen insufficiency condition.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	91-147	estrogen receptor 1	Rattus norvegicus	73-80
32516271-10	2020	Further, ovariectomy-induced decrease in the extent of phosphorylation of ERalpha in both the brain regions was attenuated with the monotherapy of either roflumilast or PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	169-172	estrogen receptor 1	Rattus norvegicus	74-81
32516271-12	2020	In addition, roflumilast facilitated PPT-induced increase in the level of expression of phosphorylated protein kinase-B (Akt) in both the rat brain regions.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	37-40	AKT serine/threonine kinase 1	Rattus norvegicus	121-124
32368827-8	2020	Oral administration of PPT significantly induced itch behavior and proinflammatory responses, including the levels of interleukin (IL)-17 and IL-22, whereas DPN treatment did not influence either pruritic or proinflammatory responses.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	23-26	interleukin 17A	Mus musculus	118-137
32368827-8	2020	Oral administration of PPT significantly induced itch behavior and proinflammatory responses, including the levels of interleukin (IL)-17 and IL-22, whereas DPN treatment did not influence either pruritic or proinflammatory responses.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	23-26	interleukin 22	Mus musculus	142-147
32825553-7	2020	The estrogen receptor-alpha (ER-alpha)-selective agonist 4,4",4""-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT, 10 nM) affected similarly to E2 in terms of the expression of EMT markers and cell migration, and the treatment with the ER-alpha antagonist methyl-piperidino-pyrazole (MPP, 1 muM) blocked E2 and PPT effects.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	57-112	estrogen receptor 1	Homo sapiens	4-27
32593544-2	2020	The specific estrogen receptor alpha (ERalpha) agonist, (4,4",4""-(4-propyl-[1 H] pyrazole-1,3,5-triyl) tris phenol (PPT), is reported to exhibit therapeutic activity similar to that of estrogen replacement therapy.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	56-115	estrogen receptor 1	Rattus norvegicus	38-45
32593544-2	2020	The specific estrogen receptor alpha (ERalpha) agonist, (4,4",4""-(4-propyl-[1 H] pyrazole-1,3,5-triyl) tris phenol (PPT), is reported to exhibit therapeutic activity similar to that of estrogen replacement therapy.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	117-120	estrogen receptor 1	Rattus norvegicus	38-45
32593544-10	2020	Further, ovariectomy-induced decrease in the extent of phosphorylation of ERalpha in all brain regions was attenuated with the monotherapy of either vinpocetine or PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	164-167	estrogen receptor 1	Rattus norvegicus	74-81
32593544-12	2020	However, vinpocetine attenuated the PPT-induced increased level of phosphorylated Akt in discrete brain regions and weight of uterus of these rodents.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	36-39	AKT serine/threonine kinase 1	Rattus norvegicus	82-85
32735801-7	2020	We demonstrate that estradiol benzoate and the ERbeta agonist (DPN) demasculinize male sexual behavior and decrease the density of VT-ir fibers in the medial preoptic nucleus and the bed nucleus of the stria terminalis, while PPT has no effect on these measures.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	226-229	estrogen receptor beta	Coturnix japonica	47-53
32825553-7	2020	The estrogen receptor-alpha (ER-alpha)-selective agonist 4,4",4""-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT, 10 nM) affected similarly to E2 in terms of the expression of EMT markers and cell migration, and the treatment with the ER-alpha antagonist methyl-piperidino-pyrazole (MPP, 1 muM) blocked E2 and PPT effects.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	315-318	estrogen receptor 1	Homo sapiens	29-37
32825553-7	2020	The estrogen receptor-alpha (ER-alpha)-selective agonist 4,4",4""-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT, 10 nM) affected similarly to E2 in terms of the expression of EMT markers and cell migration, and the treatment with the ER-alpha antagonist methyl-piperidino-pyrazole (MPP, 1 muM) blocked E2 and PPT effects.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	57-112	estrogen receptor 1	Homo sapiens	29-37
32825553-7	2020	The estrogen receptor-alpha (ER-alpha)-selective agonist 4,4",4""-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT, 10 nM) affected similarly to E2 in terms of the expression of EMT markers and cell migration, and the treatment with the ER-alpha antagonist methyl-piperidino-pyrazole (MPP, 1 muM) blocked E2 and PPT effects.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	114-117	estrogen receptor 1	Homo sapiens	4-27
32825553-7	2020	The estrogen receptor-alpha (ER-alpha)-selective agonist 4,4",4""-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT, 10 nM) affected similarly to E2 in terms of the expression of EMT markers and cell migration, and the treatment with the ER-alpha antagonist methyl-piperidino-pyrazole (MPP, 1 muM) blocked E2 and PPT effects.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	114-117	estrogen receptor 1	Homo sapiens	29-37
31711895-7	2020	Intra-medial preoptic injection of the ERalpha-agonist propylpyrazoletriol (PPT) increased wheel-running ~3.5-fold in WT rats, while injections of the ERbeta-agonist diarylpropionitrile (DPN) or a combination of the two agonists had no effect.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	55-74	estrogen receptor 1	Rattus norvegicus	39-46
32083755-3	2020	An NGF receptor inhibitor was injected intramuscularly to assess the relationship between PPT and NGF levels.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	90-93	nerve growth factor	Rattus norvegicus	98-101
32083755-5	2020	Injection of NGF receptor inhibitor reversed the decrease in PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	61-64	nerve growth factor	Rattus norvegicus	13-16
32407858-6	2020	Use of ERalpha agonist PPT rather than ERbeta agonist DPN enhanced AVPV-kisspepetin expression, which decreased after treatment with BPA.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	23-26	estrogen receptor 1 (alpha)	Mus musculus	7-14
32665986-8	2020	This effect was mimicked by ERalpha agonist PPT (1.63 +-0.27-fold; n = 7; p = 0.0489) and was abrogated by co-incubation with ERalpha antagonist MPP (1.17 +-0.18-fold; n = 3; p vs. control > 0.05).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	44-47	estrogen receptor 1	Homo sapiens	28-35
31711895-7	2020	Intra-medial preoptic injection of the ERalpha-agonist propylpyrazoletriol (PPT) increased wheel-running ~3.5-fold in WT rats, while injections of the ERbeta-agonist diarylpropionitrile (DPN) or a combination of the two agonists had no effect.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	76-79	estrogen receptor 1	Rattus norvegicus	39-46
31711895-8	2020	Similarly, ERalpha-agonism (PPT) increased Fos and Homer1 induction ~3-fold in WT and LVR isolated mPOA neurons, with no effect of the ERbeta-agonist DPN alone or in combination with PPT, suggesting medial-preoptic ERbeta activity may blunt ERalpha signaling.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	28-31	estrogen receptor 1	Rattus norvegicus	11-18
31711895-8	2020	Similarly, ERalpha-agonism (PPT) increased Fos and Homer1 induction ~3-fold in WT and LVR isolated mPOA neurons, with no effect of the ERbeta-agonist DPN alone or in combination with PPT, suggesting medial-preoptic ERbeta activity may blunt ERalpha signaling.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	28-31	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	43-46
31711895-8	2020	Similarly, ERalpha-agonism (PPT) increased Fos and Homer1 induction ~3-fold in WT and LVR isolated mPOA neurons, with no effect of the ERbeta-agonist DPN alone or in combination with PPT, suggesting medial-preoptic ERbeta activity may blunt ERalpha signaling.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	28-31	homer scaffold protein 1	Rattus norvegicus	51-57
31711895-8	2020	Similarly, ERalpha-agonism (PPT) increased Fos and Homer1 induction ~3-fold in WT and LVR isolated mPOA neurons, with no effect of the ERbeta-agonist DPN alone or in combination with PPT, suggesting medial-preoptic ERbeta activity may blunt ERalpha signaling.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	28-31	estrogen receptor 2	Rattus norvegicus	215-221
31711895-8	2020	Similarly, ERalpha-agonism (PPT) increased Fos and Homer1 induction ~3-fold in WT and LVR isolated mPOA neurons, with no effect of the ERbeta-agonist DPN alone or in combination with PPT, suggesting medial-preoptic ERbeta activity may blunt ERalpha signaling.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	28-31	estrogen receptor 1	Rattus norvegicus	241-248
30958885-13	2019	CONCLUSIONS: Our findings show that patients with CH have lower PPT levels at cranial and extracranial points, suggesting, as in other primary headaches, the presence of CS.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	64-67	citrate synthase	Homo sapiens	170-172
32150359-0	2019	The estrogen receptor alpha-selective agonist propyl pyrazole triol improves glucose tolerance in ob/ob mice: potential molecular mechanisms The authors and journal apologise for an error in the above paper, which appeared in volume 199 part 2, pages 275-286.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	46-67	estrogen receptor 1 (alpha)	Mus musculus	4-27
31560517-5	2019	The thiocholine generated from acetylcholinesterase (AChE)-induced catalyzed hydrolysis of acetylthiocholine (ATCh) efficiently directed CdS QDs away from PPT/ITO via electrostatic repulsion, subsequently decreasing PEC current, whereas chlorpyrifos prohibited the generation of thiocholine through inhibiting AChE activity.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	155-158	acetylcholinesterase (Cartwright blood group)	Homo sapiens	31-51
31560517-5	2019	The thiocholine generated from acetylcholinesterase (AChE)-induced catalyzed hydrolysis of acetylthiocholine (ATCh) efficiently directed CdS QDs away from PPT/ITO via electrostatic repulsion, subsequently decreasing PEC current, whereas chlorpyrifos prohibited the generation of thiocholine through inhibiting AChE activity.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	155-158	acetylcholinesterase (Cartwright blood group)	Homo sapiens	53-57
31560517-5	2019	The thiocholine generated from acetylcholinesterase (AChE)-induced catalyzed hydrolysis of acetylthiocholine (ATCh) efficiently directed CdS QDs away from PPT/ITO via electrostatic repulsion, subsequently decreasing PEC current, whereas chlorpyrifos prohibited the generation of thiocholine through inhibiting AChE activity.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	155-158	acetylcholinesterase (Cartwright blood group)	Homo sapiens	310-314
31368122-1	2019	Notoginsenoside R1 (NGR1 ), a diagnostic protopanaxatriol-type (ppt-type) saponin in Panax notoginseng, possesses potent biological activities including antithrombotic, anti-inflammatory, neuron protection and improvement of microcirculation, yet its pharmacokinetics and metabolic characterization as an individual compound remain unclear.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	64-67	reticulon 4 receptor	Rattus norvegicus	20-24
30986550-4	2019	The detailed structure-activity relationship (SAR) of PPT and PTP derivatives suggested that the compound with unsubstituted phenyl ring from PPT series led to selective and potent inhibition (6a; IC50 = 0.33 +- 0.02 microM) of h-TNAP, whereas compound 6c selectively inhibited h-IAP isozyme with IC50 value of 0.86 +- 0.04 microM.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	54-57	TNAP	Homo sapiens	230-234
31055232-7	2019	Moreover, treatment with propylpyrazoletriol and diarylpropionitrile, two ERalpha and ERbeta selective agonists, respectively, inhibited both edema and neutrophil recruitment.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	25-44	estrogen receptor 1 (alpha)	Mus musculus	74-81
31055232-7	2019	Moreover, treatment with propylpyrazoletriol and diarylpropionitrile, two ERalpha and ERbeta selective agonists, respectively, inhibited both edema and neutrophil recruitment.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	25-44	estrogen receptor 1 (alpha)	Mus musculus	86-92
30548340-0	2019	Astrocyte-targeted IL-10 production decreases proliferation and induces a downregulation of activated microglia/macrophages after PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	130-133	interleukin 10	Mus musculus	19-24
31126577-8	2019	The ETA2 value was larger than 0.100 in the Schober"s and FDD tests, larger than 0.200 in the case of ODI and PPT, and larger than 0.300 for VAS.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	110-113	DNA polymerase iota	Homo sapiens	4-8
30400032-6	2019	In addition, the Dhhc7 and Dhhc21 palmitoylases were negatively regulated after sustained stimulation of E2 for 3 h. Although the uptake of BrdU into the nucleus in normal pituitary cells was not modified by E2, a significant increase in the GH3 tumoural cell, as well as ERK1/2 activation, with this effect being mimicked by PPT, a selective antagonist of ERalpha.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	326-329	zinc finger DHHC-type palmitoyltransferase 7	Rattus norvegicus	17-22
29374955-5	2018	The suppressive effects of genistein and PPT wereinhibited by an additional treatment with ICI182780 (a nonselective ER antagonist) or 1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride (MPP,a selective ERalpha antagonist).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	41-44	estrogen receptor 1	Rattus norvegicus	248-255
30445053-4	2019	We performed an in vivo experiment using an animal model of allergic airway inflammation using male BALB/c mice to confirm an increase in the proinflammatory response induced by propylpyrazoletriol (PPT), an ERalpha agonist, and diarylpropionitrile (DPN), an ERbeta agonist.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	178-197	estrogen receptor 1 (alpha)	Mus musculus	208-215
30445053-4	2019	We performed an in vivo experiment using an animal model of allergic airway inflammation using male BALB/c mice to confirm an increase in the proinflammatory response induced by propylpyrazoletriol (PPT), an ERalpha agonist, and diarylpropionitrile (DPN), an ERbeta agonist.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	178-197	estrogen receptor 2 (beta)	Mus musculus	259-265
30445053-4	2019	We performed an in vivo experiment using an animal model of allergic airway inflammation using male BALB/c mice to confirm an increase in the proinflammatory response induced by propylpyrazoletriol (PPT), an ERalpha agonist, and diarylpropionitrile (DPN), an ERbeta agonist.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	199-202	estrogen receptor 2 (beta)	Mus musculus	259-265
30445053-9	2019	The IL-33 levels in BEAS-2B cells increased significantly after exposure to PPT or DPN.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	76-79	interleukin 33	Homo sapiens	4-9
30017638-8	2018	Levels of cytokines expressed by keratinocytes, such as TSLP and IL-33, were particularly increased by exposure to E2, MXC, or PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	127-130	thymic stromal lymphopoietin	Mus musculus	56-60
30017638-8	2018	Levels of cytokines expressed by keratinocytes, such as TSLP and IL-33, were particularly increased by exposure to E2, MXC, or PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	127-130	interleukin 33	Mus musculus	65-70
30588901-8	2019	However, compared with the pre-exercise ingestion of whey protein, that of alpha-lactalbumin led to superior results during similar levels of endurance exercise: it elevated PPT and reduced the feeling of fatigue and the cortisol levels.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	174-177	lactalbumin alpha	Homo sapiens	75-92
30445053-10	2019	In addition, pretreatment with PPT or DPN increased the expression of IL-8 in activated EoL-1 cells.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	31-34	C-X-C motif chemokine ligand 8	Homo sapiens	70-74
29468740-8	2018	In addition, the expression levels of Egr-1, c-Jun, and cAMP responsive element binding in the hippocampus were significantly elevated by PPT administration.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	138-141	early growth response 1	Mus musculus	38-43
29468740-8	2018	In addition, the expression levels of Egr-1, c-Jun, and cAMP responsive element binding in the hippocampus were significantly elevated by PPT administration.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	138-141	jun proto-oncogene	Mus musculus	45-50
29281118-7	2018	Animal studies showed that ERalpha selective agonist 4,4",4""-(4-propyl-[1H]-pyrazole-1,3,5-triyl) trisphenol (PPT) was able to replicate the therapeutic effects of E2 in treating osteoporotic OVX mice.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	53-109	estrogen receptor 1 (alpha)	Mus musculus	27-34
29281118-7	2018	Animal studies showed that ERalpha selective agonist 4,4",4""-(4-propyl-[1H]-pyrazole-1,3,5-triyl) trisphenol (PPT) was able to replicate the therapeutic effects of E2 in treating osteoporotic OVX mice.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	111-114	estrogen receptor 1 (alpha)	Mus musculus	27-34
27517478-7	2016	In SHR, PPT had no effect on blood pressure, decreased astrogliosis, slightly increased BDNF mRNA, had no effect on the number of DCX+ progenitors, and increased aromatase staining.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	8-11	brain-derived neurotrophic factor	Rattus norvegicus	88-92
28266530-6	2017	In PLCs, 17beta-estradiol and the ESR1-selective agonist propylpyrazoletriol suppressed human chorionic gonadotropin (hCG)-induced progesterone production and steroidogenic gene expression.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	57-76	estrogen receptor 1	Homo sapiens	34-38
28266530-6	2017	In PLCs, 17beta-estradiol and the ESR1-selective agonist propylpyrazoletriol suppressed human chorionic gonadotropin (hCG)-induced progesterone production and steroidogenic gene expression.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	57-76	hypertrichosis 2 (generalised, congenital)	Homo sapiens	118-121
28266530-10	2017	In cultured PLCs, 17beta-estradiol, propylpyrazoletriol, and diarylpropionitrile reduced hCG-stimulated Ki67 and Pcna mRNA expression and the number of KI67-positive PLCs, suggesting that oestrogen inhibits PLC proliferation via both ESR1 and ESR2.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	36-55	hypertrichosis 2 (generalised, congenital)	Homo sapiens	89-92
28266530-10	2017	In cultured PLCs, 17beta-estradiol, propylpyrazoletriol, and diarylpropionitrile reduced hCG-stimulated Ki67 and Pcna mRNA expression and the number of KI67-positive PLCs, suggesting that oestrogen inhibits PLC proliferation via both ESR1 and ESR2.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	36-55	antigen identified by monoclonal antibody Ki 67	Mus musculus	104-108
28266530-10	2017	In cultured PLCs, 17beta-estradiol, propylpyrazoletriol, and diarylpropionitrile reduced hCG-stimulated Ki67 and Pcna mRNA expression and the number of KI67-positive PLCs, suggesting that oestrogen inhibits PLC proliferation via both ESR1 and ESR2.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	36-55	proliferating cell nuclear antigen	Mus musculus	113-117
28266530-10	2017	In cultured PLCs, 17beta-estradiol, propylpyrazoletriol, and diarylpropionitrile reduced hCG-stimulated Ki67 and Pcna mRNA expression and the number of KI67-positive PLCs, suggesting that oestrogen inhibits PLC proliferation via both ESR1 and ESR2.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	36-55	antigen identified by monoclonal antibody Ki 67	Mus musculus	152-156
28266530-10	2017	In cultured PLCs, 17beta-estradiol, propylpyrazoletriol, and diarylpropionitrile reduced hCG-stimulated Ki67 and Pcna mRNA expression and the number of KI67-positive PLCs, suggesting that oestrogen inhibits PLC proliferation via both ESR1 and ESR2.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	36-55	estrogen receptor 1 (alpha)	Mus musculus	234-238
28266530-10	2017	In cultured PLCs, 17beta-estradiol, propylpyrazoletriol, and diarylpropionitrile reduced hCG-stimulated Ki67 and Pcna mRNA expression and the number of KI67-positive PLCs, suggesting that oestrogen inhibits PLC proliferation via both ESR1 and ESR2.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	36-55	estrogen receptor 2 (beta)	Mus musculus	243-247
27999091-8	2017	Growth plate height and hypertrophic zone height were reduced in animals treated with E2 or PPT but not in those treated with DPN, supporting that the effect was mediated via ERalpha.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	92-95	estrogen receptor 1 (alpha)	Mus musculus	175-182
27999091-9	2017	Moreover, PCNA staining revealed suppressed proliferation of chondrocytes in the tibia growth plate in PPT- or E2-treated mice compared to controls.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	103-106	proliferating cell nuclear antigen	Mus musculus	10-14
27498200-5	2016	The ER subtype-selective ERalpha agonists propylpyrazole triole (PPT) and ERbeta agonist diarylpropionitrile (DPN) both increase the expression of Cav1.2 in a dose-dependent manner.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	65-68	estrogen receptor 1	Rattus norvegicus	25-32
29550797-9	2017	The increased MPO levels were inhibited with PPT in male pancreas and female lung and with 17beta-estradiol in female pancreas (P &lt; 0.05).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	45-48	myeloperoxidase	Rattus norvegicus	14-17
28959190-8	2017	These results, for the first time, suggest that the positive interaction between ERK1/2 and BDNF in the PPT is a casual factor for the development of RSHD.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	104-107	mitogen activated protein kinase 3	Rattus norvegicus	81-87
28959190-8	2017	These results, for the first time, suggest that the positive interaction between ERK1/2 and BDNF in the PPT is a casual factor for the development of RSHD.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	104-107	brain-derived neurotrophic factor	Rattus norvegicus	92-96
28602280-7	2017	The simulation plot of LOD with respect to K1 and alphaK2 showed that a K1 one order of magnitude lower than alphaK2 produced a ppt level LOD.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	128-131	keratin 1	Homo sapiens	43-57
28111785-6	2017	RESULTS: Within 1 year of data collection, 96 cases with a PPT for MCI/MI, MCI/MI and MI, and MI alone were identified; 37 of these were positive to MCI/MI, with MI alone not tested or negative, and 39 were positive to MI only, with MCI/MI and MI tested.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	59-62	multiciliate differentiation and DNA synthesis associated cell cycle protein	Homo sapiens	67-73
27363479-2	2016	We constructed the pPT-GI vector to express prepeptide glargine insulin when transformed into Escherichia coli JM109.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	19-22	insulin	Homo sapiens	64-71
27512003-3	2016	In the first experiment, ovariectomized 4-month-old rats were pre-treated subcutaneously with 17beta-estradiol (3 x 20 mug), the ESR1 (ERalpha) agonist propyl pyrazole triol (PPT) (3 x 5 mg), and the ESR2 (ERbeta) agonist diarylpropionitrile (DPN) (3 x 0.5 mg).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	152-173	estrogen receptor 1	Rattus norvegicus	129-133
27582063-5	2016	Selective ERalpha activation with 4,4",4""-(4-Propyl-[1H]-pyrazole-1,3,5-triyl) (PPT), prevented weight gain, improved insulin action, and reduced visceral fat accumulation in WHFD-fed OVX mice.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	81-84	estrogen receptor 1 (alpha)	Mus musculus	10-17
27582063-5	2016	Selective ERalpha activation with 4,4",4""-(4-Propyl-[1H]-pyrazole-1,3,5-triyl) (PPT), prevented weight gain, improved insulin action, and reduced visceral fat accumulation in WHFD-fed OVX mice.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	81-84	insulin	Homo sapiens	119-126
27582063-6	2016	PPT treatment also elevated systemic metabolism, increasing oxygen consumption and core body temperature, induced expression of several metabolic genes such as peroxisome proliferator-activated receptor gamma, coactivator 1 alpha, and nuclear respiratory factor 1 in heart, liver, skeletal muscle, and adipose tissue, and increased cardiac mitochondrial function.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	160-229
27582063-6	2016	PPT treatment also elevated systemic metabolism, increasing oxygen consumption and core body temperature, induced expression of several metabolic genes such as peroxisome proliferator-activated receptor gamma, coactivator 1 alpha, and nuclear respiratory factor 1 in heart, liver, skeletal muscle, and adipose tissue, and increased cardiac mitochondrial function.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	nuclear respiratory factor 1	Mus musculus	235-263
27582063-7	2016	Taken together, selective activation of ERalpha with PPT enhances metabolic effects including insulin resistance, whole body energy metabolism, and mitochondrial function in OVX mice with metabolic syndrome.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	53-56	estrogen receptor 1 (alpha)	Mus musculus	40-47
27582063-7	2016	Taken together, selective activation of ERalpha with PPT enhances metabolic effects including insulin resistance, whole body energy metabolism, and mitochondrial function in OVX mice with metabolic syndrome.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	53-56	insulin	Homo sapiens	94-101
26878683-8	2016	This effect was was mimicked by ERalpha agonist 4",4"",4"""-(4-propyl-[1H]-pyrazole-1,3,5-triyl) trisphenol (PPT), but not ERbeta agonist 2,3-bis-(4-hydroxyphenyl)-propionitrile (DPN), indicating that ERalpha is involved in this action.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	48-107	estrogen receptor 1	Homo sapiens	32-39
26878683-8	2016	This effect was was mimicked by ERalpha agonist 4",4"",4"""-(4-propyl-[1H]-pyrazole-1,3,5-triyl) trisphenol (PPT), but not ERbeta agonist 2,3-bis-(4-hydroxyphenyl)-propionitrile (DPN), indicating that ERalpha is involved in this action.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	48-107	estrogen receptor 1	Homo sapiens	201-208
26878683-8	2016	This effect was was mimicked by ERalpha agonist 4",4"",4"""-(4-propyl-[1H]-pyrazole-1,3,5-triyl) trisphenol (PPT), but not ERbeta agonist 2,3-bis-(4-hydroxyphenyl)-propionitrile (DPN), indicating that ERalpha is involved in this action.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	109-112	estrogen receptor 1	Homo sapiens	32-39
26878683-8	2016	This effect was was mimicked by ERalpha agonist 4",4"",4"""-(4-propyl-[1H]-pyrazole-1,3,5-triyl) trisphenol (PPT), but not ERbeta agonist 2,3-bis-(4-hydroxyphenyl)-propionitrile (DPN), indicating that ERalpha is involved in this action.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	109-112	estrogen receptor 2	Homo sapiens	123-129
26878683-8	2016	This effect was was mimicked by ERalpha agonist 4",4"",4"""-(4-propyl-[1H]-pyrazole-1,3,5-triyl) trisphenol (PPT), but not ERbeta agonist 2,3-bis-(4-hydroxyphenyl)-propionitrile (DPN), indicating that ERalpha is involved in this action.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	109-112	estrogen receptor 1	Homo sapiens	201-208
27512003-3	2016	In the first experiment, ovariectomized 4-month-old rats were pre-treated subcutaneously with 17beta-estradiol (3 x 20 mug), the ESR1 (ERalpha) agonist propyl pyrazole triol (PPT) (3 x 5 mg), and the ESR2 (ERbeta) agonist diarylpropionitrile (DPN) (3 x 0.5 mg).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	152-173	estrogen receptor 1	Rattus norvegicus	135-142
26398594-8	2016	The a-EIMS improved the pain reported on VAS, the PPT, and the score of the NPS (0-10) during the CPM-task The BDNF was negatively correlated with the PPT (r = -0.56).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	151-154	brain derived neurotrophic factor	Homo sapiens	111-115
26398594-9	2016	CONCLUSIONS: The serum BDNF revealed an inverse relationship with PPT independent of the treatment group.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	66-69	brain derived neurotrophic factor	Homo sapiens	23-27
25535091-6	2016	After the combination treatment of these two drugs (PPT + LiCl), the improved learning and memory abilities of ovariectomized rats in Morris water maze, increased dendritic spines in CA1 region, and decreased tau phosphorylation at Ser-396 in hippocampus were observed.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	52-55	carbonic anhydrase 1	Rattus norvegicus	183-186
25535091-7	2016	Furthermore, PPT + LiCl treatment significantly increased ERalpha level in the nuclear fraction of hippocampus, and in the cytoplasmic fraction, the total level of GSK-3beta was declined after treatment with its increased phosphorylation at Ser-9 (inactivation form).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	13-16	estrogen receptor 1	Rattus norvegicus	58-65
25535091-7	2016	Furthermore, PPT + LiCl treatment significantly increased ERalpha level in the nuclear fraction of hippocampus, and in the cytoplasmic fraction, the total level of GSK-3beta was declined after treatment with its increased phosphorylation at Ser-9 (inactivation form).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	13-16	glycogen synthase kinase 3 beta	Rattus norvegicus	164-173
25535091-8	2016	This study suggested that PPT + LiCl treatment could inhibit the activation of cytoplasmic GSK-3beta and promote the nuclear translocation of ERalpha, and ERalpha together with GSK-3beta maybe the targets to preserve hippocampus-dependent cognitive ability after long-term ovariectomy.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	26-29	glycogen synthase kinase 3 beta	Rattus norvegicus	91-100
25535091-8	2016	This study suggested that PPT + LiCl treatment could inhibit the activation of cytoplasmic GSK-3beta and promote the nuclear translocation of ERalpha, and ERalpha together with GSK-3beta maybe the targets to preserve hippocampus-dependent cognitive ability after long-term ovariectomy.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	26-29	estrogen receptor 1	Rattus norvegicus	142-149
25535091-8	2016	This study suggested that PPT + LiCl treatment could inhibit the activation of cytoplasmic GSK-3beta and promote the nuclear translocation of ERalpha, and ERalpha together with GSK-3beta maybe the targets to preserve hippocampus-dependent cognitive ability after long-term ovariectomy.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	26-29	estrogen receptor 1	Rattus norvegicus	155-162
25535091-8	2016	This study suggested that PPT + LiCl treatment could inhibit the activation of cytoplasmic GSK-3beta and promote the nuclear translocation of ERalpha, and ERalpha together with GSK-3beta maybe the targets to preserve hippocampus-dependent cognitive ability after long-term ovariectomy.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	26-29	glycogen synthase kinase 3 beta	Rattus norvegicus	177-186
26375425-5	2015	Moreover, we showed that propyl pyrazole triol (an ERalpha agonist) stimulates the phosphatidyl inositol 3-kinase (PI3K) pathway specifically in POMC progenitor neurons, and that blockade of PI3K attenuates propyl pyrazole triol-induced activation of POMC neurons.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	25-46	estrogen receptor 1 (alpha)	Mus musculus	51-58
25980457-6	2015	We confirmed that the ERalpha and ERbeta selective agonists (PPT and DPN) had effects on synaptic responses specific to animals that expressed the relevant receptor; however, PPT and DPN produced only a small increase in synaptic transmission relative to EB or the GPER1 agonist.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	61-64	estrogen receptor 1 (alpha)	Mus musculus	22-29
25980457-6	2015	We confirmed that the ERalpha and ERbeta selective agonists (PPT and DPN) had effects on synaptic responses specific to animals that expressed the relevant receptor; however, PPT and DPN produced only a small increase in synaptic transmission relative to EB or the GPER1 agonist.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	61-64	estrogen receptor 2 (beta)	Mus musculus	34-40
25980457-6	2015	We confirmed that the ERalpha and ERbeta selective agonists (PPT and DPN) had effects on synaptic responses specific to animals that expressed the relevant receptor; however, PPT and DPN produced only a small increase in synaptic transmission relative to EB or the GPER1 agonist.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	61-64	G protein-coupled estrogen receptor 1	Mus musculus	265-270
25980457-6	2015	We confirmed that the ERalpha and ERbeta selective agonists (PPT and DPN) had effects on synaptic responses specific to animals that expressed the relevant receptor; however, PPT and DPN produced only a small increase in synaptic transmission relative to EB or the GPER1 agonist.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	175-178	estrogen receptor 1 (alpha)	Mus musculus	22-29
26375425-5	2015	Moreover, we showed that propyl pyrazole triol (an ERalpha agonist) stimulates the phosphatidyl inositol 3-kinase (PI3K) pathway specifically in POMC progenitor neurons, and that blockade of PI3K attenuates propyl pyrazole triol-induced activation of POMC neurons.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	25-46	pro-opiomelanocortin-alpha	Mus musculus	145-149
26375425-5	2015	Moreover, we showed that propyl pyrazole triol (an ERalpha agonist) stimulates the phosphatidyl inositol 3-kinase (PI3K) pathway specifically in POMC progenitor neurons, and that blockade of PI3K attenuates propyl pyrazole triol-induced activation of POMC neurons.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	25-46	pro-opiomelanocortin-alpha	Mus musculus	251-255
26375425-5	2015	Moreover, we showed that propyl pyrazole triol (an ERalpha agonist) stimulates the phosphatidyl inositol 3-kinase (PI3K) pathway specifically in POMC progenitor neurons, and that blockade of PI3K attenuates propyl pyrazole triol-induced activation of POMC neurons.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	207-228	estrogen receptor 1 (alpha)	Mus musculus	51-58
26206299-7	2015	Treatment of OE cultures with propyl pyrazole triol (PPT), a selective agonist for ERalpha increased neurite outgrowth to comparable extent as estradiol treatment.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	30-51	estrogen receptor 1 (alpha)	Mus musculus	83-90
26206299-7	2015	Treatment of OE cultures with propyl pyrazole triol (PPT), a selective agonist for ERalpha increased neurite outgrowth to comparable extent as estradiol treatment.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	53-56	estrogen receptor 1 (alpha)	Mus musculus	83-90
26199549-4	2015	Especially, in activated bone marrow-derived mast cells, PPT inhibited the expression of Syk protein, cytokine mRNA, cyclooxygenase-1/2, and phospholipase A2 (PLA2), as well as the activities of various protein kinase C isoforms, mitogen-activated protein kinases, PLA2, and transcription factors (nuclear factor-kappaB and activator protein-1).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	57-60	spleen tyrosine kinase	Mus musculus	89-92
25808188-5	2015	RESULTS: Static and dynamic VAS score, PPT and ROM were significantly improved in the MTrP group compared with those in the non-MTrP and effleurage groups.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	39-42	lysosomal protein transmembrane 4 alpha	Homo sapiens	86-90
25892506-6	2015	ERalpha activation by its agonist 4,4",4""-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) protected dopamine neurons, an effect associated with activation of striatal Akt signaling and an increase in Bcl-2 and BDNF levels; the GPER1 antagonist G15 inhibited the decrease in glycogen synthase kinase 3beta activity and the increase in BDNF induced by PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	34-89	estrogen receptor 1 (alpha)	Mus musculus	0-7
25892506-6	2015	ERalpha activation by its agonist 4,4",4""-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) protected dopamine neurons, an effect associated with activation of striatal Akt signaling and an increase in Bcl-2 and BDNF levels; the GPER1 antagonist G15 inhibited the decrease in glycogen synthase kinase 3beta activity and the increase in BDNF induced by PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	34-89	B cell leukemia/lymphoma 2	Mus musculus	206-211
25892506-6	2015	ERalpha activation by its agonist 4,4",4""-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) protected dopamine neurons, an effect associated with activation of striatal Akt signaling and an increase in Bcl-2 and BDNF levels; the GPER1 antagonist G15 inhibited the decrease in glycogen synthase kinase 3beta activity and the increase in BDNF induced by PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	34-89	brain derived neurotrophic factor	Mus musculus	216-220
25892506-6	2015	ERalpha activation by its agonist 4,4",4""-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) protected dopamine neurons, an effect associated with activation of striatal Akt signaling and an increase in Bcl-2 and BDNF levels; the GPER1 antagonist G15 inhibited the decrease in glycogen synthase kinase 3beta activity and the increase in BDNF induced by PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	34-89	G protein-coupled estrogen receptor 1	Mus musculus	233-238
25892506-6	2015	ERalpha activation by its agonist 4,4",4""-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) protected dopamine neurons, an effect associated with activation of striatal Akt signaling and an increase in Bcl-2 and BDNF levels; the GPER1 antagonist G15 inhibited the decrease in glycogen synthase kinase 3beta activity and the increase in BDNF induced by PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	34-89	glycogen synthase kinase 3 beta	Mus musculus	280-310
25892506-6	2015	ERalpha activation by its agonist 4,4",4""-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) protected dopamine neurons, an effect associated with activation of striatal Akt signaling and an increase in Bcl-2 and BDNF levels; the GPER1 antagonist G15 inhibited the decrease in glycogen synthase kinase 3beta activity and the increase in BDNF induced by PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	34-89	brain derived neurotrophic factor	Mus musculus	340-344
25892506-6	2015	ERalpha activation by its agonist 4,4",4""-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) protected dopamine neurons, an effect associated with activation of striatal Akt signaling and an increase in Bcl-2 and BDNF levels; the GPER1 antagonist G15 inhibited the decrease in glycogen synthase kinase 3beta activity and the increase in BDNF induced by PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	91-94	estrogen receptor 1 (alpha)	Mus musculus	0-7
25892506-6	2015	ERalpha activation by its agonist 4,4",4""-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) protected dopamine neurons, an effect associated with activation of striatal Akt signaling and an increase in Bcl-2 and BDNF levels; the GPER1 antagonist G15 inhibited the decrease in glycogen synthase kinase 3beta activity and the increase in BDNF induced by PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	91-94	B cell leukemia/lymphoma 2	Mus musculus	206-211
25892506-6	2015	ERalpha activation by its agonist 4,4",4""-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) protected dopamine neurons, an effect associated with activation of striatal Akt signaling and an increase in Bcl-2 and BDNF levels; the GPER1 antagonist G15 inhibited the decrease in glycogen synthase kinase 3beta activity and the increase in BDNF induced by PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	91-94	brain derived neurotrophic factor	Mus musculus	216-220
25892506-6	2015	ERalpha activation by its agonist 4,4",4""-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) protected dopamine neurons, an effect associated with activation of striatal Akt signaling and an increase in Bcl-2 and BDNF levels; the GPER1 antagonist G15 inhibited the decrease in glycogen synthase kinase 3beta activity and the increase in BDNF induced by PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	91-94	G protein-coupled estrogen receptor 1	Mus musculus	233-238
25892506-6	2015	ERalpha activation by its agonist 4,4",4""-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) protected dopamine neurons, an effect associated with activation of striatal Akt signaling and an increase in Bcl-2 and BDNF levels; the GPER1 antagonist G15 inhibited the decrease in glycogen synthase kinase 3beta activity and the increase in BDNF induced by PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	91-94	glycogen synthase kinase 3 beta	Mus musculus	280-310
25892506-6	2015	ERalpha activation by its agonist 4,4",4""-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) protected dopamine neurons, an effect associated with activation of striatal Akt signaling and an increase in Bcl-2 and BDNF levels; the GPER1 antagonist G15 inhibited the decrease in glycogen synthase kinase 3beta activity and the increase in BDNF induced by PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	91-94	brain derived neurotrophic factor	Mus musculus	340-344
25892506-6	2015	ERalpha activation by its agonist 4,4",4""-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) protected dopamine neurons, an effect associated with activation of striatal Akt signaling and an increase in Bcl-2 and BDNF levels; the GPER1 antagonist G15 inhibited the decrease in glycogen synthase kinase 3beta activity and the increase in BDNF induced by PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	356-359	estrogen receptor 1 (alpha)	Mus musculus	0-7
26183823-10	2015	Moreover, expression of ACOX2-i9 was shown to be estrogen regulated, being induced by propyl pyrazoletriol and inhibited by tamoxifen and fulvestrant in ER+ T47D and Mcf-7 cells, but not in the ER- MDA-MB 436 cell line.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	86-106	acyl-CoA oxidase 2	Homo sapiens	24-32
25730107-7	2015	The ERalpha agonist, 1,3,5-Tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole, produced similar increases in expression, indicating that these events were mediated by ERalpha.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	21-69	estrogen receptor 1 (alpha)	Mus musculus	4-11
25730107-7	2015	The ERalpha agonist, 1,3,5-Tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole, produced similar increases in expression, indicating that these events were mediated by ERalpha.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	21-69	estrogen receptor 1 (alpha)	Mus musculus	159-166
26069273-4	2015	We investigated the effect of E2 and the ESR1-selective agonist (4,4",4""-(4-propyl-(1H)-pyrazole-1,3,5-triyl)trisphenol (PPT) on the activation of extracellular signal-regulated protein kinases (ERK1/2), CREB protein, and ETS oncogene-related protein (ELK1).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	65-120	estrogen receptor 1	Homo sapiens	41-45
26069273-4	2015	We investigated the effect of E2 and the ESR1-selective agonist (4,4",4""-(4-propyl-(1H)-pyrazole-1,3,5-triyl)trisphenol (PPT) on the activation of extracellular signal-regulated protein kinases (ERK1/2), CREB protein, and ETS oncogene-related protein (ELK1).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	65-120	mitogen-activated protein kinase 3	Homo sapiens	196-202
26069273-4	2015	We investigated the effect of E2 and the ESR1-selective agonist (4,4",4""-(4-propyl-(1H)-pyrazole-1,3,5-triyl)trisphenol (PPT) on the activation of extracellular signal-regulated protein kinases (ERK1/2), CREB protein, and ETS oncogene-related protein (ELK1).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	65-120	cAMP responsive element binding protein 1	Homo sapiens	205-209
26069273-5	2015	Treatment with PPT did not affect ERK1/2 phosphorylation in the cauda, but it rapidly increased ERK1/2 phosphorylation in the initial segment/caput and corpus of the epididymis.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	15-18	mitogen-activated protein kinase 3	Homo sapiens	96-102
26069273-6	2015	PPT also activated CREB and ELK1 in the corpus of the epididymis.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	cAMP responsive element binding protein 1	Homo sapiens	19-23
26069273-6	2015	PPT also activated CREB and ELK1 in the corpus of the epididymis.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	ETS transcription factor ELK1	Homo sapiens	28-32
26069273-7	2015	The PPT-induced phosphorylation of ERK1/2, CREB, and ELK1 was blocked by the ESR1-selective antagonist MPP and by pretreatment with a non-receptor tyrosine kinase SRC inhibitor, an EGFR kinase inhibitor, an MEK1/2 inhibitor, and a phosphatidylinositol-3-kinase inhibitor.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	4-7	mitogen-activated protein kinase 3	Homo sapiens	35-41
26069273-7	2015	The PPT-induced phosphorylation of ERK1/2, CREB, and ELK1 was blocked by the ESR1-selective antagonist MPP and by pretreatment with a non-receptor tyrosine kinase SRC inhibitor, an EGFR kinase inhibitor, an MEK1/2 inhibitor, and a phosphatidylinositol-3-kinase inhibitor.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	4-7	cAMP responsive element binding protein 1	Homo sapiens	43-47
26069273-7	2015	The PPT-induced phosphorylation of ERK1/2, CREB, and ELK1 was blocked by the ESR1-selective antagonist MPP and by pretreatment with a non-receptor tyrosine kinase SRC inhibitor, an EGFR kinase inhibitor, an MEK1/2 inhibitor, and a phosphatidylinositol-3-kinase inhibitor.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	4-7	ETS transcription factor ELK1	Homo sapiens	53-57
26069273-7	2015	The PPT-induced phosphorylation of ERK1/2, CREB, and ELK1 was blocked by the ESR1-selective antagonist MPP and by pretreatment with a non-receptor tyrosine kinase SRC inhibitor, an EGFR kinase inhibitor, an MEK1/2 inhibitor, and a phosphatidylinositol-3-kinase inhibitor.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	4-7	estrogen receptor 1	Homo sapiens	77-81
26069273-7	2015	The PPT-induced phosphorylation of ERK1/2, CREB, and ELK1 was blocked by the ESR1-selective antagonist MPP and by pretreatment with a non-receptor tyrosine kinase SRC inhibitor, an EGFR kinase inhibitor, an MEK1/2 inhibitor, and a phosphatidylinositol-3-kinase inhibitor.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	4-7	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	163-166
26069273-7	2015	The PPT-induced phosphorylation of ERK1/2, CREB, and ELK1 was blocked by the ESR1-selective antagonist MPP and by pretreatment with a non-receptor tyrosine kinase SRC inhibitor, an EGFR kinase inhibitor, an MEK1/2 inhibitor, and a phosphatidylinositol-3-kinase inhibitor.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	4-7	epidermal growth factor receptor	Homo sapiens	181-185
26069273-7	2015	The PPT-induced phosphorylation of ERK1/2, CREB, and ELK1 was blocked by the ESR1-selective antagonist MPP and by pretreatment with a non-receptor tyrosine kinase SRC inhibitor, an EGFR kinase inhibitor, an MEK1/2 inhibitor, and a phosphatidylinositol-3-kinase inhibitor.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	4-7	mitogen-activated protein kinase kinase 1	Homo sapiens	207-213
26019323-9	2015	Treatment with an intra-NAc injection of the ESR1 agonist propyl pyrazole triol (10 nm) or the CDK5 inhibitor roscovitine (28 mum) on day 30 of withdrawal significantly decreased cue-induced cocaine seeking.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	58-79	estrogen receptor 1	Rattus norvegicus	45-49
26146031-10	2015	These results, for the first time, suggest that selective RSD-induced increased expression of BDNF in the PPT and SubCD are determinant factors in the development of the homeostatic drive for REM sleep.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	106-109	brain-derived neurotrophic factor	Rattus norvegicus	94-98
26199549-4	2015	Especially, in activated bone marrow-derived mast cells, PPT inhibited the expression of Syk protein, cytokine mRNA, cyclooxygenase-1/2, and phospholipase A2 (PLA2), as well as the activities of various protein kinase C isoforms, mitogen-activated protein kinases, PLA2, and transcription factors (nuclear factor-kappaB and activator protein-1).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	57-60	prostaglandin-endoperoxide synthase 1	Mus musculus	117-135
26199549-4	2015	Especially, in activated bone marrow-derived mast cells, PPT inhibited the expression of Syk protein, cytokine mRNA, cyclooxygenase-1/2, and phospholipase A2 (PLA2), as well as the activities of various protein kinase C isoforms, mitogen-activated protein kinases, PLA2, and transcription factors (nuclear factor-kappaB and activator protein-1).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	57-60	phospholipase A2, group IB, pancreas	Mus musculus	141-157
26199549-4	2015	Especially, in activated bone marrow-derived mast cells, PPT inhibited the expression of Syk protein, cytokine mRNA, cyclooxygenase-1/2, and phospholipase A2 (PLA2), as well as the activities of various protein kinase C isoforms, mitogen-activated protein kinases, PLA2, and transcription factors (nuclear factor-kappaB and activator protein-1).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	57-60	phospholipase A2, group IB, pancreas	Mus musculus	159-163
26199549-4	2015	Especially, in activated bone marrow-derived mast cells, PPT inhibited the expression of Syk protein, cytokine mRNA, cyclooxygenase-1/2, and phospholipase A2 (PLA2), as well as the activities of various protein kinase C isoforms, mitogen-activated protein kinases, PLA2, and transcription factors (nuclear factor-kappaB and activator protein-1).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	57-60	phospholipase A2, group IB, pancreas	Mus musculus	265-269
26199549-5	2015	CONCLUSION: PPT reduces the release of inflammatory mediators via inhibiting multiple cellular signaling pathways comprising the Ca(2+) influx, protein kinase C, and PLA2, which are propagated by Syk activation upon allergic stimulation of mast cells.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	12-15	phospholipase A2, group IB, pancreas	Mus musculus	166-170
26199549-5	2015	CONCLUSION: PPT reduces the release of inflammatory mediators via inhibiting multiple cellular signaling pathways comprising the Ca(2+) influx, protein kinase C, and PLA2, which are propagated by Syk activation upon allergic stimulation of mast cells.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	12-15	spleen tyrosine kinase	Mus musculus	196-199
25714813-7	2015	We identified specific pharmaceutical agonists for each ESR using an in vitro transactivation assay employing American alligator ESR1 and ESR2; these were 4,4",4""-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) and 7-bromo-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol (WAY 200070), respectively.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	155-210	estrogen receptor	Alligator mississippiensis	56-59
25714813-7	2015	We identified specific pharmaceutical agonists for each ESR using an in vitro transactivation assay employing American alligator ESR1 and ESR2; these were 4,4",4""-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) and 7-bromo-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol (WAY 200070), respectively.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	212-215	estrogen receptor	Alligator mississippiensis	56-59
25736522-3	2015	Two non-muscle myosin IIs (NMIIs) are expressed in MKs; however, only NMII-A (MYH9), but not NMII-B (MYH10), is expressed in mature MKs and is implicated in PPT formation.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	157-160	myosin, heavy polypeptide 9, non-muscle	Mus musculus	78-82
25736522-4	2015	OBJECTIVES: To provide in vivo evidence on the specific role of NMII-A and IIB in MK PPT formation.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	85-88	ATPase, class II, type 9B	Mus musculus	64-78
25791936-4	2015	In this study, we attempt to determine the effect of Bim on Photofrin photodynamic treatment (PPT)-induced apoptosis in human lung adenocarcinoma ASTC-a-1 cells.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	94-97	BCL2 like 11	Homo sapiens	53-56
25791936-9	2015	The effect of Bim on PPT-induced apoptosis was determined by RNAi.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	21-24	BCL2 like 11	Homo sapiens	14-17
25791936-11	2015	PPT increased the level of Bim and activated caspase-3 in cells and that knockdown of Bim by RNAi significantly protected against caspase-3 activity.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	BCL2 like 11	Homo sapiens	27-30
25791936-11	2015	PPT increased the level of Bim and activated caspase-3 in cells and that knockdown of Bim by RNAi significantly protected against caspase-3 activity.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	caspase 3	Homo sapiens	45-54
25791936-11	2015	PPT increased the level of Bim and activated caspase-3 in cells and that knockdown of Bim by RNAi significantly protected against caspase-3 activity.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	caspase 3	Homo sapiens	130-139
25791936-12	2015	PPT-induced apoptosis were suppressed in cells transfected with shRNA-Bim.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	BCL2 like 11	Homo sapiens	70-73
25791936-13	2015	CONCLUSION: We demonstrated the involvement of Bim in PPT-induced apoptosis in human ASTC-a-1 lung adenocarcinoma cells and suggested that enhancing Bim activity might be a potential strategy for treating human cancers.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	54-57	BCL2 like 11	Homo sapiens	47-50
25791936-13	2015	CONCLUSION: We demonstrated the involvement of Bim in PPT-induced apoptosis in human ASTC-a-1 lung adenocarcinoma cells and suggested that enhancing Bim activity might be a potential strategy for treating human cancers.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	54-57	BCL2 like 11	Homo sapiens	149-152
24355074-7	2014	This is the first report of mutations affecting PPT and ESE in the ASAH1 gene resulting in FD.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	48-51	N-acylsphingosine amidohydrolase 1	Homo sapiens	67-72
25258388-9	2014	The oestrogenic signal was transmitted via ERA (ESR1) and ERB (ESR2) activation as administration of PPT and DPN resulted in 97 and 62%, respectively, elevation in Egr1 mRNA expression.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	101-104	estrogen receptor 1	Rattus norvegicus	48-52
25258388-9	2014	The oestrogenic signal was transmitted via ERA (ESR1) and ERB (ESR2) activation as administration of PPT and DPN resulted in 97 and 62%, respectively, elevation in Egr1 mRNA expression.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	101-104	estrogen receptor 2	Rattus norvegicus	63-67
25258388-9	2014	The oestrogenic signal was transmitted via ERA (ESR1) and ERB (ESR2) activation as administration of PPT and DPN resulted in 97 and 62%, respectively, elevation in Egr1 mRNA expression.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	101-104	early growth response 1	Rattus norvegicus	164-168
25258388-12	2014	pulses, s.c. oestrogenic supplementation (with E2, PPT or DPN) consistently decreased (by -46, -48 and -41% respectively) the Pitx1 mRNA in the anterior pituitary gland.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	51-54	paired-like homeodomain 1	Rattus norvegicus	126-131
25005881-8	2014	Serum BDNF (log) was inversely associated with PPT (log) (beta = -1.01, SE = 0.41), age (beta = -0.02, SE = 0.15) and obsessive compulsive disorder (beta = -0.36, SE = 0.15), while serum S100B (log) was inversely associated with PPT (log) (beta = -1.38, SE = 0.50), only.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	47-50	brain derived neurotrophic factor	Homo sapiens	6-10
25051443-6	2014	A cyclic regimen of E2 or 4,4",4""-(4-propyl-[1H]-pyrazole-1,3,5-triyl) trisphenol treatment for 8 cycles (4 d/cycle, mimicking the ovarian cycle of female rats) in ovariectomized female rats significantly reduced food intake and body weight gain and increased apo A-IV gene expression in the nucleus tractus solitarius, relative to vehicle.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	26-82	apolipoprotein A4	Rattus norvegicus	261-269
25157819-6	2014	Administration of ERalpha-selective agonist propylpyrazole triol (PPT) to murine DRN 5-HT neurons activated these neurons in an ERalpha-dependent manner.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	44-64	estrogen receptor 1 (alpha)	Mus musculus	18-25
25157819-6	2014	Administration of ERalpha-selective agonist propylpyrazole triol (PPT) to murine DRN 5-HT neurons activated these neurons in an ERalpha-dependent manner.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	44-64	estrogen receptor 1 (alpha)	Mus musculus	128-135
25157819-6	2014	Administration of ERalpha-selective agonist propylpyrazole triol (PPT) to murine DRN 5-HT neurons activated these neurons in an ERalpha-dependent manner.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	66-69	estrogen receptor 1 (alpha)	Mus musculus	18-25
25157819-6	2014	Administration of ERalpha-selective agonist propylpyrazole triol (PPT) to murine DRN 5-HT neurons activated these neurons in an ERalpha-dependent manner.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	66-69	estrogen receptor 1 (alpha)	Mus musculus	128-135
25017047-6	2014	Using ERalpha knock-out (alpha-ERKO) mice and wild type (WT) littermates, the present study demonstrated that ERalpha-specific agonist propylpyrazole triol (PPT) promoted non-amyloidogenic processing of platelet APP via the mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase (ERK) pathway.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	135-155	estrogen receptor 1 (alpha)	Mus musculus	6-13
25017047-6	2014	Using ERalpha knock-out (alpha-ERKO) mice and wild type (WT) littermates, the present study demonstrated that ERalpha-specific agonist propylpyrazole triol (PPT) promoted non-amyloidogenic processing of platelet APP via the mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase (ERK) pathway.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	135-155	estrogen receptor 1 (alpha)	Mus musculus	110-117
25017047-6	2014	Using ERalpha knock-out (alpha-ERKO) mice and wild type (WT) littermates, the present study demonstrated that ERalpha-specific agonist propylpyrazole triol (PPT) promoted non-amyloidogenic processing of platelet APP via the mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase (ERK) pathway.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	135-155	mitogen-activated protein kinase 1	Mus musculus	31-34
25017047-6	2014	Using ERalpha knock-out (alpha-ERKO) mice and wild type (WT) littermates, the present study demonstrated that ERalpha-specific agonist propylpyrazole triol (PPT) promoted non-amyloidogenic processing of platelet APP via the mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase (ERK) pathway.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	157-160	estrogen receptor 1 (alpha)	Mus musculus	6-13
25017047-6	2014	Using ERalpha knock-out (alpha-ERKO) mice and wild type (WT) littermates, the present study demonstrated that ERalpha-specific agonist propylpyrazole triol (PPT) promoted non-amyloidogenic processing of platelet APP via the mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase (ERK) pathway.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	157-160	estrogen receptor 1 (alpha)	Mus musculus	110-117
25017047-6	2014	Using ERalpha knock-out (alpha-ERKO) mice and wild type (WT) littermates, the present study demonstrated that ERalpha-specific agonist propylpyrazole triol (PPT) promoted non-amyloidogenic processing of platelet APP via the mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase (ERK) pathway.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	157-160	mitogen-activated protein kinase 1	Mus musculus	31-34
25005881-8	2014	Serum BDNF (log) was inversely associated with PPT (log) (beta = -1.01, SE = 0.41), age (beta = -0.02, SE = 0.15) and obsessive compulsive disorder (beta = -0.36, SE = 0.15), while serum S100B (log) was inversely associated with PPT (log) (beta = -1.38, SE = 0.50), only.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	229-232	brain derived neurotrophic factor	Homo sapiens	6-10
24872356-10	2014	The estrogen activation of INa could be mimicked by the ERalpha agonist PPT (1 nmol/L).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	72-75	estrogen receptor 1 (alpha)	Mus musculus	56-63
24819599-7	2014	In contrast, 4,4",4""-(4-propyl-[1H]-pyrazole-1,3,5-triyl) trisphenol (PPT) (ERalpha agonist) or 4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]-pyrimidin-3-yl]phenol (PHTPP) (ERbeta antagonist) significantly enhanced cell growth.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	13-69	estrogen receptor 1	Homo sapiens	77-84
23820624-6	2013	The ERalpha-selective agonist propyl pyrazole triol mimicked the effects of <protein-id="11973;20450">E2.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	30-51	estrogen receptor 1 (alpha)	Mus musculus	4-11
24275521-4	2014	Despite strong conservation, some mature miR166 sequences, such as ppt-miR166m, have undergone sequence variation.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	67-70	MIR166a	Arabidopsis thaliana	41-47
24284820-5	2014	Estrogen receptor (ER) alpha- and ERbeta-selective agonists, propylpyrazole triol (PPT), and 2,3-bis(4-hydroxyphenyl) propionitrile (DPN), respectively, augmented GH mRNA expression and secretion, whereas E2 and PPT, but not DPN increased prolactin (PRL) mRNA levels.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	61-81	prolactin	Mus musculus	239-248
24284820-5	2014	Estrogen receptor (ER) alpha- and ERbeta-selective agonists, propylpyrazole triol (PPT), and 2,3-bis(4-hydroxyphenyl) propionitrile (DPN), respectively, augmented GH mRNA expression and secretion, whereas E2 and PPT, but not DPN increased prolactin (PRL) mRNA levels.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	61-81	prolactin	Mus musculus	250-253
24284820-6	2014	E2, PPT, and DPN stimulated expression of the pituitary transcription factor Pou1f1 and increased its binding to the GH promoter.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	4-7	POU domain, class 1, transcription factor 1	Mus musculus	77-83
24118285-7	2013	Significant effects of PPT on CRH mRNA within the PVN were observed after the administration of PPT but only in primiparous females tested on the EPM.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	23-26	corticotropin releasing hormone	Rattus norvegicus	30-33
24118285-7	2013	Significant effects of PPT on CRH mRNA within the PVN were observed after the administration of PPT but only in primiparous females tested on the EPM.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	96-99	corticotropin releasing hormone	Rattus norvegicus	30-33
24118285-8	2013	PPT also increased Fos expression within the PVN of EPM-exposed females; however, both vehicle- and PPT-treated primiparous females had reduced Fos expression compared to nulliparous females.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	19-22
24118285-8	2013	PPT also increased Fos expression within the PVN of EPM-exposed females; however, both vehicle- and PPT-treated primiparous females had reduced Fos expression compared to nulliparous females.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	100-103	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	144-147
24118285-9	2013	In the amygdala, PPT increased Fos immunoreactivity in the central but not the medial or basolateral amygdala, although these effects were only observed in home cage females.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	17-20	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	31-34
24118285-10	2013	Additionally, both vehicle- and PPT-treated home cage, primiparous females had increased Fos in the central nucleus of the amygdala compared to nulliparous controls.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	32-35	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	89-92
23954748-6	2013	Propylpyrazole-triol (PPT), a selective ERalpha agonist was used to confirm the induction of apoptosis by c9, t11 CLA may relate to ERalpha-mediated pathway.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-20	estrogen receptor 1	Homo sapiens	40-47
23954748-6	2013	Propylpyrazole-triol (PPT), a selective ERalpha agonist was used to confirm the induction of apoptosis by c9, t11 CLA may relate to ERalpha-mediated pathway.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-20	estrogen receptor 1	Homo sapiens	132-139
23954748-6	2013	Propylpyrazole-triol (PPT), a selective ERalpha agonist was used to confirm the induction of apoptosis by c9, t11 CLA may relate to ERalpha-mediated pathway.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	22-25	estrogen receptor 1	Homo sapiens	40-47
23954748-6	2013	Propylpyrazole-triol (PPT), a selective ERalpha agonist was used to confirm the induction of apoptosis by c9, t11 CLA may relate to ERalpha-mediated pathway.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	22-25	estrogen receptor 1	Homo sapiens	132-139
23913447-12	2013	E2 and PPT treatment significantly increased tropomyosin-related kinase and pERK1/2 expression in the MEA and MPOA and increased pERK1/2 expression in the CA1.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	7-10	carbonic anhydrase 1	Rattus norvegicus	155-158
24938798-7	2014	17beta-Estradiol and propyl pyrazole triol (PPT, ER-alpha agonist) induced increase in VTG II and ApoVLDL II mRNA expressions in a dose-dependent manner.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	21-42	estrogen receptor 1	Gallus gallus	49-57
24938798-7	2014	17beta-Estradiol and propyl pyrazole triol (PPT, ER-alpha agonist) induced increase in VTG II and ApoVLDL II mRNA expressions in a dose-dependent manner.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	21-42	vitellogenin 2	Gallus gallus	87-93
24938798-7	2014	17beta-Estradiol and propyl pyrazole triol (PPT, ER-alpha agonist) induced increase in VTG II and ApoVLDL II mRNA expressions in a dose-dependent manner.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	21-42	apovitellenin 1	Gallus gallus	98-108
24938798-7	2014	17beta-Estradiol and propyl pyrazole triol (PPT, ER-alpha agonist) induced increase in VTG II and ApoVLDL II mRNA expressions in a dose-dependent manner.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	44-47	vitellogenin 2	Gallus gallus	87-93
24938798-7	2014	17beta-Estradiol and propyl pyrazole triol (PPT, ER-alpha agonist) induced increase in VTG II and ApoVLDL II mRNA expressions in a dose-dependent manner.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	44-47	apovitellenin 1	Gallus gallus	98-108
24938798-10	2014	Methyl-piperidino-pyrazole (a highly selective ER-alpha antagonist) fully blocked the expression of both yolk precursors, which were upregulated by 17beta-estradiol, PPT, and DPN.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	166-169	estrogen receptor 1	Gallus gallus	47-55
24128867-5	2014	Ovariectomized rats administered 10 mug E2 and 10 mug DPN showed more central entries in the open field, more open-arm duration in the elevated plus maze, and less immobility duration in the forced-swim test compared with rats administered vehicle or 10 mug PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	258-261	dihydrolipoamide S-succinyltransferase	Rattus norvegicus	40-49
23857051-5	2013	In the cells treated with 10-5 mol/l PPT, RBP4 expression significantly increased (P&lt;0.05) in a dose-dependent manner.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	37-40	retinol binding protein 4	Homo sapiens	42-46
23885094-4	2013	Inhibition by the ERalpha-selective ligand propyl pyrazole triol was less marked than with the pan-agonist (E2) or the ERbeta-selective (8beta-vinyl-estradiol) ligands, indicating that ERbeta activation reinforced the inhibitory effects of ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	43-64	estrogen receptor 1	Homo sapiens	18-25
23885094-4	2013	Inhibition by the ERalpha-selective ligand propyl pyrazole triol was less marked than with the pan-agonist (E2) or the ERbeta-selective (8beta-vinyl-estradiol) ligands, indicating that ERbeta activation reinforced the inhibitory effects of ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	43-64	estrogen receptor 2	Homo sapiens	185-191
23885094-4	2013	Inhibition by the ERalpha-selective ligand propyl pyrazole triol was less marked than with the pan-agonist (E2) or the ERbeta-selective (8beta-vinyl-estradiol) ligands, indicating that ERbeta activation reinforced the inhibitory effects of ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	43-64	estrogen receptor 2	Homo sapiens	185-191
23608653-3	2013	Intracerebroventricular infusions of either diarylpropionitrile, a selective ERbeta agonist, or propyl-pyrazole-triol, a selective ERalpha agonist, attenuated Aldo/NaCl-induced hypertension in ovariectomized rats.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	96-117	estrogen receptor 1	Rattus norvegicus	131-138
23887629-11	2013	The use of a p53 shRNA rescued apoptosis, and only partially the defect in PPT formation.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	75-78	tumor protein p53	Homo sapiens	13-16
23401288-10	2013	Furthermore, the expression of ROCK was inhibited by ERalpha-selective ligand agonist propyl pyrazole triol.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	86-107	estrogen receptor 1	Rattus norvegicus	53-60
23610132-4	2013	The ERalpha agonist 4,49,499-(4-propyl-[1H]-pyrazole-1,3,5-triyl) trisphenol (PPT) and G protein-coupled receptor 30 (GPR30) agonist G-1 mimicked the estrogen effect, whereas the ERbeta agonist diarylpropionitrile (DPN) had no effect.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	78-81	estrogen receptor 1	Rattus norvegicus	4-11
23610132-9	2013	Furthermore, the ERK1/2 inhibitor U0126 reversed the inhibitory effect of E2 on alpha,beta-me-ATP-induced pain and of PPT or G-1 on P2X3 receptor-mediated currents.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	118-121	mitogen activated protein kinase 3	Rattus norvegicus	17-23
22999489-6	2013	Prompt 4,4",4""-(4-propyl-[1H]-pyrazole-1,3,5-triyl) trisphenol (PPT) treatment (1 mg/kg.d), an agonist of ERalpha, improved the spatial learning and memory ability of ovariectomized rats and rescued ovariectomy-induced neuron loss by up-regulating the level of BCLxl, an important anti-apoptosis protein.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	7-63	estrogen receptor 1	Rattus norvegicus	107-114
22999489-7	2013	Furthermore, PPT treatment also improved ovariectomy-induced hippocampal synapse loss and up-regulated the levels of synaptic proteins (synapsin I, NR2A and GluR1) and the activates of CaMK Pialpha, ERK and Akt.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	13-16	synapsin I	Rattus norvegicus	136-146
22999489-7	2013	Furthermore, PPT treatment also improved ovariectomy-induced hippocampal synapse loss and up-regulated the levels of synaptic proteins (synapsin I, NR2A and GluR1) and the activates of CaMK Pialpha, ERK and Akt.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	13-16	glutamate ionotropic receptor NMDA type subunit 2A	Rattus norvegicus	148-152
22999489-7	2013	Furthermore, PPT treatment also improved ovariectomy-induced hippocampal synapse loss and up-regulated the levels of synaptic proteins (synapsin I, NR2A and GluR1) and the activates of CaMK Pialpha, ERK and Akt.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	13-16	glutamate ionotropic receptor AMPA type subunit 1	Rattus norvegicus	157-162
22999489-7	2013	Furthermore, PPT treatment also improved ovariectomy-induced hippocampal synapse loss and up-regulated the levels of synaptic proteins (synapsin I, NR2A and GluR1) and the activates of CaMK Pialpha, ERK and Akt.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	13-16	Eph receptor B1	Rattus norvegicus	199-202
23695162-5	2013	PPT-triggered activation of ERalpha at the membrane induced adenosine monophosphate-activated protein kinase to phosphorylate sterol regulatory element-binding factor 1 (Srebf1), preventing its association with and therefore its proteolytic cleavage by site-1 protease.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	estrogen receptor 1 (alpha)	Mus musculus	28-35
23695162-5	2013	PPT-triggered activation of ERalpha at the membrane induced adenosine monophosphate-activated protein kinase to phosphorylate sterol regulatory element-binding factor 1 (Srebf1), preventing its association with and therefore its proteolytic cleavage by site-1 protease.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	sterol regulatory element binding transcription factor 1	Mus musculus	126-168
23695162-5	2013	PPT-triggered activation of ERalpha at the membrane induced adenosine monophosphate-activated protein kinase to phosphorylate sterol regulatory element-binding factor 1 (Srebf1), preventing its association with and therefore its proteolytic cleavage by site-1 protease.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	sterol regulatory element binding transcription factor 1	Mus musculus	170-176
23695162-5	2013	PPT-triggered activation of ERalpha at the membrane induced adenosine monophosphate-activated protein kinase to phosphorylate sterol regulatory element-binding factor 1 (Srebf1), preventing its association with and therefore its proteolytic cleavage by site-1 protease.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	membrane-bound transcription factor peptidase, site 1	Mus musculus	253-268
22999489-7	2013	Furthermore, PPT treatment also improved ovariectomy-induced hippocampal synapse loss and up-regulated the levels of synaptic proteins (synapsin I, NR2A and GluR1) and the activates of CaMK Pialpha, ERK and Akt.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	13-16	AKT serine/threonine kinase 1	Rattus norvegicus	207-210
22751110-5	2013	In vivo, ERbeta agonists induced mammary gland hyperplasia and MC4-L2 tumour growth to a similar extent as the ERalpha agonist 4,4",4""-(4-propyl-(1H)-pyrazole-1,3,5-triyl) trisphenol (PPT) or 17beta-estradiol (E2) and correlated with higher number of mitotic and lower number of apoptotic features.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	185-188	estrogen receptor 2 (beta)	Mus musculus	9-15
23485817-7	2013	The observation that PPT increases the number of PR-immunoreactive neurons and the levels of PR protein far less than EB shows that the estradiol induction of PRs in the VMNvl does not involve solely the activation of the ERalpha and suggests that it might also implicate the activation of membrane receptors.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	21-24	estrogen receptor 1	Rattus norvegicus	222-229
23229410-4	2013	This increased proliferative activity was             reversed by treatment with ICI 182,780, a well-known ER antagonist, while cell             proliferation was further promoted in the presence of propyl pyrazole triol (PPT),             an ERalpha agonist.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	199-220	estrogen receptor 1	Homo sapiens	243-250
23305904-7	2013	Selective ERalpha (propylpyrazole triol, PPT) and ERbeta (diarylproprionitrile, DPN) agonists activated PKC in female RCs only.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	19-39	estrogen receptor 1	Rattus norvegicus	10-17
23821951-3	2013	Lox-mediated expression of bar gene, recognized by resistance of transgenic plants to PPT, occurred only in plants obtained via Agrobacterium-mediated transformation.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	86-89	probable linoleate 9S-lipoxygenase 5	Nicotiana tabacum	0-3
23229410-4	2013	This increased proliferative activity was             reversed by treatment with ICI 182,780, a well-known ER antagonist, while cell             proliferation was further promoted in the presence of propyl pyrazole triol (PPT),             an ERalpha agonist.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	222-225	estrogen receptor 1	Homo sapiens	243-250
22981216-1	2012	Estrogen receptor (ER) subtype specific agonists, diarylpropionitrile (DPN) for ERbeta and propylpyrazoletriol (PPT) for ERalpha, are pharmacological probes used frequently to define mechanisms for estrogen actions in vitro and in vivo.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	91-110	estrogen receptor 1	Rattus norvegicus	121-128
23211707-4	2013	We further showed that central administration of an ERalpha agonist, propyl pyrazole triol, acutely increases physical interaction between SRC1 and ERalpha in the hypothalamus.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	69-90	estrogen receptor 1 (alpha)	Mus musculus	52-59
23211707-4	2013	We further showed that central administration of an ERalpha agonist, propyl pyrazole triol, acutely increases physical interaction between SRC1 and ERalpha in the hypothalamus.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	69-90	nuclear receptor coactivator 1	Mus musculus	139-143
23211707-4	2013	We further showed that central administration of an ERalpha agonist, propyl pyrazole triol, acutely increases physical interaction between SRC1 and ERalpha in the hypothalamus.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	69-90	estrogen receptor 1 (alpha)	Mus musculus	148-155
23021811-6	2012	The biosensor developed by immobilization of acetylcholinesterase (AChE) in sol-gel allowed the detection of two reference AChE inhibitors, paraoxon-methyl and chlorpyrifos with detection limits of 30 pM (7 ppt) and 0.4 nM (0.1 ppb), respectively.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	207-210	acetylcholinesterase (Cartwright blood group)	Homo sapiens	45-65
22850433-4	2012	The cell cycle-related gene, p21, a cyclin-dependent kinase inhibitor, showed upregulation in the vagina, and p21 protein was localized in the basal layer of the vaginal epithelium in mice exposed neonatally to DES and an estrogen receptor alpha agonist, propyl pyrazole triol (PPT).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	255-276	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	29-32
22850433-4	2012	The cell cycle-related gene, p21, a cyclin-dependent kinase inhibitor, showed upregulation in the vagina, and p21 protein was localized in the basal layer of the vaginal epithelium in mice exposed neonatally to DES and an estrogen receptor alpha agonist, propyl pyrazole triol (PPT).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	278-281	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	29-32
22850433-5	2012	The expressions of Notch receptors and Notch ligands were unchanged; however, the mRNAs of hairy-related basic helix-loop-helix (bHLH) transcription factor genes, Hes1, Hey1 and Heyl were persistently downregulated in the vagina, indicating estrogen-independent epithelial cell proliferation in mice exposed neonatally to DES and PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	330-333	hes family bHLH transcription factor 1	Mus musculus	163-167
23021811-6	2012	The biosensor developed by immobilization of acetylcholinesterase (AChE) in sol-gel allowed the detection of two reference AChE inhibitors, paraoxon-methyl and chlorpyrifos with detection limits of 30 pM (7 ppt) and 0.4 nM (0.1 ppb), respectively.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	207-210	acetylcholinesterase (Cartwright blood group)	Homo sapiens	67-71
23021811-6	2012	The biosensor developed by immobilization of acetylcholinesterase (AChE) in sol-gel allowed the detection of two reference AChE inhibitors, paraoxon-methyl and chlorpyrifos with detection limits of 30 pM (7 ppt) and 0.4 nM (0.1 ppb), respectively.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	207-210	acetylcholinesterase (Cartwright blood group)	Homo sapiens	123-127
22562172-5	2012	A similar CORT increase was seen after PVN infusion of the ERalpha agonist propylpyrazoletriol, whereas the ERbeta agonist diarylpropiolnitrile had no effect.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	75-94	cortistatin	Rattus norvegicus	10-14
22759564-4	2012	MIF production was blocked by Fulvestrant, an estrogen receptor (ER) antagonist, and induced by ERalpha and ERbeta selective agonists propyl-pyrazole-triol (PPT) and diarylpropionrile (DPN), respectively, thus demonstrating a specific receptor-mediated effect.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	134-155	macrophage migration inhibitory factor	Homo sapiens	0-3
22759564-4	2012	MIF production was blocked by Fulvestrant, an estrogen receptor (ER) antagonist, and induced by ERalpha and ERbeta selective agonists propyl-pyrazole-triol (PPT) and diarylpropionrile (DPN), respectively, thus demonstrating a specific receptor-mediated effect.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	134-155	estrogen receptor 1	Homo sapiens	96-103
22759564-4	2012	MIF production was blocked by Fulvestrant, an estrogen receptor (ER) antagonist, and induced by ERalpha and ERbeta selective agonists propyl-pyrazole-triol (PPT) and diarylpropionrile (DPN), respectively, thus demonstrating a specific receptor-mediated effect.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	134-155	estrogen receptor 2	Homo sapiens	108-114
22759564-4	2012	MIF production was blocked by Fulvestrant, an estrogen receptor (ER) antagonist, and induced by ERalpha and ERbeta selective agonists propyl-pyrazole-triol (PPT) and diarylpropionrile (DPN), respectively, thus demonstrating a specific receptor-mediated effect.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	157-160	macrophage migration inhibitory factor	Homo sapiens	0-3
22759564-4	2012	MIF production was blocked by Fulvestrant, an estrogen receptor (ER) antagonist, and induced by ERalpha and ERbeta selective agonists propyl-pyrazole-triol (PPT) and diarylpropionrile (DPN), respectively, thus demonstrating a specific receptor-mediated effect.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	157-160	estrogen receptor 1	Homo sapiens	96-103
22759564-4	2012	MIF production was blocked by Fulvestrant, an estrogen receptor (ER) antagonist, and induced by ERalpha and ERbeta selective agonists propyl-pyrazole-triol (PPT) and diarylpropionrile (DPN), respectively, thus demonstrating a specific receptor-mediated effect.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	157-160	estrogen receptor 2	Homo sapiens	108-114
22562172-5	2012	A similar CORT increase was seen after PVN infusion of the ERalpha agonist propylpyrazoletriol, whereas the ERbeta agonist diarylpropiolnitrile had no effect.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	75-94	estrogen receptor 1	Rattus norvegicus	59-66
22562172-8	2012	E2 and propylpyrazoletriol administration in the PVN enhanced the stress-induced plasma CORT increase (8-fold vs. baseline), whereas ICI 182,780 and diarylpropiolnitrile reduced it, as compared with both E2 and vehicle administration in the PVN.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	7-26	cortistatin	Rattus norvegicus	88-92
22266284-4	2012	In this study, we used ERalpha-selective agonist propylpyrazole-triol (PPT) and ERbeta-selective agonist diarylpropionitrile (DPN) to activate ERalpha and estrogen receptor-beta (ERbeta) separately in an ovariectomized rat model and determined whether PPT-activated ERalpha function in the mammary gland can be suppressed by DPN activated ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	252-255	estrogen receptor 2	Rattus norvegicus	155-177
22266284-4	2012	In this study, we used ERalpha-selective agonist propylpyrazole-triol (PPT) and ERbeta-selective agonist diarylpropionitrile (DPN) to activate ERalpha and estrogen receptor-beta (ERbeta) separately in an ovariectomized rat model and determined whether PPT-activated ERalpha function in the mammary gland can be suppressed by DPN activated ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	252-255	estrogen receptor 2	Rattus norvegicus	179-185
22266284-4	2012	In this study, we used ERalpha-selective agonist propylpyrazole-triol (PPT) and ERbeta-selective agonist diarylpropionitrile (DPN) to activate ERalpha and estrogen receptor-beta (ERbeta) separately in an ovariectomized rat model and determined whether PPT-activated ERalpha function in the mammary gland can be suppressed by DPN activated ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	252-255	estrogen receptor 2	Rattus norvegicus	179-185
22266284-6	2012	In the mammary gland, PPT but not DPN increased cell proliferation and amphiregulin gene expression; importantly, the stimulatory effect of PPT on mammary cell proliferation and amphiregulin gene expression can be suppressed by DPN.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	22-25	amphiregulin	Rattus norvegicus	71-83
22266284-6	2012	In the mammary gland, PPT but not DPN increased cell proliferation and amphiregulin gene expression; importantly, the stimulatory effect of PPT on mammary cell proliferation and amphiregulin gene expression can be suppressed by DPN.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	22-25	amphiregulin	Rattus norvegicus	178-190
22266284-6	2012	In the mammary gland, PPT but not DPN increased cell proliferation and amphiregulin gene expression; importantly, the stimulatory effect of PPT on mammary cell proliferation and amphiregulin gene expression can be suppressed by DPN.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	140-143	amphiregulin	Rattus norvegicus	178-190
22260364-7	2012	GnRH and Fos co-labeling, a marker of GnRH activation, following ovariectomy and hormone priming was reduced by approximately half at all doses; the magnitude of which was not as large as with EB or what we have previously observed with the ERalpha agonist PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	257-260	gonadotropin releasing hormone 1	Rattus norvegicus	0-4
22114114-9	2012	In cultured hepatocytes, 17beta-estradiol and the selective estrogen receptor alpha-agonist, propyl pyrazole triol, caused a decrease in AQP9 expression.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	93-114	aquaporin 9	Rattus norvegicus	137-141
22142990-7	2012	The number of U373 and D54 cells significantly increased after PPT (ERalpha agonist) treatment but not after DPN (ERbeta agonist) one.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	63-66	estrogen receptor 1	Homo sapiens	68-75
22142990-11	2012	Western blot analysis showed that in U373 cells the content of PR isoforms (PR-A and PR-B), EGFR, VEGF and cyclin D1 increased after PPT treatment while in D54 cells only the content of EGFR was increased.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	133-136	S100 calcium binding protein A6	Homo sapiens	76-80
22142990-11	2012	Western blot analysis showed that in U373 cells the content of PR isoforms (PR-A and PR-B), EGFR, VEGF and cyclin D1 increased after PPT treatment while in D54 cells only the content of EGFR was increased.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	133-136	RB transcriptional corepressor 1	Homo sapiens	85-89
22142990-11	2012	Western blot analysis showed that in U373 cells the content of PR isoforms (PR-A and PR-B), EGFR, VEGF and cyclin D1 increased after PPT treatment while in D54 cells only the content of EGFR was increased.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	133-136	epidermal growth factor receptor	Homo sapiens	92-96
22142990-11	2012	Western blot analysis showed that in U373 cells the content of PR isoforms (PR-A and PR-B), EGFR, VEGF and cyclin D1 increased after PPT treatment while in D54 cells only the content of EGFR was increased.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	133-136	vascular endothelial growth factor A	Homo sapiens	98-102
22142990-11	2012	Western blot analysis showed that in U373 cells the content of PR isoforms (PR-A and PR-B), EGFR, VEGF and cyclin D1 increased after PPT treatment while in D54 cells only the content of EGFR was increased.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	133-136	cyclin D1	Homo sapiens	107-116
22142990-11	2012	Western blot analysis showed that in U373 cells the content of PR isoforms (PR-A and PR-B), EGFR, VEGF and cyclin D1 increased after PPT treatment while in D54 cells only the content of EGFR was increased.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	133-136	epidermal growth factor receptor	Homo sapiens	186-190
22266284-0	2012	Estrogen receptor-beta agonist diarylpropionitrile counteracts the estrogenic activity of estrogen receptor-alpha agonist propylpyrazole-triol in the mammary gland of ovariectomized Sprague Dawley rats.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	122-142	estrogen receptor 2	Rattus norvegicus	0-22
22266284-4	2012	In this study, we used ERalpha-selective agonist propylpyrazole-triol (PPT) and ERbeta-selective agonist diarylpropionitrile (DPN) to activate ERalpha and estrogen receptor-beta (ERbeta) separately in an ovariectomized rat model and determined whether PPT-activated ERalpha function in the mammary gland can be suppressed by DPN activated ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	49-69	estrogen receptor 1	Rattus norvegicus	23-30
22266284-4	2012	In this study, we used ERalpha-selective agonist propylpyrazole-triol (PPT) and ERbeta-selective agonist diarylpropionitrile (DPN) to activate ERalpha and estrogen receptor-beta (ERbeta) separately in an ovariectomized rat model and determined whether PPT-activated ERalpha function in the mammary gland can be suppressed by DPN activated ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	49-69	estrogen receptor 2	Rattus norvegicus	155-177
22266284-4	2012	In this study, we used ERalpha-selective agonist propylpyrazole-triol (PPT) and ERbeta-selective agonist diarylpropionitrile (DPN) to activate ERalpha and estrogen receptor-beta (ERbeta) separately in an ovariectomized rat model and determined whether PPT-activated ERalpha function in the mammary gland can be suppressed by DPN activated ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	71-74	estrogen receptor 1	Rattus norvegicus	23-30
22266284-4	2012	In this study, we used ERalpha-selective agonist propylpyrazole-triol (PPT) and ERbeta-selective agonist diarylpropionitrile (DPN) to activate ERalpha and estrogen receptor-beta (ERbeta) separately in an ovariectomized rat model and determined whether PPT-activated ERalpha function in the mammary gland can be suppressed by DPN activated ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	71-74	estrogen receptor 1	Rattus norvegicus	143-150
22266284-4	2012	In this study, we used ERalpha-selective agonist propylpyrazole-triol (PPT) and ERbeta-selective agonist diarylpropionitrile (DPN) to activate ERalpha and estrogen receptor-beta (ERbeta) separately in an ovariectomized rat model and determined whether PPT-activated ERalpha function in the mammary gland can be suppressed by DPN activated ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	71-74	estrogen receptor 2	Rattus norvegicus	155-177
22266284-4	2012	In this study, we used ERalpha-selective agonist propylpyrazole-triol (PPT) and ERbeta-selective agonist diarylpropionitrile (DPN) to activate ERalpha and estrogen receptor-beta (ERbeta) separately in an ovariectomized rat model and determined whether PPT-activated ERalpha function in the mammary gland can be suppressed by DPN activated ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	71-74	estrogen receptor 1	Rattus norvegicus	143-150
22260364-7	2012	GnRH and Fos co-labeling, a marker of GnRH activation, following ovariectomy and hormone priming was reduced by approximately half at all doses; the magnitude of which was not as large as with EB or what we have previously observed with the ERalpha agonist PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	257-260	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	9-12
22260364-10	2012	The second experiment revealed that EB, PPT and the combination of DPN+PPT significantly abrogated preoptic Kiss1 expression at both ages but ARC expression was only reduced by EB.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	40-43	KiSS-1 metastasis-suppressor	Rattus norvegicus	108-113
22260364-10	2012	The second experiment revealed that EB, PPT and the combination of DPN+PPT significantly abrogated preoptic Kiss1 expression at both ages but ARC expression was only reduced by EB.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	71-74	KiSS-1 metastasis-suppressor	Rattus norvegicus	108-113
22033279-8	2012	Unexpectedly, the ERalpha agonist PPT selectively increased the time spent exploring the open arms of the EPM in non-lactating, primiparous females, with no significant effects of DPN observed in either nulliparous or primiparous subjects.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	34-37	estrogen receptor 1	Rattus norvegicus	18-25
22033279-10	2012	In addition, significant effects of both reproductive experience and PPT administration on CRH mRNA expression were observed in both the paraventricular nucleus and amygdala using qPCR.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	69-72	corticotropin releasing hormone	Rattus norvegicus	91-94
21901291-6	2011	The downregulation of HAS1 was abrogated by the estrogen receptor (ER) alpha and beta antagonist ICI182780 and could be mimicked by the ERalpha-agonist propyl-pyrazole triol (PPT).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	152-173	hyaluronan synthase 1	Homo sapiens	22-26
22213775-7	2012	The ERalpha and ERbeta agonists PPT and DPN show a similar neuroprotective effect to that of 17beta-E(2), but DPN is more efficient.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	32-35	estrogen receptor 1	Rattus norvegicus	4-11
22213775-7	2012	The ERalpha and ERbeta agonists PPT and DPN show a similar neuroprotective effect to that of 17beta-E(2), but DPN is more efficient.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	32-35	estrogen receptor 2	Rattus norvegicus	16-22
21881567-7	2012	Interestingly, both an ERalpha agonist (propyl-pyrazole triol (PPT)) and an ERbeta agonist (diarylpropionitrile (DPN)) increased choice on the high-reward lever when administered independently, but when these two agonists were combined, a decrease in choice for the high-reward lever was observed.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	40-61	estrogen receptor 1	Rattus norvegicus	23-30
21881567-7	2012	Interestingly, both an ERalpha agonist (propyl-pyrazole triol (PPT)) and an ERbeta agonist (diarylpropionitrile (DPN)) increased choice on the high-reward lever when administered independently, but when these two agonists were combined, a decrease in choice for the high-reward lever was observed.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	63-66	estrogen receptor 1	Rattus norvegicus	23-30
23236424-10	2012	The Y(1)R protein was up-regulated (100%) by 17beta-estradiol (EC(50) 20 pM) and the predominant role of ERalpha was demonstrated by using the ERalpha-selective agonist "propylpyrazole triol".	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	170-190	estrogen receptor 1	Homo sapiens	143-150
22052998-5	2011	The SERM-bound ERalpha and ERbeta form the strongest dimers, and subtype-preferential homodimerization was seen with ERalpha-selective ligands (methyl piperidino pyrazole/propyl pyrazole triol) and the ERbeta-selective ligands (diarylpropionitrile/tetrahydrochrysene/genistein).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	171-192	estrogen receptor 1	Homo sapiens	15-22
22052998-5	2011	The SERM-bound ERalpha and ERbeta form the strongest dimers, and subtype-preferential homodimerization was seen with ERalpha-selective ligands (methyl piperidino pyrazole/propyl pyrazole triol) and the ERbeta-selective ligands (diarylpropionitrile/tetrahydrochrysene/genistein).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	171-192	estrogen receptor 2	Homo sapiens	27-33
22052998-5	2011	The SERM-bound ERalpha and ERbeta form the strongest dimers, and subtype-preferential homodimerization was seen with ERalpha-selective ligands (methyl piperidino pyrazole/propyl pyrazole triol) and the ERbeta-selective ligands (diarylpropionitrile/tetrahydrochrysene/genistein).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	171-192	estrogen receptor 1	Homo sapiens	117-124
22052998-5	2011	The SERM-bound ERalpha and ERbeta form the strongest dimers, and subtype-preferential homodimerization was seen with ERalpha-selective ligands (methyl piperidino pyrazole/propyl pyrazole triol) and the ERbeta-selective ligands (diarylpropionitrile/tetrahydrochrysene/genistein).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	171-192	estrogen receptor 2	Homo sapiens	202-208
23284665-7	2012	MAGL immunoreaction underwent a redistribution after PPT and excitotoxic lesion since MAGL IR disappeared in astrocytes of lesioned OHSC.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	53-56	monoglyceride lipase	Homo sapiens	0-4
21971047-4	2011	E2 and an ERalpha-selective agonist propylpyrazole-triol depressed myosin heavy chain (MHC), tropomyosin, and myogenin levels and repressed the fusion of myoblasts into myotubes.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	36-56	estrogen receptor 1 (alpha)	Mus musculus	10-17
21971047-4	2011	E2 and an ERalpha-selective agonist propylpyrazole-triol depressed myosin heavy chain (MHC), tropomyosin, and myogenin levels and repressed the fusion of myoblasts into myotubes.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	36-56	myogenin	Mus musculus	110-118
21901291-6	2011	The downregulation of HAS1 was abrogated by the estrogen receptor (ER) alpha and beta antagonist ICI182780 and could be mimicked by the ERalpha-agonist propyl-pyrazole triol (PPT).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	152-173	estrogen receptor 1	Homo sapiens	136-143
21901291-6	2011	The downregulation of HAS1 was abrogated by the estrogen receptor (ER) alpha and beta antagonist ICI182780 and could be mimicked by the ERalpha-agonist propyl-pyrazole triol (PPT).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	175-178	hyaluronan synthase 1	Homo sapiens	22-26
21901291-6	2011	The downregulation of HAS1 was abrogated by the estrogen receptor (ER) alpha and beta antagonist ICI182780 and could be mimicked by the ERalpha-agonist propyl-pyrazole triol (PPT).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	175-178	estrogen receptor 1	Homo sapiens	136-143
21125400-6	2011	Presence of PPT was correlated with the presence of renal abscess, extension of renal hypoperfusion areas as well with levels of CRP, leukocytosis, and urine leukocytes using the Fisher"s exact Test and the Wilcoxon Test.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	12-15	C-reactive protein	Homo sapiens	129-132
21125400-8	2011	Twenty-nine patients (11%) showed PPT which was significantly associated with the extension of the wedge-shaped renal hypoperfusion areas (P &lt; 0.001), the presence of a renal abscess (P &lt; 0.01), as well as the level of CRP (P &lt; 0.001) and urine leukocytes (P &lt; 0.01).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	34-37	C-reactive protein	Homo sapiens	225-228
21734267-5	2011	Also, increased GnRH analog binding in response to E2 and the selective ESR1 agonist propylpyrazole triol was blocked by expression of a dominant-negative form of ESR1 (L540Q).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	85-105	estrogen receptor 1	Homo sapiens	72-76
21734267-5	2011	Also, increased GnRH analog binding in response to E2 and the selective ESR1 agonist propylpyrazole triol was blocked by expression of a dominant-negative form of ESR1 (L540Q).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	85-105	estrogen receptor 1	Homo sapiens	163-167
21636213-6	2011	On the other hand, the ERalpha selective agonist PPT did not influence MB tumorigenesis relative to untreated ovariectomized mice.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	49-52	estrogen receptor 1 (alpha)	Mus musculus	23-30
21392887-8	2011	The ERalpha selective agonist, 4,4",4""-[4-propyl-(1H)-pyrazole-1,3,5-triyl]tris-phenol (PPT; s.c. or i.t.)	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	89-92	estrogen receptor 1	Rattus norvegicus	4-11
21717270-4	2011	PHGPx mRNA expression was significantly increased in all the fetuses treated with E(2) (1-1,000 ng/ml), PPT, and DPN (p &lt; 0.05).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	104-107	glutathione peroxidase 4	Mus musculus	0-5
21377511-9	2011	These results were confirmed by the injection of ERalpha-selective agonist PPT in ovariectomized mice.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	75-78	estrogen receptor 1 (alpha)	Mus musculus	49-56
21420409-4	2011	Activation of ERalpha by PPT caused disturbed differentiation of the reproductive organs in both sexes.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	25-28	estrogen receptor 1	Gallus gallus	14-21
21420409-7	2011	PPT also induced hepatic expression of mRNA for the estrogen-regulated egg yolk protein apoVLDL II.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	apovitellenin 1	Gallus gallus	88-98
21420409-9	2011	ERalpha-inactivation by MPP counteracted the action of PPT but had little effect by its own.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	55-58	estrogen receptor 1	Gallus gallus	0-7
21486807-3	2011	The purpose of the current study was to determine the impact of ERalpha activation, using the ER subtype-selective ligand propylpyrazoletriyl (PPT), on skeletal muscle glucose uptake.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	143-146	estrogen receptor 1	Rattus norvegicus	64-71
21486807-5	2011	On the fourth day, insulin-stimulated skeletal muscle glucose uptake was measured in vitro and insulin signalling intermediates were assessed via Western blotting.Activation of ERalpha with PPT resulted in increased insulin-stimulated glucose uptake into the slow-twitch soleus and fast-twitch extensor digitorum longus (EDL)muscles, activation of insulin signalling intermediates (as measured by phospho-Akt (pAkt) and pAkt substrate (PAS)) and phosphorylation of AMP-activated protein kinase (AMPK).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	190-193	estrogen receptor 1	Rattus norvegicus	177-184
21486807-5	2011	On the fourth day, insulin-stimulated skeletal muscle glucose uptake was measured in vitro and insulin signalling intermediates were assessed via Western blotting.Activation of ERalpha with PPT resulted in increased insulin-stimulated glucose uptake into the slow-twitch soleus and fast-twitch extensor digitorum longus (EDL)muscles, activation of insulin signalling intermediates (as measured by phospho-Akt (pAkt) and pAkt substrate (PAS)) and phosphorylation of AMP-activated protein kinase (AMPK).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	190-193	AKT serine/threonine kinase 1	Rattus norvegicus	405-408
21247705-5	2011	The current study assesses the effects of the ERalpha selective agonist 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole (PPT) on the social and agonistic responses of gonadally intact and gonadex male and female CD1 mice to a gonadex, same-sex intruder.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	72-120	estrogen receptor 1 (alpha)	Mus musculus	46-53
21247705-5	2011	The current study assesses the effects of the ERalpha selective agonist 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole (PPT) on the social and agonistic responses of gonadally intact and gonadex male and female CD1 mice to a gonadex, same-sex intruder.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	72-120	palmitoyl-protein thioesterase 1	Mus musculus	122-125
21247705-5	2011	The current study assesses the effects of the ERalpha selective agonist 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole (PPT) on the social and agonistic responses of gonadally intact and gonadex male and female CD1 mice to a gonadex, same-sex intruder.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	72-120	CD1 antigen complex	Mus musculus	213-216
21167607-10	2011	PPT correlated significantly with TNF-alpha in women but not in men.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	tumor necrosis factor	Homo sapiens	34-43
21392887-12	2011	In addition, s.c. E2 or PPT increased CRD-induced spinal extracellular signal-regulated kinase (ERK) phosphorylation that was not observed in OVx rats and a mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor blocked facilitation of the visceromotor response by PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	24-27	Eph receptor B1	Rattus norvegicus	57-94
21392887-12	2011	In addition, s.c. E2 or PPT increased CRD-induced spinal extracellular signal-regulated kinase (ERK) phosphorylation that was not observed in OVx rats and a mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor blocked facilitation of the visceromotor response by PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	24-27	Eph receptor B1	Rattus norvegicus	96-99
21392887-12	2011	In addition, s.c. E2 or PPT increased CRD-induced spinal extracellular signal-regulated kinase (ERK) phosphorylation that was not observed in OVx rats and a mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor blocked facilitation of the visceromotor response by PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	273-276	Eph receptor B1	Rattus norvegicus	57-94
21392887-12	2011	In addition, s.c. E2 or PPT increased CRD-induced spinal extracellular signal-regulated kinase (ERK) phosphorylation that was not observed in OVx rats and a mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor blocked facilitation of the visceromotor response by PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	273-276	Eph receptor B1	Rattus norvegicus	96-99
21248144-6	2011	Treatment with E(2) and 1,3,5-Tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole, an estrogen receptor-alpha (ERalpha) specific agonist, significantly up-regulated MMP2 expression in WPMY-1 and PrSC cells at both mRNA and protein levels.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	24-72	estrogen receptor 1	Homo sapiens	77-100
21847390-10	2011	The effect of PPT on regulating CLDN6 expression in MCF-7 cells was blocked by ICI.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	14-17	claudin 6	Homo sapiens	32-37
21248144-6	2011	Treatment with E(2) and 1,3,5-Tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole, an estrogen receptor-alpha (ERalpha) specific agonist, significantly up-regulated MMP2 expression in WPMY-1 and PrSC cells at both mRNA and protein levels.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	24-72	estrogen receptor 1	Homo sapiens	102-109
21248144-6	2011	Treatment with E(2) and 1,3,5-Tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole, an estrogen receptor-alpha (ERalpha) specific agonist, significantly up-regulated MMP2 expression in WPMY-1 and PrSC cells at both mRNA and protein levels.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	24-72	matrix metallopeptidase 2	Homo sapiens	156-160
21068071-3	2011	We tested whether 1,3,5-tris (4-hydroxyphenyl)-4-propyl-1H-pyrazole (PPT) (EST receptor alpha (ERalpha) agonist), 2,3-bis (4-hydroxyphenyl) propionitrile (DPN) (EST receptor beta (ERbeta) agonist), or EST itself would prevent apoptosis in VSC4.1 motoneurons following exposure to TNF-alpha.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	18-67	tachykinin precursor 1	Homo sapiens	69-72
21166678-6	2011	The results of regression analyses revealed significant positive relationships between the levels of ERK1/2 expression, phosphorylation, and activity in the PPT and amounts of time spent in slow-wave sleep, rapid eye movement sleep, and total sleep.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	157-160	mitogen activated protein kinase 3	Rattus norvegicus	101-107
21166678-7	2011	Additionally, these regression analyses revealed significant negative relationships between the levels of ERK1/2 expression, phosphorylation, and activity in the PPT and amounts of time spent in wakefulness.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	162-165	mitogen activated protein kinase 3	Rattus norvegicus	106-112
21166678-8	2011	Collectively, these results, for the first time, suggest that the increased ERK1/2 signaling in the PPT is associated with maintenance of sleep via suppression of wakefulness.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	100-103	mitogen activated protein kinase 3	Rattus norvegicus	76-82
20012353-9	2010	Apoptosis-inducing factor (Aif) expression was increased in DPN-treated tumors, while active caspase 9 was up-regulated in PPT-treated mice, demonstrating the involvement of the intrinsic apoptotic pathway in estrogen-induced regression in this model.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	123-126	caspase 9	Mus musculus	93-102
21847390-9	2011	PPT, an ERalpha-selective ligand, upregulated CLDN6 expression at 10(-5) mol/L after 24 hours.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	estrogen receptor 1	Homo sapiens	8-15
21847390-9	2011	PPT, an ERalpha-selective ligand, upregulated CLDN6 expression at 10(-5) mol/L after 24 hours.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	claudin 6	Homo sapiens	46-51
21254080-9	2011	We conclude that the PPT is a valid and reliable tool to quantify functional impairment caused by CTS.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	21-24	transthyretin	Homo sapiens	98-101
20553864-4	2010	ERalpha was more sensitive and responsive to PPT than ERbeta1 or ERbeta2 in transactivation assays.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	45-48	estrogen receptor 1	Homo sapiens	0-7
20881113-5	2010	The selective ERalpha agonist propylpyrazole triole (PPT) and STX most closely mimicked the estradiol-induced [Ca(2+)](i) responses, where PPT was more potent but less efficacious than STX.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	139-142	Era (G-protein)-like 1 (E. coli)	Mus musculus	14-21
20164203-5	2010	The stereoisomer 17alpha-estradiol showed lesser relaxant effects, and the selective estrogen receptor (ER) agonists 4,4",4""-(4-propyl-[(1)H]pyrazole-1,3,5-triyl)tris-phenol (ERalpha) and 2,3-bis(4-hydroxyphenyl)-propionitrile (ERbeta) did not show any effect.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	117-174	estrogen receptor 1	Gallus gallus	176-183
20881113-5	2010	The selective ERalpha agonist propylpyrazole triole (PPT) and STX most closely mimicked the estradiol-induced [Ca(2+)](i) responses, where PPT was more potent but less efficacious than STX.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	53-56	Era (G-protein)-like 1 (E. coli)	Mus musculus	14-21
20644008-4	2010	Propyl-pyrazole-triol (PPT; 100 nmol/L; estrogen receptor [ER]-alpha agonist), but not diarylpropionitrile (ER-beta agonist), mimicked the stimulatory effects of estradiol on capillary formation, and methyl-piperidino-pyrazole (ER-alpha antagonist) abolished the effects of estradiol and PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-21	estrogen receptor 1	Homo sapiens	228-236
20644008-4	2010	Propyl-pyrazole-triol (PPT; 100 nmol/L; estrogen receptor [ER]-alpha agonist), but not diarylpropionitrile (ER-beta agonist), mimicked the stimulatory effects of estradiol on capillary formation, and methyl-piperidino-pyrazole (ER-alpha antagonist) abolished the effects of estradiol and PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	23-26	estrogen receptor 1	Homo sapiens	228-236
20644008-5	2010	Three different RTK activators (vascular endothelial growth factor, hepatocyte growth factor, and stromal derived growth factor 1) mimicked the capillary-stimulating effects of estradiol and PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	191-194	vascular endothelial growth factor A	Homo sapiens	32-66
20644008-7	2010	Estradiol increased HO-1 expression by 2- to 3-fold, an effect blocked by SU5416, and PPT mimicked the effects of estradiol on HO-1.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	86-89	heme oxygenase 1	Homo sapiens	127-131
20534756-7	2010	Propylpyrazoletriol (estrogen receptor-alpha agonist, 100 nmol/liter), but not diarylpropionitrile (estrogen receptor-beta agonist, 10 nmol/liter), inhibited VSMC mitogenesis, and this effect was blocked by resveratrol (5 micromol/liter).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-19	estrogen receptor 1	Homo sapiens	21-44
20400328-7	2010	Results indicate PP T cell proliferation, cytokine production and MAPK activation decreased significantly following T-H. E2, PPT or DPN administration normalized these parameters.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	125-128	palmitoyl-protein thioesterase 1	Mus musculus	17-21
20400328-8	2010	Since PPT or DPN administration following T-H was effective in normalizing PP T cell functions, the salutary effects of E2 are mediated via ER-alpha and ER-beta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	6-9	palmitoyl-protein thioesterase 1	Mus musculus	75-79
20203089-2	2010	On the basis of previous work indicating a major role for estrogen receptor (ER)-alpha in maintaining cardiovascular health, we evaluated the tissue selectivity of the ER alpha-selective agonist propyl pyrazole triol (PPT) compared with 17beta-estradiol (E2) in vivo.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	195-216	estrogen receptor 1	Homo sapiens	168-176
20070947-4	2010	Furthermore, the ERalpha-selective agonist 4,4",4""-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT), but not the ERbeta-agonist 2,3-bis(4-hydroxyphenyl)-propionitrile, significantly increased hIP mRNA and PrmIP-directed gene expression.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	43-98	estrogen receptor 1	Homo sapiens	17-24
20035322-6	2010	The results showed that ICB, which mainly blocks large-diameter myelinated muscle afferents, was associated with an increase in PPT and PTRP (all P &lt; 0.001) at MTrP regions but not at non-MTrP regions.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	128-131	lysosomal protein transmembrane 4 alpha	Homo sapiens	163-167
20070947-4	2010	Furthermore, the ERalpha-selective agonist 4,4",4""-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT), but not the ERbeta-agonist 2,3-bis(4-hydroxyphenyl)-propionitrile, significantly increased hIP mRNA and PrmIP-directed gene expression.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	100-103	estrogen receptor 1	Homo sapiens	17-24
19535786-9	2009	FOS induction in hypothalamic gonadotropic (GnRH) neurons after hormone priming was impaired in the EB- and PPT-treated groups but neither of the BPA-treated groups.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	108-111	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	0-3
20087596-4	2010	We show that the rpt2a-3, rpn10-1 and rpn12a-1 mutants are hypersensitive to the antibiotic hygromycin B, and tolerant to the translation inhibitor cycloheximide (CHX) and herbicide L-phosphinothricin (PPT).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	202-205	Phototropic-responsive NPH3 family protein	Arabidopsis thaliana	17-24
19631674-6	2009	Although ERalpha ligand-induced signaling by endogenous estrogens is lost in ENERKI females, the ERalpha selective agonist propyl pyrazole triol (PPT), a synthetic nonsteroidal compound, is still able to activate G525L ERalphain vivo to increase uterine weight.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	123-144	estrogen receptor 1 (alpha)	Mus musculus	97-104
19631674-6	2009	Although ERalpha ligand-induced signaling by endogenous estrogens is lost in ENERKI females, the ERalpha selective agonist propyl pyrazole triol (PPT), a synthetic nonsteroidal compound, is still able to activate G525L ERalphain vivo to increase uterine weight.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	146-149	estrogen receptor 1 (alpha)	Mus musculus	9-16
19631674-9	2009	In accordance with this result, preputial gland weight and LH levels were also lowered in these animals, indicating PPT treatments most likely led to restoration of ERalpha negative feedback of the hypothalamic-pituitary axis.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	116-119	estrogen receptor 1 (alpha)	Mus musculus	165-172
19860859-2	2010	Here we demonstrate that the levels of calcium/calmodulin kinase II (CaMKII) and phosphorylated CaMKII expression in the PPT decreased and increased with "low W with high REM sleep" and "high W/low REM sleep" periods, respectively.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	121-124	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	39-67
19860859-2	2010	Here we demonstrate that the levels of calcium/calmodulin kinase II (CaMKII) and phosphorylated CaMKII expression in the PPT decreased and increased with "low W with high REM sleep" and "high W/low REM sleep" periods, respectively.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	121-124	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	69-75
19860859-2	2010	Here we demonstrate that the levels of calcium/calmodulin kinase II (CaMKII) and phosphorylated CaMKII expression in the PPT decreased and increased with "low W with high REM sleep" and "high W/low REM sleep" periods, respectively.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	121-124	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	96-102
19860859-4	2010	Next, we demonstrate that CaMKII activity in the PPT is negatively and positively correlated with the "low W with high REM sleep" and "high W/low REM sleep" periods, respectively.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	49-52	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	26-32
19574278-2	2009	METHODS: Two weeks or 1 year after OVX, rats were injected over 3 days with 125 microg/kg of estradiol benzoate (EB), 7.5 mg/kg of the selective ERalpha agonist propylpyrazole triol (PPT), or 15 mg/kg of the selective ER modulator tamoxifen (TX).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	161-181	estrogen receptor 1	Rattus norvegicus	145-152
19660865-9	2009	Hind paw injection of IL-6 and NGF dose dependently produced less mechanical allodynia in the ppt-A(-/-) compared to wt mice.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	94-97	interleukin 6	Mus musculus	22-26
19660865-9	2009	Hind paw injection of IL-6 and NGF dose dependently produced less mechanical allodynia in the ppt-A(-/-) compared to wt mice.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	94-97	nerve growth factor	Mus musculus	31-34
19505948-8	2009	4,4",4""-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol, an ER alpha-selective agonist, and 2,3-bis(4-hydroxyphenyl)-propionitrile, an ER beta-selective agonist, both inhibited cyst breakdown in organ culture, suggesting that E(2) can signal through both the receptors to regulate cyst breakdown.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-55	estrogen receptor 1 (alpha)	Mus musculus	60-68
19596275-3	2009	The present study generated a profile of synaptic proteins altered by administration of estradiol benzoate, the ERalpha selective agonist PPT (1,3,5-tris (4-hydroxyphenyl)-4-propyl-1H-pyrazole) and the ERbeta selective agonist DPN (2,3-bis (4-hydroxyphenyl) propionitrile) alone and in combination in comparison to vehicle in the CA1 region of the dorsal hippocampus.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	143-192	estrogen receptor 1	Rattus norvegicus	112-119
19596275-3	2009	The present study generated a profile of synaptic proteins altered by administration of estradiol benzoate, the ERalpha selective agonist PPT (1,3,5-tris (4-hydroxyphenyl)-4-propyl-1H-pyrazole) and the ERbeta selective agonist DPN (2,3-bis (4-hydroxyphenyl) propionitrile) alone and in combination in comparison to vehicle in the CA1 region of the dorsal hippocampus.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	143-192	tachykinin, precursor 1	Rattus norvegicus	138-141
19628068-12	2009	However, higher levels of myocardial VEGF were noted in the PPT-treated group compared with controls.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	60-63	vascular endothelial growth factor A	Rattus norvegicus	37-41
19409966-5	2009	Our results further show that both ER subtypes are involved in the mediation of the synaptogenic effects of estrogens on VMNvl neurons since the administration of the selective ERalpha, propyl-pyrazole-triol (PPT), and ERbeta, diarylpropionitrile (DPN), agonists induced a significant increase in the number of synapses that, however, was more exuberant for PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	186-207	estrogen receptor 1	Rattus norvegicus	35-37
19409966-5	2009	Our results further show that both ER subtypes are involved in the mediation of the synaptogenic effects of estrogens on VMNvl neurons since the administration of the selective ERalpha, propyl-pyrazole-triol (PPT), and ERbeta, diarylpropionitrile (DPN), agonists induced a significant increase in the number of synapses that, however, was more exuberant for PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	209-212	estrogen receptor 1	Rattus norvegicus	35-37
19409966-5	2009	Our results further show that both ER subtypes are involved in the mediation of the synaptogenic effects of estrogens on VMNvl neurons since the administration of the selective ERalpha, propyl-pyrazole-triol (PPT), and ERbeta, diarylpropionitrile (DPN), agonists induced a significant increase in the number of synapses that, however, was more exuberant for PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	209-212	estrogen receptor 1	Rattus norvegicus	177-184
19409966-5	2009	Our results further show that both ER subtypes are involved in the mediation of the synaptogenic effects of estrogens on VMNvl neurons since the administration of the selective ERalpha, propyl-pyrazole-triol (PPT), and ERbeta, diarylpropionitrile (DPN), agonists induced a significant increase in the number of synapses that, however, was more exuberant for PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	209-212	estrogen receptor 2	Rattus norvegicus	219-225
19409966-5	2009	Our results further show that both ER subtypes are involved in the mediation of the synaptogenic effects of estrogens on VMNvl neurons since the administration of the selective ERalpha, propyl-pyrazole-triol (PPT), and ERbeta, diarylpropionitrile (DPN), agonists induced a significant increase in the number of synapses that, however, was more exuberant for PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	358-361	estrogen receptor 1	Rattus norvegicus	35-37
19410635-8	2009	Activation of ERalpha and/or ERbeta with 17beta-estradiol (E2), propyl-pyrazole-triol or diarylpropionitrile did not provide effective neuroprotection, and pretreatment with ICI 182,780 did not inhibit the protective effect of R,R-THC in either type of cell.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	64-85	estrogen receptor 1	Rattus norvegicus	14-21
19531642-6	2009	Moreover, ERalpha (propylpyrazoletriol; 100 nM, 10 microl it) and ERbeta (diarylpropionitrile; 100 microM, 10 microl it) agonists both facilitated the SRP, similar to results with a beta-estradiol injection.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	19-38	estrogen receptor 1	Rattus norvegicus	10-17
19627578-4	2009	Early (3 h) and late (24 h) responses to estrogen were evaluated and the participation of the estrogen receptors (ER), ERalpha and ERbeta, was analyzed by treating mice with propylpyrazole triol, a selective ERalpha agonist, or diarylpropionitrile, a selective agonist of ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	174-194	estrogen receptor 2 (beta)	Mus musculus	131-137
19627578-4	2009	Early (3 h) and late (24 h) responses to estrogen were evaluated and the participation of the estrogen receptors (ER), ERalpha and ERbeta, was analyzed by treating mice with propylpyrazole triol, a selective ERalpha agonist, or diarylpropionitrile, a selective agonist of ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	174-194	estrogen receptor 1 (alpha)	Mus musculus	208-215
19583861-10	2009	In contrast, the selective ERalpha agonist 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole (5 pmol) did not influence the same cardiovascular parameters.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	43-91	estrogen receptor 1	Rattus norvegicus	27-34
19420002-6	2009	Exposure of different ER-selective agonists propyl-(1H)-pyrazole-1,3,5-triyl-trisphenol or 2,3-bis-(4-hydroxyphenyl)-propionitrile demonstrated an ER subtype-specific regulation of IL-6R alpha in mouse fallopian tubes.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	44-87	interleukin 6 receptor, alpha	Mus musculus	181-192
19406003-0	2009	Endothelium-independent vasorelaxation by the selective alpha estrogen receptor agonist propyl pyrazole triol in rat aortic smooth muscle.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	88-109	estrogen receptor 1	Rattus norvegicus	62-79
19627578-6	2009	Estrogen increased Tac1 and Tacr1 mRNA after 3 h and decreased Tac1 and Tac4 expression after 24 h. Tac2 and Tacr3 mRNA levels were decreased by estrogen at both 3 and 24 h. Most effects of estrogen were also observed in animals treated with propylpyrazole triol.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	242-262	tachykinin 2	Mus musculus	100-104
19627578-6	2009	Estrogen increased Tac1 and Tacr1 mRNA after 3 h and decreased Tac1 and Tac4 expression after 24 h. Tac2 and Tacr3 mRNA levels were decreased by estrogen at both 3 and 24 h. Most effects of estrogen were also observed in animals treated with propylpyrazole triol.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	242-262	tachykinin receptor 3	Mus musculus	109-114
19264877-6	2009	By treating estrogen nonresponsive ERalpha knock-in (ENERKI) mice with the ERalpha selective synthetic agonist propyl pyrazole triol, which is able to bind and activate G525L ERalpha in vivo, we discovered male fertility required neonatal estrogen-mediated ERalpha signaling.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	111-132	estrogen receptor 1 (alpha)	Mus musculus	35-42
19264877-6	2009	By treating estrogen nonresponsive ERalpha knock-in (ENERKI) mice with the ERalpha selective synthetic agonist propyl pyrazole triol, which is able to bind and activate G525L ERalpha in vivo, we discovered male fertility required neonatal estrogen-mediated ERalpha signaling.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	111-132	estrogen receptor 1 (alpha)	Mus musculus	75-82
19264877-6	2009	By treating estrogen nonresponsive ERalpha knock-in (ENERKI) mice with the ERalpha selective synthetic agonist propyl pyrazole triol, which is able to bind and activate G525L ERalpha in vivo, we discovered male fertility required neonatal estrogen-mediated ERalpha signaling.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	111-132	estrogen receptor 1 (alpha)	Mus musculus	75-82
19264877-6	2009	By treating estrogen nonresponsive ERalpha knock-in (ENERKI) mice with the ERalpha selective synthetic agonist propyl pyrazole triol, which is able to bind and activate G525L ERalpha in vivo, we discovered male fertility required neonatal estrogen-mediated ERalpha signaling.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	111-132	estrogen receptor 1 (alpha)	Mus musculus	75-82
19406003-1	2009	OBJECTIVES: This study investigated the signalling mechanism of the relaxant responses to the estrogen receptor (ERalpha) agonist PPT (propyl pyrazole triol) in endothelium-denuded rat aortic rings.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	130-133	estrogen receptor 1	Rattus norvegicus	94-111
19406003-1	2009	OBJECTIVES: This study investigated the signalling mechanism of the relaxant responses to the estrogen receptor (ERalpha) agonist PPT (propyl pyrazole triol) in endothelium-denuded rat aortic rings.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	130-133	estrogen receptor 1	Rattus norvegicus	113-120
19406003-1	2009	OBJECTIVES: This study investigated the signalling mechanism of the relaxant responses to the estrogen receptor (ERalpha) agonist PPT (propyl pyrazole triol) in endothelium-denuded rat aortic rings.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	135-156	estrogen receptor 1	Rattus norvegicus	94-111
19406003-1	2009	OBJECTIVES: This study investigated the signalling mechanism of the relaxant responses to the estrogen receptor (ERalpha) agonist PPT (propyl pyrazole triol) in endothelium-denuded rat aortic rings.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	135-156	estrogen receptor 1	Rattus norvegicus	113-120
19074580-8	2009	Ovariectomized young adult female Sprague Dawley rats treated with racemic DPN, S-DPN, and the ERbeta agonist, WAY-200070, showed significantly decreased anxiety-like behaviors in both the open-field and elevated plus maze and significantly less depressive-like behaviors in the forced swim test compared with vehicle-, R-DPN-, or propylpyrazoletriol (ERalpha agonist)-treated animals.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	331-350	estrogen receptor 2	Rattus norvegicus	95-101
19671997-11	2009	The ERalpha-selective agonist propylpyrazole triol (10(-8) M) mimicked the effect of 17beta-estradiol on RALDH1 expression, but the ERbeta-selective agonist diarylpropionitrile (10(-8) M) did not.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	30-50	estrogen receptor 1	Rattus norvegicus	4-11
19176323-5	2009	Rats were injected sc with the ERalpha agonist propylpyrazole triol (PPT) or vehicle 45 min before heart isolation (5 microg/kg).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	47-67	estrogen receptor 1	Rattus norvegicus	31-38
19176323-7	2009	Increased ERalpha particulate targeting occurred after PPT in conjunction with reversal of age-related reductions in nuclear PKCepsilon, mitochondrial PKCepsilon and pAkt (P &lt; 0.05).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	55-58	estrogen receptor 1	Rattus norvegicus	10-17
19176323-8	2009	PPT also increased mRNA levels for the PKCepsilon anchoring protein, receptor for activated C kinase2 (RACK2; P &lt; 0.05).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	protein kinase C, epsilon	Rattus norvegicus	39-49
19176323-8	2009	PPT also increased mRNA levels for the PKCepsilon anchoring protein, receptor for activated C kinase2 (RACK2; P &lt; 0.05).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	COPI coat complex subunit beta 1	Rattus norvegicus	69-101
19176323-8	2009	PPT also increased mRNA levels for the PKCepsilon anchoring protein, receptor for activated C kinase2 (RACK2; P &lt; 0.05).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	COPI coat complex subunit beta 1	Rattus norvegicus	103-108
18847333-4	2009	ERalpha agonist propylpyrazoletriol (PPT) and ERbeta agonist diarylpropionitrile (DPN) attenuated EtOH-induced ERalpha and ERbeta gene overexpression, respectively.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	16-35	estrogen receptor 1	Rattus norvegicus	0-7
18847333-4	2009	ERalpha agonist propylpyrazoletriol (PPT) and ERbeta agonist diarylpropionitrile (DPN) attenuated EtOH-induced ERalpha and ERbeta gene overexpression, respectively.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	16-35	estrogen receptor 1	Rattus norvegicus	111-118
18847333-4	2009	ERalpha agonist propylpyrazoletriol (PPT) and ERbeta agonist diarylpropionitrile (DPN) attenuated EtOH-induced ERalpha and ERbeta gene overexpression, respectively.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	16-35	estrogen receptor 2	Rattus norvegicus	123-129
18847333-4	2009	ERalpha agonist propylpyrazoletriol (PPT) and ERbeta agonist diarylpropionitrile (DPN) attenuated EtOH-induced ERalpha and ERbeta gene overexpression, respectively.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	37-40	estrogen receptor 1	Rattus norvegicus	0-7
18847333-4	2009	ERalpha agonist propylpyrazoletriol (PPT) and ERbeta agonist diarylpropionitrile (DPN) attenuated EtOH-induced ERalpha and ERbeta gene overexpression, respectively.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	37-40	estrogen receptor 1	Rattus norvegicus	111-118
18847333-4	2009	ERalpha agonist propylpyrazoletriol (PPT) and ERbeta agonist diarylpropionitrile (DPN) attenuated EtOH-induced ERalpha and ERbeta gene overexpression, respectively.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	37-40	estrogen receptor 2	Rattus norvegicus	123-129
18950659-3	2009	Here we demonstrate that postnatal administration of the ERalpha agonist 1,3,5-tris(4-Hydroxyphenyl)-4-propyl-1H-pyrazole (PPT), but not the ERbeta agonist diarylpropionitrile (DPN), also masculinizes 5-HT-ir in the female VMNvl, suggesting a mechanistic role for ERalpha in this process.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	73-121	estrogen receptor 1	Rattus norvegicus	57-64
18950659-3	2009	Here we demonstrate that postnatal administration of the ERalpha agonist 1,3,5-tris(4-Hydroxyphenyl)-4-propyl-1H-pyrazole (PPT), but not the ERbeta agonist diarylpropionitrile (DPN), also masculinizes 5-HT-ir in the female VMNvl, suggesting a mechanistic role for ERalpha in this process.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	73-121	tachykinin, precursor 1	Rattus norvegicus	123-126
18950659-3	2009	Here we demonstrate that postnatal administration of the ERalpha agonist 1,3,5-tris(4-Hydroxyphenyl)-4-propyl-1H-pyrazole (PPT), but not the ERbeta agonist diarylpropionitrile (DPN), also masculinizes 5-HT-ir in the female VMNvl, suggesting a mechanistic role for ERalpha in this process.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	73-121	estrogen receptor 1	Rattus norvegicus	264-271
19671997-11	2009	The ERalpha-selective agonist propylpyrazole triol (10(-8) M) mimicked the effect of 17beta-estradiol on RALDH1 expression, but the ERbeta-selective agonist diarylpropionitrile (10(-8) M) did not.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	30-50	aldehyde dehydrogenase 1 family, member A1	Rattus norvegicus	105-111
19090407-7	2008	RESULTS: It was found that NGF significantly reduced PPT and PPTOL 3 hours, 1 and 7 days postinjection (P &lt; .001).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	53-56	nerve growth factor	Homo sapiens	27-30
18832085-3	2008	We hypothesized that administration of the selective ER-alpha agonist propylpyrazole triol (PPT) and/or the selective ER-beta agonist diarylpropiolnitrile (DPN) rapidly decreases PA vasoconstriction induced by pharmacologic and hypoxic stimuli via a nitric oxide (NO)-dependent mechanism.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	70-90	estrogen receptor 1	Rattus norvegicus	53-61
18832085-3	2008	We hypothesized that administration of the selective ER-alpha agonist propylpyrazole triol (PPT) and/or the selective ER-beta agonist diarylpropiolnitrile (DPN) rapidly decreases PA vasoconstriction induced by pharmacologic and hypoxic stimuli via a nitric oxide (NO)-dependent mechanism.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	70-90	tachykinin, precursor 1	Rattus norvegicus	92-95
18832649-4	2009	The production of inducible nitric-oxide synthase (iNOS), a classical indicator of vascular inflammation, was significantly reduced by PPT in control but not diabetic SMCs, whereas it was further enhanced by DPN treatment in both groups.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	135-138	nitric oxide synthase 2, inducible	Mus musculus	18-49
18832649-4	2009	The production of inducible nitric-oxide synthase (iNOS), a classical indicator of vascular inflammation, was significantly reduced by PPT in control but not diabetic SMCs, whereas it was further enhanced by DPN treatment in both groups.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	135-138	nitric oxide synthase 2, inducible	Mus musculus	51-55
18835417-5	2008	Transactivation assays using mouse ERalpha and ERbeta showed that 10(-10)M DES activated both ER subtypes and that the ERalpha agonist (propyl pyrazole triol, PPT) and the ERbeta agonist (diarylpropionitrile, DPN) selectively activated their respective ERs at 10(-9)M. Neonatal female mice were injected subcutaneously with DES, PPT or DPN and the animals were examined at 13 and 15 weeks of age, respectively.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	136-157	estrogen receptor 1 (alpha)	Mus musculus	119-126
18805896-8	2008	DPN also induced a greater effect than PPT in the reduction of ET-1-induced vasoconstriction in the kidneys and lungs.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	39-42	endothelin 1	Homo sapiens	63-67
18805896-9	2008	In contrast, PPT attenuated ET-1-induced vasoconstriction in the liver, whereas both DPN and PPT were equally effective in the small intestine.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	13-16	endothelin 1	Homo sapiens	28-32
18757549-0	2008	The estrogen receptor {alpha}-selective agonist propyl pyrazole triol improves glucose tolerance in ob/ob mice; potential molecular mechanisms.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	48-69	estrogen receptor 1 (alpha)	Mus musculus	4-28
18757549-1	2008	The aim of this study was to validate the role of estrogen receptor alpha (ERalpha) signaling in the regulation of glucose metabolism, and to compare the molecular events upon treatment with the ERalpha-selective agonist propyl pyrazole triol (PPT) or 17beta-estradiol (E(2)) in ob/ob mice.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	221-242	estrogen receptor 1 (alpha)	Mus musculus	195-202
18757549-1	2008	The aim of this study was to validate the role of estrogen receptor alpha (ERalpha) signaling in the regulation of glucose metabolism, and to compare the molecular events upon treatment with the ERalpha-selective agonist propyl pyrazole triol (PPT) or 17beta-estradiol (E(2)) in ob/ob mice.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	244-247	estrogen receptor 1 (alpha)	Mus musculus	195-202
18757549-11	2008	In the liver, treatment with E(2) and PPT increased and decreased the respective expression levels of the transcription factor signal transducer and activator of transcription 3, and of glucose-6-phosphatase.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	38-41	signal transducer and activator of transcription 3	Mus musculus	127-177
18757549-11	2008	In the liver, treatment with E(2) and PPT increased and decreased the respective expression levels of the transcription factor signal transducer and activator of transcription 3, and of glucose-6-phosphatase.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	38-41	glucose-6-phosphatase, catalytic	Mus musculus	186-207
18757549-12	2008	In summary, our data demonstrate that PPT exerts anti-diabetic effects, and these effects are mediated via ERalpha.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	38-41	estrogen receptor 1 (alpha)	Mus musculus	107-114
18644836-4	2008	Using human osteosarcoma (U2OS) ERalpha or ERbeta reporter cells, propyl-pyrazole-triol (PPT) was shown to be a selective ERalpha and diarylpropionitrile (DPN) a preferential ERbeta modulator.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	66-87	estrogen receptor 1	Homo sapiens	32-39
18644836-4	2008	Using human osteosarcoma (U2OS) ERalpha or ERbeta reporter cells, propyl-pyrazole-triol (PPT) was shown to be a selective ERalpha and diarylpropionitrile (DPN) a preferential ERbeta modulator.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	66-87	estrogen receptor 2	Homo sapiens	43-49
18644836-4	2008	Using human osteosarcoma (U2OS) ERalpha or ERbeta reporter cells, propyl-pyrazole-triol (PPT) was shown to be a selective ERalpha and diarylpropionitrile (DPN) a preferential ERbeta modulator.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	66-87	estrogen receptor 1	Homo sapiens	122-129
18644836-4	2008	Using human osteosarcoma (U2OS) ERalpha or ERbeta reporter cells, propyl-pyrazole-triol (PPT) was shown to be a selective ERalpha and diarylpropionitrile (DPN) a preferential ERbeta modulator.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	66-87	estrogen receptor 2	Homo sapiens	175-181
18644836-4	2008	Using human osteosarcoma (U2OS) ERalpha or ERbeta reporter cells, propyl-pyrazole-triol (PPT) was shown to be a selective ERalpha and diarylpropionitrile (DPN) a preferential ERbeta modulator.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	89-92	estrogen receptor 1	Homo sapiens	32-39
18644836-4	2008	Using human osteosarcoma (U2OS) ERalpha or ERbeta reporter cells, propyl-pyrazole-triol (PPT) was shown to be a selective ERalpha and diarylpropionitrile (DPN) a preferential ERbeta modulator.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	89-92	estrogen receptor 2	Homo sapiens	43-49
18644836-4	2008	Using human osteosarcoma (U2OS) ERalpha or ERbeta reporter cells, propyl-pyrazole-triol (PPT) was shown to be a selective ERalpha and diarylpropionitrile (DPN) a preferential ERbeta modulator.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	89-92	estrogen receptor 1	Homo sapiens	122-129
18644836-4	2008	Using human osteosarcoma (U2OS) ERalpha or ERbeta reporter cells, propyl-pyrazole-triol (PPT) was shown to be a selective ERalpha and diarylpropionitrile (DPN) a preferential ERbeta modulator.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	89-92	estrogen receptor 2	Homo sapiens	175-181
18511507-6	2008	Furthermore, a selective ERalpha agonist 4,4",4""-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (like 17beta-estradiol) enhanced FSH-stimulated progesterone production, and this was abolished by pretreatment with MPP.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	41-96	estrogen receptor 1	Rattus norvegicus	25-32
18535112-5	2008	The ERalpha agonist, propylpyrazoletriol, did not induce regrowth by itself, but exposure to propylpyrazoletriol on d 3-5 of testosterone replacement resulted in cyclin D1-positive cells in the ductal epithelium, invasion of FGF10-positive immune cells in the regrowing prostate, and budding 14 d later.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	21-40	estrogen receptor 1 (alpha)	Mus musculus	4-11
18535112-5	2008	The ERalpha agonist, propylpyrazoletriol, did not induce regrowth by itself, but exposure to propylpyrazoletriol on d 3-5 of testosterone replacement resulted in cyclin D1-positive cells in the ductal epithelium, invasion of FGF10-positive immune cells in the regrowing prostate, and budding 14 d later.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	93-112	cyclin D1	Mus musculus	162-171
18535112-5	2008	The ERalpha agonist, propylpyrazoletriol, did not induce regrowth by itself, but exposure to propylpyrazoletriol on d 3-5 of testosterone replacement resulted in cyclin D1-positive cells in the ductal epithelium, invasion of FGF10-positive immune cells in the regrowing prostate, and budding 14 d later.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	93-112	fibroblast growth factor 10	Mus musculus	225-230
18433893-5	2008	The ERalpha agonist PPT, but not the ERbeta agonist DPN, elicited both proceptive and receptive behavior.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	20-23	estrogen receptor 1	Rattus norvegicus	4-11
18562618-7	2008	We find that only ERalpha is involved in the early signaling events using the ERalpha agonist 4,4",4""-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol and the ERbeta agonist 2,3-bis(4-hydroxyphenyl)-propionitrile.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	94-149	estrogen receptor 1	Homo sapiens	18-25
18566133-8	2008	E2, the selective GPR30 agonist G1, and the selective ERalpha agonist 4,4",4""-(4-propyl-[1H]pyrazole-1,3,5-triyl) trisphenol activated the rapid ERK1/2-fos signaling cascade.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	70-125	estrogen receptor 1 (alpha)	Mus musculus	54-61
18566133-8	2008	E2, the selective GPR30 agonist G1, and the selective ERalpha agonist 4,4",4""-(4-propyl-[1H]pyrazole-1,3,5-triyl) trisphenol activated the rapid ERK1/2-fos signaling cascade.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	70-125	mitogen-activated protein kinase 3	Mus musculus	146-152
18566133-8	2008	E2, the selective GPR30 agonist G1, and the selective ERalpha agonist 4,4",4""-(4-propyl-[1H]pyrazole-1,3,5-triyl) trisphenol activated the rapid ERK1/2-fos signaling cascade.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	70-125	FBJ osteosarcoma oncogene	Mus musculus	153-156
18455292-12	2008	E2, PPT, DNP and Osp also inhibited etoposide-induced death and cytokine changes in SAOS-2 osteosarcoma cells expressing endogenous ERalpha and ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	4-7	estrogen receptor 1	Homo sapiens	132-139
18455292-5	2008	The ER isotype selective agonists propyl-pyrazole-triol (PPT) and diarylpropionitrile (DPN) had the same effect in U2OS/ERalpha and U2OS/ERbeta cells, respectively.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	34-55	estrogen receptor 1	Homo sapiens	120-127
18455292-5	2008	The ER isotype selective agonists propyl-pyrazole-triol (PPT) and diarylpropionitrile (DPN) had the same effect in U2OS/ERalpha and U2OS/ERbeta cells, respectively.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	34-55	estrogen receptor 2	Homo sapiens	137-143
18455292-5	2008	The ER isotype selective agonists propyl-pyrazole-triol (PPT) and diarylpropionitrile (DPN) had the same effect in U2OS/ERalpha and U2OS/ERbeta cells, respectively.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	57-60	estrogen receptor 1	Homo sapiens	120-127
18455292-5	2008	The ER isotype selective agonists propyl-pyrazole-triol (PPT) and diarylpropionitrile (DPN) had the same effect in U2OS/ERalpha and U2OS/ERbeta cells, respectively.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	57-60	estrogen receptor 2	Homo sapiens	137-143
18556135-4	2008	We have also shown that the mERalpha is under regulation of estradiol, and the ERalpha agonist, 4,4",4""-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol, induced extracellular-signal-regulated kinase signaling in a dose-dependent manner and in a time-course not compatible with genomic actions, supporting the notion of a membrane-initiated phenomenon.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	96-151	estrogen receptor 1	Rattus norvegicus	29-36
18468914-8	2008	PPT addition in vitro (10(-7) and 10(-6)M) significantly reduced KC CINC-1 production.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	C-X-C motif chemokine ligand 1	Rattus norvegicus	68-74
18562618-7	2008	We find that only ERalpha is involved in the early signaling events using the ERalpha agonist 4,4",4""-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol and the ERbeta agonist 2,3-bis(4-hydroxyphenyl)-propionitrile.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	94-149	estrogen receptor 1	Homo sapiens	78-85
18339713-7	2008	In addition, the synthetic ERalpha selective agonist propyl pyrazole triol (PPT) and ER agonist diethylstilbestrol (DES) were still able to activate ligand-induced G525L ERalpha pathways in vitro.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	53-74	estrogen receptor 1 (alpha)	Mus musculus	27-34
18339713-7	2008	In addition, the synthetic ERalpha selective agonist propyl pyrazole triol (PPT) and ER agonist diethylstilbestrol (DES) were still able to activate ligand-induced G525L ERalpha pathways in vitro.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	53-74	estrogen receptor 1 (alpha)	Mus musculus	170-177
18339713-7	2008	In addition, the synthetic ERalpha selective agonist propyl pyrazole triol (PPT) and ER agonist diethylstilbestrol (DES) were still able to activate ligand-induced G525L ERalpha pathways in vitro.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	76-79	estrogen receptor 1 (alpha)	Mus musculus	27-34
18339713-7	2008	In addition, the synthetic ERalpha selective agonist propyl pyrazole triol (PPT) and ER agonist diethylstilbestrol (DES) were still able to activate ligand-induced G525L ERalpha pathways in vitro.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	76-79	estrogen receptor 1 (alpha)	Mus musculus	170-177
18339713-8	2008	PPT treatments initiated at puberty stimulated ENERKI uterine development, whereas neonatal treatments were needed to restore mammary gland ductal elongation, indicating that neonatal ligand-induced ERalpha activation may prime mammary ducts to become more responsive to estrogens in adult tissues.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	estrogen receptor 1 (alpha)	Mus musculus	199-206
18317592-6	2008	The ERalpha-selective agonist, propyl(1H) pyrazole-1,3,5-triyl-trisphenol (PPT), partially protected ARKO mice from trauma, while the ERbeta-selective agonist, 2,3-bis (4-hydroxyphenyl)-propionitrile (DPN), protected WT and ARKO mice.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	31-73	estrogen receptor 1 (alpha)	Mus musculus	4-11
18276750-7	2008	PPT treatment was similar to E2 in terms of reducing Abeta accumulation in hippocampus, subiculum, and amygdala but comparatively less effective in frontal cortex.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	amyloid beta (A4) precursor protein	Mus musculus	53-58
18317592-6	2008	The ERalpha-selective agonist, propyl(1H) pyrazole-1,3,5-triyl-trisphenol (PPT), partially protected ARKO mice from trauma, while the ERbeta-selective agonist, 2,3-bis (4-hydroxyphenyl)-propionitrile (DPN), protected WT and ARKO mice.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	75-78	estrogen receptor 1 (alpha)	Mus musculus	4-11
18313836-11	2008	In addition, the estrogenicity of PPT in the induction of CaBP-9k expression was completely blocked by an estrogen antagonist, ICI, indicating that pituitary CaBP-9k expression is solely induced by ERalpha.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	34-37	estrogen receptor 1	Rattus norvegicus	198-205
17962869-9	2007	The prevalence of PPt was 5.6% (95% CI = 3.6 to 8.3%), and it was significantly associated with a low CD4 lymphocyte count (p&lt;0.048).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	18-21	CD4 molecule	Homo sapiens	102-105
17962348-6	2008	An ERbeta-selective agonist, 2,3-bis(4-hydroxyphenyl)-propionitrile, augmented the K(Ca) currents, although an ERalpha-selective agonist, 4,4",4""-[4-propyl-(1H)-pyrazole-1,3,5-triyl]tris-phenol, had no effect.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	136-194	estrogen receptor 1 (alpha)	Mus musculus	111-118
17981312-6	2008	Expression of UGT1A10 mRNA was also stimulated by other estrogenic compounds including propylpyrazoletriol (PPT) and genistein (Gen).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	87-106	UDP glucuronosyltransferase family 1 member A10	Homo sapiens	14-21
17981312-6	2008	Expression of UGT1A10 mRNA was also stimulated by other estrogenic compounds including propylpyrazoletriol (PPT) and genistein (Gen).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	108-111	UDP glucuronosyltransferase family 1 member A10	Homo sapiens	14-21
17959706-3	2008	Responses to changes in intraluminal flow and pressure were obtained before and after incubation with 17beta-estradiol or ER-alpha agonist propyl-pyrazole-triol (3 h; 10 nM).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	139-160	estrogen receptor 1 (alpha)	Mus musculus	122-130
17901129-7	2008	To correlate ERalpha binding to the promoter of specific genes, with changes in expression levels of the corresponding mRNAs, expression levels of selected mRNAs were assayed in livers 2, 4, and 6 h after treatment with ERalpha-selective agonist propyl pyrazole triol.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	246-267	estrogen receptor 1 (alpha)	Mus musculus	13-20
17901129-7	2008	To correlate ERalpha binding to the promoter of specific genes, with changes in expression levels of the corresponding mRNAs, expression levels of selected mRNAs were assayed in livers 2, 4, and 6 h after treatment with ERalpha-selective agonist propyl pyrazole triol.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	246-267	estrogen receptor 1 (alpha)	Mus musculus	220-227
17901129-8	2008	Five of these eight selected genes, Shp, Stat3, Pdgds, Pck1, and Pdk4, all responded to propyl pyrazole triol after 4 h treatment.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	88-109	nuclear receptor subfamily 0, group B, member 2	Mus musculus	36-39
17901129-8	2008	Five of these eight selected genes, Shp, Stat3, Pdgds, Pck1, and Pdk4, all responded to propyl pyrazole triol after 4 h treatment.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	88-109	signal transducer and activator of transcription 3	Mus musculus	41-46
17901129-8	2008	Five of these eight selected genes, Shp, Stat3, Pdgds, Pck1, and Pdk4, all responded to propyl pyrazole triol after 4 h treatment.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	88-109	phosphoenolpyruvate carboxykinase 1, cytosolic	Mus musculus	55-59
17901129-8	2008	Five of these eight selected genes, Shp, Stat3, Pdgds, Pck1, and Pdk4, all responded to propyl pyrazole triol after 4 h treatment.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	88-109	pyruvate dehydrogenase kinase, isoenzyme 4	Mus musculus	65-69
17996549-7	2007	The outcome measure was the PPT on the MTrP in the upper trapezius muscle ipsilateral to the side of the joint dysfunction, which was assessed pretreatment and 1, 5, and 10 minutes posttreatment by an assessor blinded to the treatment allocation of the subject.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	28-31	lysosomal protein transmembrane 4 alpha	Homo sapiens	39-43
17470727-7	2007	17beta-Estradiol and PPT, but not DPN, attenuated the responses to U46619 and bradykinin.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	21-24	kininogen 1	Homo sapiens	78-88
17592047-7	2007	The downstream PTB binding sites are essential for full repression and promote binding of PTB to the PPT with a consequent reduction in U2AF(65) binding.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	101-104	polypyrimidine tract binding protein 1	Homo sapiens	15-18
17592047-7	2007	The downstream PTB binding sites are essential for full repression and promote binding of PTB to the PPT with a consequent reduction in U2AF(65) binding.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	101-104	polypyrimidine tract binding protein 1	Homo sapiens	90-93
17592047-7	2007	The downstream PTB binding sites are essential for full repression and promote binding of PTB to the PPT with a consequent reduction in U2AF(65) binding.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	101-104	U2 small nuclear RNA auxiliary factor 2	Homo sapiens	136-143
17592047-8	2007	Our results are consistent with a repressive mechanism in which cooperative binding of PTB to the PPT competes with binding of U2AF(65), thereby specifically blocking splicing of the SM exon.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	98-101	polypyrimidine tract binding protein 1	Homo sapiens	87-90
17507257-9	2007	Thus, performance in the object placement task is better when E(2) and/or P are naturally elevated or when E(2), the ERalpha selective ER modulator PPT, P, or its metabolite, 3alpha,5alpha-THP, are administered post-training.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	148-151	estrogen receptor 1	Rattus norvegicus	117-124
17470727-4	2007	Within 5 minutes, selective ERalpha activation by PPT, but not 17beta-estradiol or the ERbeta agonist DPN, caused rapid, NO-dependent, and endothelium-dependent relaxation (49+/-5%; P&lt;0.001 versus ethanol).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	50-53	estrogen receptor 1	Homo sapiens	28-35
17133264-10	2007	Selective activation of ERbeta with DPN also increased cocaine-induced reinstatement responding, whereas selective activation of ERalpha with PPT did not affect cocaine-seeking behavior.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	142-145	estrogen receptor 1	Rattus norvegicus	129-136
17336162-2	2007	Herein we found that ovariectomized NZB/NZW F1 mice treated with propyl pyrazole triol (ERalpha-selective agonist) had significantly shorter survival, earlier development of albuminuria, higher serum concentrations of total IgG and prolactin, increased serum levels of anti-DNA IgG3, IgG2a and IgG2b and decreased anti-DNA IgG1 level compared to vehicle controls.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	65-86	estrogen receptor 1 (alpha)	Mus musculus	88-95
17336162-2	2007	Herein we found that ovariectomized NZB/NZW F1 mice treated with propyl pyrazole triol (ERalpha-selective agonist) had significantly shorter survival, earlier development of albuminuria, higher serum concentrations of total IgG and prolactin, increased serum levels of anti-DNA IgG3, IgG2a and IgG2b and decreased anti-DNA IgG1 level compared to vehicle controls.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	65-86	Immunoglobulin heavy constant gamma 3	Mus musculus	278-282
17336162-2	2007	Herein we found that ovariectomized NZB/NZW F1 mice treated with propyl pyrazole triol (ERalpha-selective agonist) had significantly shorter survival, earlier development of albuminuria, higher serum concentrations of total IgG and prolactin, increased serum levels of anti-DNA IgG3, IgG2a and IgG2b and decreased anti-DNA IgG1 level compared to vehicle controls.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	65-86	immunoglobulin heavy variable V1-9	Mus musculus	284-289
17336162-2	2007	Herein we found that ovariectomized NZB/NZW F1 mice treated with propyl pyrazole triol (ERalpha-selective agonist) had significantly shorter survival, earlier development of albuminuria, higher serum concentrations of total IgG and prolactin, increased serum levels of anti-DNA IgG3, IgG2a and IgG2b and decreased anti-DNA IgG1 level compared to vehicle controls.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	65-86	immunoglobulin heavy constant gamma 2B	Mus musculus	294-299
17336162-2	2007	Herein we found that ovariectomized NZB/NZW F1 mice treated with propyl pyrazole triol (ERalpha-selective agonist) had significantly shorter survival, earlier development of albuminuria, higher serum concentrations of total IgG and prolactin, increased serum levels of anti-DNA IgG3, IgG2a and IgG2b and decreased anti-DNA IgG1 level compared to vehicle controls.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	65-86	LOC105243590	Mus musculus	323-327
17378970-8	2007	The PPT of the HP group at SP6 was significantly lower than that of the LP group (13.50 +/- 0.73 vs. 16.30 +/- 0.66 kilopascals, P &lt; 0.05), but not at other APs or at non-APs.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	4-7	Sp6 transcription factor	Homo sapiens	27-30
17400808-6	2007	Results showed that i) EB and DPN potentiated the negative feedback of TX on basal LH release; ii) DPN reduced TX-induced PR expression; iii) EB and PPT blocked TX-elicited LHRH self-priming and iv) ZK299 reduced LHRH-stimulated LH secretion and blocked LHRH self-priming.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	149-152	progesterone receptor	Rattus norvegicus	122-124
17400808-6	2007	Results showed that i) EB and DPN potentiated the negative feedback of TX on basal LH release; ii) DPN reduced TX-induced PR expression; iii) EB and PPT blocked TX-elicited LHRH self-priming and iv) ZK299 reduced LHRH-stimulated LH secretion and blocked LHRH self-priming.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	149-152	gonadotropin releasing hormone 1	Rattus norvegicus	173-177
17400808-6	2007	Results showed that i) EB and DPN potentiated the negative feedback of TX on basal LH release; ii) DPN reduced TX-induced PR expression; iii) EB and PPT blocked TX-elicited LHRH self-priming and iv) ZK299 reduced LHRH-stimulated LH secretion and blocked LHRH self-priming.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	149-152	gonadotropin releasing hormone 1	Rattus norvegicus	213-217
17400808-6	2007	Results showed that i) EB and DPN potentiated the negative feedback of TX on basal LH release; ii) DPN reduced TX-induced PR expression; iii) EB and PPT blocked TX-elicited LHRH self-priming and iv) ZK299 reduced LHRH-stimulated LH secretion and blocked LHRH self-priming.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	149-152	gonadotropin releasing hormone 1	Rattus norvegicus	213-217
17258238-7	2007	The estrogen receptor-alpha (ERalpha) selective agonist, propyl pyrazole triol (PPT, 2mg/kg), exerted a similar protective effect, but the estrogen receptor-beta (ERbeta) agonist, diarylpropiolnitrile (DPN, 8mg/kg), failed to do so.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	57-78	estrogen receptor 1	Rattus norvegicus	29-36
17332286-6	2007	Using ERalpha-specific (propyl pyrazole triol) and ERbeta-specific (diarylpropionitrile) agonists, the gene expression modulations produced by E(2) could be replicated by propyl pyrazole triol but not by diarylpropionitrile.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	24-45	estrogen receptor 1	Homo sapiens	6-13
17332286-6	2007	Using ERalpha-specific (propyl pyrazole triol) and ERbeta-specific (diarylpropionitrile) agonists, the gene expression modulations produced by E(2) could be replicated by propyl pyrazole triol but not by diarylpropionitrile.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	171-192	estrogen receptor 1	Homo sapiens	6-13
17332286-6	2007	Using ERalpha-specific (propyl pyrazole triol) and ERbeta-specific (diarylpropionitrile) agonists, the gene expression modulations produced by E(2) could be replicated by propyl pyrazole triol but not by diarylpropionitrile.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	171-192	estrogen receptor 2	Homo sapiens	51-57
17258238-7	2007	The estrogen receptor-alpha (ERalpha) selective agonist, propyl pyrazole triol (PPT, 2mg/kg), exerted a similar protective effect, but the estrogen receptor-beta (ERbeta) agonist, diarylpropiolnitrile (DPN, 8mg/kg), failed to do so.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	80-83	estrogen receptor 1	Rattus norvegicus	29-36
17272673-7	2007	Treatment with 17beta-estradiol and an ERbeta-selective agonist, diarylpropionitrile, increased protein expression of NM23-H2; an effect that was not seen with an ERalpha-selective agonist, propylpyrazole-triol.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	190-210	estrogen receptor 2	Homo sapiens	39-45
17272673-7	2007	Treatment with 17beta-estradiol and an ERbeta-selective agonist, diarylpropionitrile, increased protein expression of NM23-H2; an effect that was not seen with an ERalpha-selective agonist, propylpyrazole-triol.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	190-210	NME/NM23 nucleoside diphosphate kinase 2	Homo sapiens	118-125
17266735-6	2007	Only the estrogen receptor (ER) alpha agonist, (propyl-pyrazole-trinyl)tris-phenol (PPT), induced the same enhancing effect as estradiol on both LTD and spinogenesis in the CA1.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	84-87	estrogen receptor 1	Rattus norvegicus	9-37
17266735-6	2007	Only the estrogen receptor (ER) alpha agonist, (propyl-pyrazole-trinyl)tris-phenol (PPT), induced the same enhancing effect as estradiol on both LTD and spinogenesis in the CA1.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	84-87	carbonic anhydrase 1	Rattus norvegicus	173-176
16690804-5	2006	UGT2B15 up-regulation is also evoked by other estrogens (propylpyrazoletriol, genistein) and by the androgen 5alpha-dihydrotestosterone working through the ER, but not by other steroid hormone receptor ligands.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	57-76	UDP glucuronosyltransferase family 2 member B15	Homo sapiens	0-7
17213481-7	2007	The ER-beta agonist DPN counteracted ET-1-induced vasoconstriction, whereas the ER-alpha agonist PPT was ineffective.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	97-100	estrogen receptor 1	Rattus norvegicus	80-88
17075034-6	2006	We determined that E2 receptor (ER) beta mediates the effect of E2, because activation of ERbeta with diarylpropionitrile (50 pmol) attenuated the response by 57%, whereas activation of ERalpha with propyl-pyrazole-triol (20 pmol) had no effect.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	199-220	estrogen receptor 2	Rattus norvegicus	19-40
17075034-6	2006	We determined that E2 receptor (ER) beta mediates the effect of E2, because activation of ERbeta with diarylpropionitrile (50 pmol) attenuated the response by 57%, whereas activation of ERalpha with propyl-pyrazole-triol (20 pmol) had no effect.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	199-220	estrogen receptor 1	Rattus norvegicus	186-193
16937413-9	2006	Estradiol and PPT treatment but not DPN decreased GluR2 subunit mRNA levels in the prefrontal cortex and the striatum of ovariectomized rats, whereas no significant change was observed in the cingulate cortex or the nucleus accumbens.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	14-17	glutamate ionotropic receptor AMPA type subunit 2	Rattus norvegicus	50-55
16901764-12	2006	Since Myc could be oncogenic, it might be involved in the transforming properties of PPT-I and NK1 while SDF-1alpha could be involved in cell-homing of BCCs through the regulation of PPT-I.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	85-88	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	6-9
16763067-9	2006	By contrast, propyl pyrazole triol reduces LH beta expression whereas diarylpropionitrile does not.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	13-34	luteinizing hormone subunit beta	Rattus norvegicus	43-50
16846835-4	2006	Treatment with ERalpha-selective agonist propyl pyrazole triol (PPT) caused thymic atrophy and significant changes in thymic CD4/CD8 phenotypic profile.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	41-62	estrogen receptor 1 (alpha)	Mus musculus	15-22
16846835-4	2006	Treatment with ERalpha-selective agonist propyl pyrazole triol (PPT) caused thymic atrophy and significant changes in thymic CD4/CD8 phenotypic profile.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	41-62	CD4 antigen	Mus musculus	125-128
16846835-4	2006	Treatment with ERalpha-selective agonist propyl pyrazole triol (PPT) caused thymic atrophy and significant changes in thymic CD4/CD8 phenotypic profile.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	64-67	estrogen receptor 1 (alpha)	Mus musculus	15-22
16846835-4	2006	Treatment with ERalpha-selective agonist propyl pyrazole triol (PPT) caused thymic atrophy and significant changes in thymic CD4/CD8 phenotypic profile.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	64-67	CD4 antigen	Mus musculus	125-128
16846835-8	2006	In addition, PPT administration induced a reduction in the percentage of mature B cells in the spleen, and enhanced IFN-gamma production but suppressed IL-6 production from in vitro Con A-stimulated splenocytes as estradiol (E(2)) did, whereas DPN treatment had no effects either alone or with PPT, suggesting ERalpha mediates these estrogen actions.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	13-16	interferon gamma	Mus musculus	116-125
16846835-8	2006	In addition, PPT administration induced a reduction in the percentage of mature B cells in the spleen, and enhanced IFN-gamma production but suppressed IL-6 production from in vitro Con A-stimulated splenocytes as estradiol (E(2)) did, whereas DPN treatment had no effects either alone or with PPT, suggesting ERalpha mediates these estrogen actions.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	13-16	interleukin 6	Mus musculus	152-156
16846835-8	2006	In addition, PPT administration induced a reduction in the percentage of mature B cells in the spleen, and enhanced IFN-gamma production but suppressed IL-6 production from in vitro Con A-stimulated splenocytes as estradiol (E(2)) did, whereas DPN treatment had no effects either alone or with PPT, suggesting ERalpha mediates these estrogen actions.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	13-16	estrogen receptor 1 (alpha)	Mus musculus	310-317
16943549-2	2006	In the current studies, the role of PPT intracellular protein kinase A (PKA) in the regulation of REM sleep was evaluated by comparing PKA subunit [catalytic (PKA(C alpha)) and regulatory (PKA(RI), PKA(RII alpha), and PKA(RII beta)) types] expression and activity in the PPT at normal, high, and low REM sleep conditions.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	36-39	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	54-70
16943549-2	2006	In the current studies, the role of PPT intracellular protein kinase A (PKA) in the regulation of REM sleep was evaluated by comparing PKA subunit [catalytic (PKA(C alpha)) and regulatory (PKA(RI), PKA(RII alpha), and PKA(RII beta)) types] expression and activity in the PPT at normal, high, and low REM sleep conditions.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	36-39	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	72-75
16943549-9	2006	The results of this pharmacological study demonstrated that the localized inhibition of cAMP-dependent PKA activation in the PPT dose-dependently suppressed REM sleep.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	125-128	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	103-106
16943549-10	2006	Together, these results provide the first evidence that the activation of the PPT intracellular PKA system is involved in the generation of REM sleep.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	78-81	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	96-99
17023568-5	2007	17beta-Estradiol or PPT administration following trauma-hemorrhage prevented the increase in plasma IL-6 and IL-10 levels that were observed in vehicle-treated animals.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	20-23	interleukin 6	Rattus norvegicus	100-104
17023568-5	2007	17beta-Estradiol or PPT administration following trauma-hemorrhage prevented the increase in plasma IL-6 and IL-10 levels that were observed in vehicle-treated animals.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	20-23	interleukin 10	Rattus norvegicus	109-114
17023568-10	2007	The same effects as 17beta-estradiol on IL-10 production were observed by PPT on Kupffer cells and DPN on PBMC.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	74-77	interleukin 10	Rattus norvegicus	40-45
16901971-4	2006	Propyl pyrazole triol (PPT) is a highly selective ERalpha agonist, whereas, 17beta-estradiol activates both ERalpha and ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-21	estrogen receptor 1	Homo sapiens	50-57
16901971-4	2006	Propyl pyrazole triol (PPT) is a highly selective ERalpha agonist, whereas, 17beta-estradiol activates both ERalpha and ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-21	estrogen receptor 1	Homo sapiens	108-115
16901971-4	2006	Propyl pyrazole triol (PPT) is a highly selective ERalpha agonist, whereas, 17beta-estradiol activates both ERalpha and ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-21	estrogen receptor 2	Homo sapiens	120-126
16901971-4	2006	Propyl pyrazole triol (PPT) is a highly selective ERalpha agonist, whereas, 17beta-estradiol activates both ERalpha and ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	23-26	estrogen receptor 1	Homo sapiens	50-57
17077142-4	2006	Results of these analyses demonstrated that activation of ERalpha either by 17beta-estradiol or a specific-agonist, propylpyrazole triol, up-regulated ApoE mRNA and protein expression.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	116-136	estrogen receptor 1	Rattus norvegicus	58-65
17077142-4	2006	Results of these analyses demonstrated that activation of ERalpha either by 17beta-estradiol or a specific-agonist, propylpyrazole triol, up-regulated ApoE mRNA and protein expression.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	116-136	apolipoprotein E	Rattus norvegicus	151-155
16904963-10	2006	CONCLUSIONS: Since PPT administration after T-H was more effective in decreasing KC cytokine production and MAPK activation than DPN, the salutary effects of E2 on KC functions are mediated predominantly via ER-alpha and normalization of MAPK following T-H.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	19-22	estrogen receptor 1	Rattus norvegicus	208-216
16793889-5	2006	EAE was induced in wild-type, ERalpha-, or ERbeta-deficient mice, and each was treated with the highly selective ERalpha agonist, propyl pyrazole triol, to determine the effect on clinical outcomes, as well as on inflammatory and neurodegenerative changes.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	130-151	estrogen receptor 1 (alpha)	Mus musculus	113-120
16478916-8	2006	These parameters were improved significantly in rats receiving E2 after T-H. Administration of the ER-alpha agonist PPT but not the ER-beta agonist DPN improved the measured parameters in the liver.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	116-119	estrogen receptor 1	Rattus norvegicus	99-107
16531562-7	2006	Administration of E2 or PPT following trauma-hemorrhage produced a significant reduction in systemic TNF-alpha and IL-6 concentrations in WT and KO mice.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	24-27	tumor necrosis factor	Mus musculus	101-110
16531562-7	2006	Administration of E2 or PPT following trauma-hemorrhage produced a significant reduction in systemic TNF-alpha and IL-6 concentrations in WT and KO mice.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	24-27	interleukin 6	Mus musculus	115-119
16627587-9	2006	Cotransfection of HC11 cells with human DAX-1 inhibited estrogen response element-reporter and receptor-interacting protein 140 kDa expression induced by 17beta-estradiol, the ERalpha-selective agonist 4,4",4"-(4-propyl-(1H)-pyrazole-1,3,5-triyl)trisphenol, or the ERbeta-selective agonist 2,3-bis(4-hydroxyphenyl)-propionitrile.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	202-256	nuclear receptor subfamily 0 group B member 1	Homo sapiens	40-45
16627587-9	2006	Cotransfection of HC11 cells with human DAX-1 inhibited estrogen response element-reporter and receptor-interacting protein 140 kDa expression induced by 17beta-estradiol, the ERalpha-selective agonist 4,4",4"-(4-propyl-(1H)-pyrazole-1,3,5-triyl)trisphenol, or the ERbeta-selective agonist 2,3-bis(4-hydroxyphenyl)-propionitrile.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	202-256	estrogen receptor 1	Homo sapiens	176-183
16461544-4	2006	Ovariectomized rats were daily injected over 3 days with 25 microg oestradiol benzoate, 0.3 or 1.5 mg of the selective ERalpha agonist propylpyrazole triol (PPT) with or without 1.5, 3.0 or 4.5 mg of the selective ERbeta agonist diarylpropionitrile (DPN), DPN alone, and 0.3 or 3 mg of tamoxifen.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	135-155	estrogen receptor 1	Rattus norvegicus	119-126
16434614-6	2006	The phosphorylation of protein kinase B (Akt) (at serine 473), an essential mediator of IGF-I neuroprotective actions, increased after 17beta-estradiol and tended to increase with PPT but not with Delta5-diol treatments in MPTP mice.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	180-183	thymoma viral proto-oncogene 1	Mus musculus	41-44
16434614-7	2006	Glycogen synthase kinase 3beta (GSK3beta) phosphorylation (at serine 9) was greatly reduced in MPTP mice; this was completely prevented by PPT, whereas 17beta-estradiol and Delta5-diol treatments were less effective.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	139-142	glycogen synthase kinase 3 beta	Mus musculus	0-30
16434614-7	2006	Glycogen synthase kinase 3beta (GSK3beta) phosphorylation (at serine 9) was greatly reduced in MPTP mice; this was completely prevented by PPT, whereas 17beta-estradiol and Delta5-diol treatments were less effective.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	139-142	glycogen synthase kinase 3 beta	Mus musculus	32-40
16434614-10	2006	In nonlesioned mice, 17beta-estradiol and PPT increased phosphorylation of striatal Akt and GSK3beta, whereas the other markers measured remained unchanged.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	42-45	thymoma viral proto-oncogene 1	Mus musculus	84-87
16434614-10	2006	In nonlesioned mice, 17beta-estradiol and PPT increased phosphorylation of striatal Akt and GSK3beta, whereas the other markers measured remained unchanged.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	42-45	glycogen synthase kinase 3 beta	Mus musculus	92-100
16513095-9	2006	PPT, but not DPN, induced PR expression in the neonatal MPN and arcuate nucleus (Arc), demonstrating that PR expression in the neonatal rat brain depends solely on E2 activated ERalpha.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	estrogen receptor 1	Rattus norvegicus	177-184
16619655-11	2006	The results suggest that the PPT may differentiate among patients better than the GOS, mRS, or mBL The PPT is a valid and reliable instrument for measuring functional status in patients with cerebral aneurysms.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	103-106	mannose-binding lectin (protein C) 2	Mus musculus	95-98
16461544-8	2006	When combined with PPT, DPN attenuated ERalpha effects without interfering with its LH-releasing activity.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	19-22	estrogen receptor 1	Rattus norvegicus	39-46
16452668-6	2006	Compared with controls, E2 and the ERalpha-selective agonists moxestrol and propyl-pyrazole-triol significantly increased the stress induced release of corticosterone and ACTH.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	76-97	estrogen receptor 1	Rattus norvegicus	35-42
15798780-4	2005	ERalpha-selective SERMs were propyl pyrazole triol (PPT), which has more selective effects at ERalpha, than does the other ERalpha SERM utilized, 17alpha-E2, which also binds ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	29-50	estrogen receptor 1	Rattus norvegicus	0-7
16007178-5	2005	The ERalpha-selective agonist 4,4",4""-(4-propyl-(1H)-pyrazole-1,3,5-triyl)trisphenol (PPT) stimulated proliferation.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	30-85	estrogen receptor 1 (alpha)	Mus musculus	4-11
16007178-5	2005	The ERalpha-selective agonist 4,4",4""-(4-propyl-(1H)-pyrazole-1,3,5-triyl)trisphenol (PPT) stimulated proliferation.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	87-90	estrogen receptor 1 (alpha)	Mus musculus	4-11
15994857-8	2005	PPT reduced the release of cardiac-specific troponin-I and reduced the tissue deposition of the membrane attack complex and C-reactive protein similar to that of E2.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	C-reactive protein	Oryctolagus cuniculus	124-142
15798780-4	2005	ERalpha-selective SERMs were propyl pyrazole triol (PPT), which has more selective effects at ERalpha, than does the other ERalpha SERM utilized, 17alpha-E2, which also binds ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	29-50	estrogen receptor 1	Rattus norvegicus	94-101
15798780-4	2005	ERalpha-selective SERMs were propyl pyrazole triol (PPT), which has more selective effects at ERalpha, than does the other ERalpha SERM utilized, 17alpha-E2, which also binds ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	29-50	estrogen receptor 1	Rattus norvegicus	94-101
15798780-4	2005	ERalpha-selective SERMs were propyl pyrazole triol (PPT), which has more selective effects at ERalpha, than does the other ERalpha SERM utilized, 17alpha-E2, which also binds ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	52-55	estrogen receptor 1	Rattus norvegicus	0-7
15798780-4	2005	ERalpha-selective SERMs were propyl pyrazole triol (PPT), which has more selective effects at ERalpha, than does the other ERalpha SERM utilized, 17alpha-E2, which also binds ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	52-55	estrogen receptor 1	Rattus norvegicus	94-101
15798780-4	2005	ERalpha-selective SERMs were propyl pyrazole triol (PPT), which has more selective effects at ERalpha, than does the other ERalpha SERM utilized, 17alpha-E2, which also binds ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	52-55	estrogen receptor 1	Rattus norvegicus	94-101
15798780-4	2005	ERalpha-selective SERMs were propyl pyrazole triol (PPT), which has more selective effects at ERalpha, than does the other ERalpha SERM utilized, 17alpha-E2, which also binds ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	52-55	estrogen receptor 2	Rattus norvegicus	175-181
15798780-8	2005	Anxiety behavior of rats administered ERalpha-selective SERMs (PPT, 17alpha-E2) was not different from vehicle; however, PPT and 17alpha-E2 enhanced sexual receptivity in a manner similar to 17beta-E2.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	63-66	estrogen receptor 1	Rattus norvegicus	38-45
15772257-5	2005	When cells were treated with subtype-selective ER agonists, the ERalpha agonist (propylpyrazole-triol), but not the ERbeta agonist (diarylpropionitrile), decreased (P &lt; 0.01) the GnRH-induced secretion of LH.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	81-101	estrogen receptor 1	Homo sapiens	64-71
15944374-8	2005	Moreover, whole-cell recordings from rat-brain slices show that UII selectively excites cholinergic PPT neurons via an inward current and membrane depolarization that were accompanied by membrane conductance decreases.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	100-103	urotensin 2	Rattus norvegicus	64-67
15817665-7	2005	The ERalpha-selective agonist propyl pyrazole triol (PPT, 10 mg/kg) and ERbeta-selective agonist WAY 200070-3 (1 mg/kg) produced nearly complete protection of CA1 neurons in approximately 50% of the animals.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	30-51	estrogen receptor 1	Rattus norvegicus	4-11
15817665-7	2005	The ERalpha-selective agonist propyl pyrazole triol (PPT, 10 mg/kg) and ERbeta-selective agonist WAY 200070-3 (1 mg/kg) produced nearly complete protection of CA1 neurons in approximately 50% of the animals.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	30-51	carbonic anhydrase 1	Rattus norvegicus	159-162
15585566-10	2005	The effect of estrogen appears mainly mediated by ERalpha because the selective ERalpha agonist propylpyrazole-triol determined a much greater increase of seladin-1 expression than the ERbeta agonist diarylpropionitrile.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	96-116	estrogen receptor 1	Homo sapiens	50-57
15722404-3	2005	Acute administration of the selective ERalpha agonist 4,4",4""-(4-propyl-[(1)H]pyrazole-1,3,5-triyl) tris-phenol (PPT) to precontracted aortic rings from intact female rats dose-dependently induced an ER-dependent vascular relaxation fully overlapping to that induced by 17beta-estradiol.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	54-112	estrogen receptor 1	Rattus norvegicus	38-45
15722404-3	2005	Acute administration of the selective ERalpha agonist 4,4",4""-(4-propyl-[(1)H]pyrazole-1,3,5-triyl) tris-phenol (PPT) to precontracted aortic rings from intact female rats dose-dependently induced an ER-dependent vascular relaxation fully overlapping to that induced by 17beta-estradiol.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	114-117	estrogen receptor 1	Rattus norvegicus	38-45
15661860-5	2005	The E2 effects involved the estrogen receptor (ER) alpha because they were similarly obtained with the specific ER alpha agonist 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	129-177	estrogen receptor 1	Rattus norvegicus	28-56
15635152-6	2005	In addition, an estrogenicity of PPT in inducing CaBP-9k expression was completely blocked by the anti-estrogen ICI 182,780, implying that uterine CaBP-9k is solely induced by ERalpha.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	33-36	estrogen receptor 1	Rattus norvegicus	176-183
15635152-7	2005	A single treatment with PPT rapidly increased the protein levels of ERalpha and PR, an E2-mediated gene, in these tissues.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	24-27	estrogen receptor 1	Rattus norvegicus	68-75
15615701-7	2005	We demonstrate for the first time that ERalpha-and ERbeta-selective agonists propylpyrazole triol and diarylpropionitrile, respectively, stimulate MAPK and eNOS activity.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	77-97	estrogen receptor 1	Homo sapiens	39-46
15615701-7	2005	We demonstrate for the first time that ERalpha-and ERbeta-selective agonists propylpyrazole triol and diarylpropionitrile, respectively, stimulate MAPK and eNOS activity.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	77-97	estrogen receptor 2	Homo sapiens	51-57
15585566-10	2005	The effect of estrogen appears mainly mediated by ERalpha because the selective ERalpha agonist propylpyrazole-triol determined a much greater increase of seladin-1 expression than the ERbeta agonist diarylpropionitrile.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	96-116	estrogen receptor 1	Homo sapiens	80-87
15585566-10	2005	The effect of estrogen appears mainly mediated by ERalpha because the selective ERalpha agonist propylpyrazole-triol determined a much greater increase of seladin-1 expression than the ERbeta agonist diarylpropionitrile.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	96-116	24-dehydrocholesterol reductase	Homo sapiens	155-164
15582497-2	2004	The aim of this study was to determine whether novel ERalpha-selective agonists, propyl pyrazole triol (PPT) and the tetrahydrochrysene (R,R-THC), up-regulate the expression of vascular endothelial growth factor receptor-2 (VEGFR-2), and promote VEGF-stimulated endothelial cell proliferation in primary cultures of adult female microvascular endothelial cells co-expressing endogenous ERalpha and ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	81-102	estrogen receptor 1	Homo sapiens	53-60
15582497-2	2004	The aim of this study was to determine whether novel ERalpha-selective agonists, propyl pyrazole triol (PPT) and the tetrahydrochrysene (R,R-THC), up-regulate the expression of vascular endothelial growth factor receptor-2 (VEGFR-2), and promote VEGF-stimulated endothelial cell proliferation in primary cultures of adult female microvascular endothelial cells co-expressing endogenous ERalpha and ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	81-102	kinase insert domain receptor	Homo sapiens	177-222
15582497-2	2004	The aim of this study was to determine whether novel ERalpha-selective agonists, propyl pyrazole triol (PPT) and the tetrahydrochrysene (R,R-THC), up-regulate the expression of vascular endothelial growth factor receptor-2 (VEGFR-2), and promote VEGF-stimulated endothelial cell proliferation in primary cultures of adult female microvascular endothelial cells co-expressing endogenous ERalpha and ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	81-102	kinase insert domain receptor	Homo sapiens	224-231
15582497-2	2004	The aim of this study was to determine whether novel ERalpha-selective agonists, propyl pyrazole triol (PPT) and the tetrahydrochrysene (R,R-THC), up-regulate the expression of vascular endothelial growth factor receptor-2 (VEGFR-2), and promote VEGF-stimulated endothelial cell proliferation in primary cultures of adult female microvascular endothelial cells co-expressing endogenous ERalpha and ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	81-102	vascular endothelial growth factor A	Homo sapiens	224-228
15582497-2	2004	The aim of this study was to determine whether novel ERalpha-selective agonists, propyl pyrazole triol (PPT) and the tetrahydrochrysene (R,R-THC), up-regulate the expression of vascular endothelial growth factor receptor-2 (VEGFR-2), and promote VEGF-stimulated endothelial cell proliferation in primary cultures of adult female microvascular endothelial cells co-expressing endogenous ERalpha and ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	81-102	estrogen receptor 1	Homo sapiens	386-393
15582497-2	2004	The aim of this study was to determine whether novel ERalpha-selective agonists, propyl pyrazole triol (PPT) and the tetrahydrochrysene (R,R-THC), up-regulate the expression of vascular endothelial growth factor receptor-2 (VEGFR-2), and promote VEGF-stimulated endothelial cell proliferation in primary cultures of adult female microvascular endothelial cells co-expressing endogenous ERalpha and ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	81-102	estrogen receptor 2	Homo sapiens	398-404
15582497-2	2004	The aim of this study was to determine whether novel ERalpha-selective agonists, propyl pyrazole triol (PPT) and the tetrahydrochrysene (R,R-THC), up-regulate the expression of vascular endothelial growth factor receptor-2 (VEGFR-2), and promote VEGF-stimulated endothelial cell proliferation in primary cultures of adult female microvascular endothelial cells co-expressing endogenous ERalpha and ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	104-107	estrogen receptor 1	Homo sapiens	53-60
15582497-2	2004	The aim of this study was to determine whether novel ERalpha-selective agonists, propyl pyrazole triol (PPT) and the tetrahydrochrysene (R,R-THC), up-regulate the expression of vascular endothelial growth factor receptor-2 (VEGFR-2), and promote VEGF-stimulated endothelial cell proliferation in primary cultures of adult female microvascular endothelial cells co-expressing endogenous ERalpha and ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	104-107	kinase insert domain receptor	Homo sapiens	177-222
15582497-2	2004	The aim of this study was to determine whether novel ERalpha-selective agonists, propyl pyrazole triol (PPT) and the tetrahydrochrysene (R,R-THC), up-regulate the expression of vascular endothelial growth factor receptor-2 (VEGFR-2), and promote VEGF-stimulated endothelial cell proliferation in primary cultures of adult female microvascular endothelial cells co-expressing endogenous ERalpha and ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	104-107	kinase insert domain receptor	Homo sapiens	224-231
15582497-2	2004	The aim of this study was to determine whether novel ERalpha-selective agonists, propyl pyrazole triol (PPT) and the tetrahydrochrysene (R,R-THC), up-regulate the expression of vascular endothelial growth factor receptor-2 (VEGFR-2), and promote VEGF-stimulated endothelial cell proliferation in primary cultures of adult female microvascular endothelial cells co-expressing endogenous ERalpha and ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	104-107	vascular endothelial growth factor A	Homo sapiens	224-228
15582497-2	2004	The aim of this study was to determine whether novel ERalpha-selective agonists, propyl pyrazole triol (PPT) and the tetrahydrochrysene (R,R-THC), up-regulate the expression of vascular endothelial growth factor receptor-2 (VEGFR-2), and promote VEGF-stimulated endothelial cell proliferation in primary cultures of adult female microvascular endothelial cells co-expressing endogenous ERalpha and ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	104-107	estrogen receptor 1	Homo sapiens	386-393
15582497-2	2004	The aim of this study was to determine whether novel ERalpha-selective agonists, propyl pyrazole triol (PPT) and the tetrahydrochrysene (R,R-THC), up-regulate the expression of vascular endothelial growth factor receptor-2 (VEGFR-2), and promote VEGF-stimulated endothelial cell proliferation in primary cultures of adult female microvascular endothelial cells co-expressing endogenous ERalpha and ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	104-107	estrogen receptor 2	Homo sapiens	398-404
15582497-5	2004	RESULTS: Both PPT and R,R-THC increased VEGFR-2 expression on myometrial microvascular endothelial cells in a dose-dependent manner, reaching a maximum at 1 microM.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	14-17	kinase insert domain receptor	Homo sapiens	40-47
15582497-7	2004	PPT- or R,R-THC-stimulated increase in VEGF binding was significantly different between ERalpha+ and ERalpha- microvascular endothelial cell samples (P &lt; .001 and P &lt; .05, respectively).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	vascular endothelial growth factor A	Homo sapiens	39-43
15582497-7	2004	PPT- or R,R-THC-stimulated increase in VEGF binding was significantly different between ERalpha+ and ERalpha- microvascular endothelial cell samples (P &lt; .001 and P &lt; .05, respectively).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	estrogen receptor 1	Homo sapiens	88-95
15582497-7	2004	PPT- or R,R-THC-stimulated increase in VEGF binding was significantly different between ERalpha+ and ERalpha- microvascular endothelial cell samples (P &lt; .001 and P &lt; .05, respectively).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	estrogen receptor 1	Homo sapiens	101-108
15582497-8	2004	PPT, R,R-THC, and 17beta-estradiol significantly augmented VEGF-stimulated microvascular endothelial cell proliferation in ERalpha+ (P &lt; .05), but not in ERalpha- samples.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	vascular endothelial growth factor A	Homo sapiens	59-63
15582497-8	2004	PPT, R,R-THC, and 17beta-estradiol significantly augmented VEGF-stimulated microvascular endothelial cell proliferation in ERalpha+ (P &lt; .05), but not in ERalpha- samples.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	estrogen receptor 1	Homo sapiens	123-130
15567427-9	2004	The effect of PPT suggests the implication of an ER alpha in the estrogenic neuroprotection against MPTP.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	14-17	estrogen receptor 1 (alpha)	Mus musculus	49-57
15251261-5	2004	ERalpha-selective SERMs were propyl pyrazole triol (PPT) and 17alpha-E2.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	29-50	estrogen receptor 1	Rattus norvegicus	0-7
15155257-5	2004	In contrast, pretreatment with the ERalpha agonist PPT had no effect on the extent of neuronal damage compared with controls.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	51-54	estrogen receptor 1 (alpha)	Mus musculus	35-42
15203111-3	2004	Curcumin pre and post-treatment (PPT) was shown to decrease the levels of xanthine oxidase, superoxide anion, lipid peroxides (LPs) and myeloperoxidase while the levels of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione-S-transferase (GST) activities were significantly increased after curcumin PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	33-36	catalase	Rattus norvegicus	200-208
15203111-3	2004	Curcumin pre and post-treatment (PPT) was shown to decrease the levels of xanthine oxidase, superoxide anion, lipid peroxides (LPs) and myeloperoxidase while the levels of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione-S-transferase (GST) activities were significantly increased after curcumin PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	33-36	catalase	Rattus norvegicus	210-213
15203111-3	2004	Curcumin pre and post-treatment (PPT) was shown to decrease the levels of xanthine oxidase, superoxide anion, lipid peroxides (LPs) and myeloperoxidase while the levels of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione-S-transferase (GST) activities were significantly increased after curcumin PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	33-36	hematopoietic prostaglandin D synthase	Rattus norvegicus	246-271
15203111-3	2004	Curcumin pre and post-treatment (PPT) was shown to decrease the levels of xanthine oxidase, superoxide anion, lipid peroxides (LPs) and myeloperoxidase while the levels of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione-S-transferase (GST) activities were significantly increased after curcumin PPT.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	33-36	hematopoietic prostaglandin D synthase	Rattus norvegicus	273-276
15251261-5	2004	ERalpha-selective SERMs were propyl pyrazole triol (PPT) and 17alpha-E2.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	52-55	estrogen receptor 1	Rattus norvegicus	0-7
14993645-7	2004	These results suggest that the interaction of PTB with the PPT may contribute to the correct functioning of the KSHV IRES in infected cells.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	59-62	polypyrimidine tract binding protein 1	Homo sapiens	46-49
15033909-10	2004	Propyl-pyrazole-triol and R,R-diethyl-tetrahydrochrysene, selective ERalpha agonists, reduced ERalpha protein by 50% while stimulating ERalpha transcriptional activity 4- to 8-fold.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-21	estrogen receptor 1	Homo sapiens	68-75
15033909-10	2004	Propyl-pyrazole-triol and R,R-diethyl-tetrahydrochrysene, selective ERalpha agonists, reduced ERalpha protein by 50% while stimulating ERalpha transcriptional activity 4- to 8-fold.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-21	estrogen receptor 1	Homo sapiens	94-101
15033909-10	2004	Propyl-pyrazole-triol and R,R-diethyl-tetrahydrochrysene, selective ERalpha agonists, reduced ERalpha protein by 50% while stimulating ERalpha transcriptional activity 4- to 8-fold.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-21	estrogen receptor 1	Homo sapiens	94-101
14714472-6	2003	The mechanisms whereby MSO and PPT affect glutamine synthetase activity are discussed in the context of nitrogen metabolism in plants.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	31-34	glutamate-ammonia ligase	Homo sapiens	42-62
15205556-8	2004	EB, PPT and PPT+DPN treatments increased PR mRNA and the number and intensity of nuclei immunoreactive (IR) for PR in gonadotropes, and reduced the number of gonadectomy cells.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	4-7	progesterone receptor	Rattus norvegicus	41-43
15205556-8	2004	EB, PPT and PPT+DPN treatments increased PR mRNA and the number and intensity of nuclei immunoreactive (IR) for PR in gonadotropes, and reduced the number of gonadectomy cells.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	4-7	progesterone receptor	Rattus norvegicus	112-114
15205556-8	2004	EB, PPT and PPT+DPN treatments increased PR mRNA and the number and intensity of nuclei immunoreactive (IR) for PR in gonadotropes, and reduced the number of gonadectomy cells.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	12-15	progesterone receptor	Rattus norvegicus	41-43
15205556-8	2004	EB, PPT and PPT+DPN treatments increased PR mRNA and the number and intensity of nuclei immunoreactive (IR) for PR in gonadotropes, and reduced the number of gonadectomy cells.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	12-15	progesterone receptor	Rattus norvegicus	112-114
15205556-9	2004	Like E, PPT alone or in combination with DPN stimulated PRL secretion, increased basal and GnRH-stimulated LH and FSH secretion and induced GnRH self-priming in the absence of ZK299 in the incubation medium.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	8-11	prolactin	Rattus norvegicus	56-59
15205556-9	2004	Like E, PPT alone or in combination with DPN stimulated PRL secretion, increased basal and GnRH-stimulated LH and FSH secretion and induced GnRH self-priming in the absence of ZK299 in the incubation medium.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	8-11	gonadotropin releasing hormone 1	Rattus norvegicus	91-95
15205556-9	2004	Like E, PPT alone or in combination with DPN stimulated PRL secretion, increased basal and GnRH-stimulated LH and FSH secretion and induced GnRH self-priming in the absence of ZK299 in the incubation medium.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	8-11	gonadotropin releasing hormone 1	Rattus norvegicus	140-144
14714472-5	2003	However, low concentrations of MSO, PPT, and their metabolites produce an opposite effect: glutamine synthetase is activated, with concomitant stimulation of plant growth and productivity.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	36-39	glutamate-ammonia ligase	Homo sapiens	91-111
14613904-5	2004	Administration of estradiol benzoate (as potent agonist for alpha and beta forms of ER) or the selective ERalpha agonist, propyl pyrazole triol, fully reversed the responses to OVX, while the ERbeta ligand, diarylpropionitrile, failed to induce any significant effect except for a partial stimulation of TERP-1 and -2 mRNA expression levels.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	122-143	estrogen receptor 1	Rattus norvegicus	105-112
14660439-5	2004	Moreover, ntl interacts with ppt and kny to synergistically regulate the posterior expression of the gene encoding bone morphogenetic protein 4 (bmp4) but not of other known T-box genes, fibroblast growth factor genes or caudal genes.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	29-32	bone morphogenetic protein 4	Danio rerio	115-143
14660439-5	2004	Moreover, ntl interacts with ppt and kny to synergistically regulate the posterior expression of the gene encoding bone morphogenetic protein 4 (bmp4) but not of other known T-box genes, fibroblast growth factor genes or caudal genes.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	29-32	bone morphogenetic protein 4	Danio rerio	145-149
12399409-2	2002	In this study, we investigated the activity of an ERalpha-selective agonist ligand, propyl pyrazole triol (PPT), in several rat animal models to define the involvement of ERalpha in these biological responses.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	84-105	estrogen receptor 1	Rattus norvegicus	50-57
12842887-4	2003	SHP is rapidly induced within 2 h following treatment of mice with ethynylestradiol (EE) or the estrogen receptor alpha (ERalpha)-selective compound propyl pyrazole triol (PPT).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	149-170	nuclear receptor subfamily 0, group B, member 2	Mus musculus	0-3
12842887-4	2003	SHP is rapidly induced within 2 h following treatment of mice with ethynylestradiol (EE) or the estrogen receptor alpha (ERalpha)-selective compound propyl pyrazole triol (PPT).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	149-170	estrogen receptor 1 (alpha)	Mus musculus	96-119
12842887-4	2003	SHP is rapidly induced within 2 h following treatment of mice with ethynylestradiol (EE) or the estrogen receptor alpha (ERalpha)-selective compound propyl pyrazole triol (PPT).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	149-170	estrogen receptor 1 (alpha)	Mus musculus	121-128
12842887-4	2003	SHP is rapidly induced within 2 h following treatment of mice with ethynylestradiol (EE) or the estrogen receptor alpha (ERalpha)-selective compound propyl pyrazole triol (PPT).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	172-175	nuclear receptor subfamily 0, group B, member 2	Mus musculus	0-3
12842887-4	2003	SHP is rapidly induced within 2 h following treatment of mice with ethynylestradiol (EE) or the estrogen receptor alpha (ERalpha)-selective compound propyl pyrazole triol (PPT).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	172-175	estrogen receptor 1 (alpha)	Mus musculus	96-119
12842887-4	2003	SHP is rapidly induced within 2 h following treatment of mice with ethynylestradiol (EE) or the estrogen receptor alpha (ERalpha)-selective compound propyl pyrazole triol (PPT).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	172-175	estrogen receptor 1 (alpha)	Mus musculus	121-128
12943986-5	2003	At all of these genes, PPT showed full stimulation through ERalpha while displaying no agonism through ERbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	23-26	estrogen receptor 1	Homo sapiens	59-66
12810572-4	2003	Administration of the ERalpha-selective ligand propyl pyrazole triol (PPT) to immature mice resulted in a significant increase in uterine weight, as well as bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression in luminal epithelial cells.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	47-68	estrogen receptor 1 (alpha)	Mus musculus	22-29
12810572-4	2003	Administration of the ERalpha-selective ligand propyl pyrazole triol (PPT) to immature mice resulted in a significant increase in uterine weight, as well as bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression in luminal epithelial cells.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	70-73	estrogen receptor 1 (alpha)	Mus musculus	22-29
12810572-6	2003	However, when compared with E(2), PPT was less effective in stimulating uterine weight, complement component 3, and G6PDH expression but was as effective as E(2) in regulating lactoferrin, AR, and PR expression.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	34-37	lactotransferrin	Mus musculus	176-187
12810572-6	2003	However, when compared with E(2), PPT was less effective in stimulating uterine weight, complement component 3, and G6PDH expression but was as effective as E(2) in regulating lactoferrin, AR, and PR expression.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	34-37	androgen receptor	Mus musculus	189-191
12810572-6	2003	However, when compared with E(2), PPT was less effective in stimulating uterine weight, complement component 3, and G6PDH expression but was as effective as E(2) in regulating lactoferrin, AR, and PR expression.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	34-37	progesterone receptor	Mus musculus	197-199
12810572-8	2003	Interestingly, DPN reduced the uterine weight stimulation by PPT, and enhanced the effect of PPT in decreasing uterine PR and AR mRNA.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	93-96	progesterone receptor	Mus musculus	119-121
12810572-8	2003	Interestingly, DPN reduced the uterine weight stimulation by PPT, and enhanced the effect of PPT in decreasing uterine PR and AR mRNA.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	93-96	androgen receptor	Mus musculus	126-128
12855334-7	2003	Injection of NGF into the masseter muscle was associated with significantly reduced PPT for 7 days (ANOVA: P&lt;0.001) and PTOL for 1 day (P&lt;0.001).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	84-87	nerve growth factor	Homo sapiens	13-16
12538633-6	2003	E2 regulations in the kidney were intact in ERbetaKO mice, and the ERalpha-selective agonist propylpyrazole triol acted similarly to E2, together suggesting an ERalpha-mediated mechanism.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	93-113	estrogen receptor 1 (alpha)	Mus musculus	67-74
12538633-6	2003	E2 regulations in the kidney were intact in ERbetaKO mice, and the ERalpha-selective agonist propylpyrazole triol acted similarly to E2, together suggesting an ERalpha-mediated mechanism.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	93-113	estrogen receptor 1 (alpha)	Mus musculus	160-167
12399409-2	2002	In this study, we investigated the activity of an ERalpha-selective agonist ligand, propyl pyrazole triol (PPT), in several rat animal models to define the involvement of ERalpha in these biological responses.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	107-110	estrogen receptor 1	Rattus norvegicus	50-57
12370285-6	2002	The PPT sequence overlaps with a binding site for transcription factor C/EBPbeta.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	4-7	CCAAT enhancer binding protein beta	Homo sapiens	71-80
12093623-3	2002	Experiments were performed in 21-day-old rats exposed to 12% CO(2) for 1 h. c-Fos expression was identified by IHH on free floating sections (40 microm) that were mounted and then hybridized with anti-sense 35S labeled ribonucleotide probe of the rat preprotachykinin A (PPT-A) gene.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	271-274	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	76-81
12107258-2	2002	Given the potential role of catecholamines and insulin in the regulation of PPT, we assessed insulin and catecholamine responses to the meal.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	76-79	insulin	Homo sapiens	47-54
11150164-8	2000	The best compound in this series, a propylpyrazole triol (PPT, compound 4g), binds to ERalpha with high affinity (ca.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	36-56	estrogen receptor 1	Homo sapiens	86-93
11438677-2	2001	SF1/mBBP utilizes a "maxi-K homology" (maxi-KH) domain for recognition of the single-stranded BPS and requires a cooperative interaction with splicing factor U2AF65 bound to an adjacent polypyrimidine tract (PPT) for high-affinity binding.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	208-211	splicing factor 1	Homo sapiens	0-3
11438677-2	2001	SF1/mBBP utilizes a "maxi-K homology" (maxi-KH) domain for recognition of the single-stranded BPS and requires a cooperative interaction with splicing factor U2AF65 bound to an adjacent polypyrimidine tract (PPT) for high-affinity binding.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	208-211	TM2 domain containing 1	Mus musculus	4-8
11438677-4	2001	We first established that SF1/mBBP and U2AF cooperatively assemble in our reporter system at RNA sites composed of the BPS, PPT, and AG dinucleotide found at 3" splice sites, with endogenous proteins assembled along with the Tat fusions.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	124-127	splicing factor 1	Homo sapiens	26-29
11438677-4	2001	We first established that SF1/mBBP and U2AF cooperatively assemble in our reporter system at RNA sites composed of the BPS, PPT, and AG dinucleotide found at 3" splice sites, with endogenous proteins assembled along with the Tat fusions.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	124-127	TM2 domain containing 1	Mus musculus	30-34
11150164-8	2000	The best compound in this series, a propylpyrazole triol (PPT, compound 4g), binds to ERalpha with high affinity (ca.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	58-61	estrogen receptor 1	Homo sapiens	86-93
10717638-5	2000	In both PPT and LDT nuclei, VAchT labeling was seen mainly on membranous organelles including the trans-Golgi network in many somata.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	8-11	solute carrier family 18 member A3	Homo sapiens	28-33
10529694-2	1999	In vitro, PPT shortened the clotting time of a high-titre human factor VIII (FVIII) inhibitor plasma in a manner similar to that of the activated prothrombin complex concentrate FEIBA and triggered coagulation in plasma samples in which factor V (FV) is present.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	10-13	coagulation factor VIII	Homo sapiens	64-75
10235636-9	1999	These results indicate that PPT B products P2 and NKB are localized in a subpopulation of enteric nerves containing TKs encoded by PPT A. Stimulation of these nerves may release NKB to activate local neurokinin receptors.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	28-31	tachykinin precursor 3	Rattus norvegicus	178-181
10529694-2	1999	In vitro, PPT shortened the clotting time of a high-titre human factor VIII (FVIII) inhibitor plasma in a manner similar to that of the activated prothrombin complex concentrate FEIBA and triggered coagulation in plasma samples in which factor V (FV) is present.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	10-13	coagulation factor VIII	Homo sapiens	77-82
8808139-8	1996	Binding of [3H]8-OH-DPAT to 5-HT1A receptors revealed few receptor sites in PPT, and a low to moderate number of receptors in LDT compared to binding in DRN.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	76-79	5-hydroxytryptamine receptor 1A	Rattus norvegicus	28-34
9398148-2	1997	Both domains are essential for high-affinity binding to the single-stranded polypyrimidine tract (PPT) within the regulated 3" splice site of the transformer (tra) pre-mRNA.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	98-101	transformer	Drosophila melanogaster	146-157
9398148-2	1997	Both domains are essential for high-affinity binding to the single-stranded polypyrimidine tract (PPT) within the regulated 3" splice site of the transformer (tra) pre-mRNA.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	98-101	transformer	Drosophila melanogaster	68-71
16535427-1	1996	Wild-type strain 21gr of the green alga Chlamydomonas reinhardtii was resistant to the ammonium salt of l-phosphinothricin (PPT, also called glufosinate), an irreversible inhibitor of glutamine synthetase activity and the main active component of the herbicide BASTA (AgrEvo, Frankfurt am Main, Germany).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	124-127	uncharacterized protein	Chlamydomonas reinhardtii	184-204
2820702-1	1987	Substance P (SP) and substance K (SK) are mammalian tachykinin peptides derived from a single preprotachykinin-A (PPT-A) gene and are widely but selectively distributed in neural and endocrine tissues.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	114-117	tachykinin precursor 1	Homo sapiens	0-11
7708665-9	1995	Sequence analysis proved that both viruses were colinear with input DNAs and that NdN virus lacked a ppt and the 5" 30 nucleotides of the LTR.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	101-104	necdin, MAGE family member	Homo sapiens	82-85
7911055-2	1994	The number of PCNA-positive cells (PCNA value) was significantly higher in PBC (375 +/- 281 parts per thousand; ppt) than in other chronic liver diseases, i.e., chronic hepatitis (95 +/- 83 ppt), liver cirrhosis (72 +/- 71 ppt), and alcoholic liver disease (73 +/- 56 ppt), and in control subjects (11 +/- 14 ppt).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	112-115	proliferating cell nuclear antigen	Homo sapiens	14-18
7911055-2	1994	The number of PCNA-positive cells (PCNA value) was significantly higher in PBC (375 +/- 281 parts per thousand; ppt) than in other chronic liver diseases, i.e., chronic hepatitis (95 +/- 83 ppt), liver cirrhosis (72 +/- 71 ppt), and alcoholic liver disease (73 +/- 56 ppt), and in control subjects (11 +/- 14 ppt).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	112-115	proliferating cell nuclear antigen	Homo sapiens	35-39
7911055-2	1994	The number of PCNA-positive cells (PCNA value) was significantly higher in PBC (375 +/- 281 parts per thousand; ppt) than in other chronic liver diseases, i.e., chronic hepatitis (95 +/- 83 ppt), liver cirrhosis (72 +/- 71 ppt), and alcoholic liver disease (73 +/- 56 ppt), and in control subjects (11 +/- 14 ppt).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	190-193	proliferating cell nuclear antigen	Homo sapiens	14-18
7911055-2	1994	The number of PCNA-positive cells (PCNA value) was significantly higher in PBC (375 +/- 281 parts per thousand; ppt) than in other chronic liver diseases, i.e., chronic hepatitis (95 +/- 83 ppt), liver cirrhosis (72 +/- 71 ppt), and alcoholic liver disease (73 +/- 56 ppt), and in control subjects (11 +/- 14 ppt).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	190-193	proliferating cell nuclear antigen	Homo sapiens	35-39
7911055-2	1994	The number of PCNA-positive cells (PCNA value) was significantly higher in PBC (375 +/- 281 parts per thousand; ppt) than in other chronic liver diseases, i.e., chronic hepatitis (95 +/- 83 ppt), liver cirrhosis (72 +/- 71 ppt), and alcoholic liver disease (73 +/- 56 ppt), and in control subjects (11 +/- 14 ppt).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	190-193	proliferating cell nuclear antigen	Homo sapiens	14-18
7911055-2	1994	The number of PCNA-positive cells (PCNA value) was significantly higher in PBC (375 +/- 281 parts per thousand; ppt) than in other chronic liver diseases, i.e., chronic hepatitis (95 +/- 83 ppt), liver cirrhosis (72 +/- 71 ppt), and alcoholic liver disease (73 +/- 56 ppt), and in control subjects (11 +/- 14 ppt).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	190-193	proliferating cell nuclear antigen	Homo sapiens	35-39
1882231-6	1991	In the case of tap water, the observed ranges for salinity, chloride and sodium were 0.7-1.5 ppt, and 280-750 and 140-400 mg l-1, respectively.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	93-96	nuclear RNA export factor 1	Homo sapiens	15-18
34749235-8	2021	Our findings indicated that PPT treatment induced non-protective autophagy in TNBC cells by inhibiting the Akt/mTOR signaling pathway.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	28-31	thymoma viral proto-oncogene 1	Mus musculus	107-110
34749235-8	2021	Our findings indicated that PPT treatment induced non-protective autophagy in TNBC cells by inhibiting the Akt/mTOR signaling pathway.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	28-31	mechanistic target of rapamycin kinase	Mus musculus	111-115
34399010-7	2021	The application of the ERalpha agonist propylpyrazoletriol (PPT) (100 nM) or the beta agonist DPN (1 muM) did not significantly affect synaptic responses.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	39-58	estrogen receptor 1	Rattus norvegicus	23-30
34399010-7	2021	The application of the ERalpha agonist propylpyrazoletriol (PPT) (100 nM) or the beta agonist DPN (1 muM) did not significantly affect synaptic responses.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	60-63	estrogen receptor 1	Rattus norvegicus	23-30
34303733-6	2021	Furthermore, pretreatment with specific ERalpha agonist PPT (1 muM) significantly attenuated the above PFOS-induced effects while specific ERbeta agonist DPN (1 muM) accelerated them.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	56-59	estrogen receptor 1 (alpha)	Mus musculus	40-47
34672299-1	2021	The present study aimed to examine whether the attenuation of estrogen receptor expression is prevented by propyl pyrazole triol (PPT), an agonist for estrogen receptor alpha (ERalpha) or and diarypropiolnitrile (DPN), an agonist for estrogen receptor beta (ERbeta) after traumatic brain injury (TBI).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	107-128	estrogen receptor 1	Rattus norvegicus	62-79
34672299-1	2021	The present study aimed to examine whether the attenuation of estrogen receptor expression is prevented by propyl pyrazole triol (PPT), an agonist for estrogen receptor alpha (ERalpha) or and diarypropiolnitrile (DPN), an agonist for estrogen receptor beta (ERbeta) after traumatic brain injury (TBI).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	107-128	estrogen receptor 1	Rattus norvegicus	176-183
34672299-1	2021	The present study aimed to examine whether the attenuation of estrogen receptor expression is prevented by propyl pyrazole triol (PPT), an agonist for estrogen receptor alpha (ERalpha) or and diarypropiolnitrile (DPN), an agonist for estrogen receptor beta (ERbeta) after traumatic brain injury (TBI).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	130-133	estrogen receptor 1	Rattus norvegicus	62-79
34672299-1	2021	The present study aimed to examine whether the attenuation of estrogen receptor expression is prevented by propyl pyrazole triol (PPT), an agonist for estrogen receptor alpha (ERalpha) or and diarypropiolnitrile (DPN), an agonist for estrogen receptor beta (ERbeta) after traumatic brain injury (TBI).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	130-133	estrogen receptor 1	Rattus norvegicus	176-183
35138554-6	2022	PPT, a ERalpha-selective agonist, but not DPN (a ERbeta-selective agonist) and G-1 (a GPER-selective agonist), was shown to stimulate TSH release in mouse pituitary cells.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	0-3	estrogen receptor 1 (alpha)	Mus musculus	7-14
2504504-7	1989	TCA ppt [3H]NAD+/5 x 10(5) cells was applied to the complete test material, it was found that ADPRT values from cancer patients were more frequently below the cut-off than values from disease-free individuals: the relative risk estimate (odds ratio) was 13.8.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	4-7	poly(ADP-ribose) polymerase 1	Homo sapiens	94-99
7834577-4	1994	Systemically administered scopolamine greatly increased the PPT stimulation evoked cortical release of ACh when the cortical probe was perfused with the cholinesterase inhibitor neostigmine.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	60-63	butyrylcholinesterase	Rattus norvegicus	153-167
2207646-9	1990	Loss of choline acetyltransferase-positive cells in PPT, but not LDT, was correlated with effects on Wave A, i.e. greatest cell loss occurred in cats in which Wave A disappeared, and least cell loss in cats with no change in Wave A.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	52-55	choline O-acetyltransferase	Felis catus	8-33
35075782-14	2022	The majority of ICU patients showed abnormal localization of GLUT4 with membranous GLUT4 distribution in 37.5% (3 of 8) of ICU patients receiving sPT, in 42.9% (3 of 7) of ICU patients receiving pPT, and in 53.8% (7 of 13) of ICU patients receiving pPT+ (no statistical testing possible).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	195-198	solute carrier family 2 member 4	Homo sapiens	61-66
35075782-14	2022	The majority of ICU patients showed abnormal localization of GLUT4 with membranous GLUT4 distribution in 37.5% (3 of 8) of ICU patients receiving sPT, in 42.9% (3 of 7) of ICU patients receiving pPT, and in 53.8% (7 of 13) of ICU patients receiving pPT+ (no statistical testing possible).	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	249-252	solute carrier family 2 member 4	Homo sapiens	61-66
2820702-1	1987	Substance P (SP) and substance K (SK) are mammalian tachykinin peptides derived from a single preprotachykinin-A (PPT-A) gene and are widely but selectively distributed in neural and endocrine tissues.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	114-117	tachykinin precursor 1	Homo sapiens	13-15
2820702-1	1987	Substance P (SP) and substance K (SK) are mammalian tachykinin peptides derived from a single preprotachykinin-A (PPT-A) gene and are widely but selectively distributed in neural and endocrine tissues.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	114-117	tachykinin precursor 1	Homo sapiens	21-32
2820702-1	1987	Substance P (SP) and substance K (SK) are mammalian tachykinin peptides derived from a single preprotachykinin-A (PPT-A) gene and are widely but selectively distributed in neural and endocrine tissues.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	114-117	tachykinin precursor 1	Homo sapiens	34-36